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Abstract
In Canada it is estimated that 76,600 people will die of cancer in 2014. Cancer, a collec-
tion of over 200 diseases, has differences existing between globally, between individuals and
overtime in one individual. Treatment options are similarly varied. These differences make
selecting the best possible treatment for every type of cancer very challenging. In addition,
with no single cure for cancer, treatments are often combined in different ways to form the best
overall option.
In an attempt to synthesize the properties of these diseases into a collection of common
cellular changes, Hanahan and Weinberg proposed “the hallmarks of cancer” – 10 differences
between healthy cells and cancer cells, present in almost every cancer. There exists the poten-
tial for treatments that are broadly applicable if they reverse these general properties.
This work seeks to simulate early cancer growth, specifically looking at these hallmarks,
and detect the best combinations of hallmarks to remove in order to stop cancer growth. This
hybrid simulation combines a discrete model of cancer cells using cellular automata, with a
continuous model of blood flow using lattice Boltzmann methods. Hallmarks relevant during
the early growth stages of solid tumour development are simulated using rules in the cellular
automata. Hallmarks were removed in pairs, triplets and quadruplets in order to model com-
bination therapy, abstracting drugs that target these properties as the removal of the hallmark
from the system. Overall growth of the tumours with “treatments” applied were compared to
tumours where all hallmarks were present.
It was found that many combinations had no effect on tumour growth. In some cases
combinations even increased growth, selecting for the most aggressive hallmarks since weaker
hallmarks were unavailable. However, in general, as more treatments were applied, cancer
growth decreased. This work is the first to simulate removing hallmarks in pairs, triplets and
quadruplets from a model with biologically relevant oxygen flow. It provides a proof of concept
that not all combinations are equally effective, even if the individual treatments are effective.
This work suggests some combinations should be avoided while others could potentially be
beneficial in a variety of diseases.
Keywords: Cellular automata, cancer hallmarks, lattice Boltzmann methods, combination
treatment, oxygen, simulation
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1
2 Chapter 1. Introduction and Literature Review
1.1 Introduction
Cancer has plagued humans for about as long as we have any knowledge of the disease. Evi-
dence of cancer has been found as far back as 3000 BC. The Edwin Smith Papyrus is a copy
of part of an ancient Egyptian textbook on trauma surgery, and describes tumours of the breast
that were removed via cauterization. In the text, the writing says of the disease – “There is no
treatment” [12].
Knowledge of cancer, the diagnosis, treatment and recovery from it have all come a long
way since then. In 1761, Giovanni Morgagni began the common practice of performing au-
topsies which assisted in scientists relating illness seen while the patient was living with the
mass of growth inside the body [12]. Around the same time, Scottish surgeon John Hunter
suggested that if a tumour seems “moveable” and has not invaded adjacent tissue one should
remove it – beginning the practice of surgical removal of cancer. In the 19th century, Rudolf
Virchow began investigating cancer using the microscope, which gave a better understanding
of the damage cancer had done, as well as allowing for more complete diagnoses and detec-
tion of whether a cancer had been completely removed by surgery [12]. Later, in 1915, cancer
was induced in a lab animal for the first time at Tokyo University by Yamagiwa and Ichikawa,
aiding in our knowledge of carcinogens (cancer causing agents). Throughout the 20th century
cancer knowledge grew as scientists around the world discovered more carcinogens and viruses
that caused cancer, the genetic code of life, the possibility and then eventuality of mutations to
this code and familial cancer links [12]. Now we are at a place of great understanding where
some cancers are almost completely curable (thyroid and prostate, for example, have survival
rates above 97% [158]). However, progress in some cancer treatments has stalled, and as of
2009, cancer was the leading cause of death in Canada [154] and the second leading cause of
death in the United States [39]. Clearly, much still needs to be done to combat this disease.
Kasia Rejniak and Alexander Anderson published a brief review titled “State of the art in
computational modelling of cancer” in 2011 in the journal Mathematical Medicine and Biology
[140]. They pointed out that while modelling of cancer has been occurring for over 60 years, it
has only recently begun being seen as a real tool in the fight against cancer. In fact, they state:
The reductionist approach that has traditionally guided biological research has
taught us a great deal about the initial steps in cancer development and subsequent
progression and still has great potential as a tool to aid the tailoring of patient-
specific treatments. But given the diversity of favourite genes, proteins or path-
ways and their limited therapeutic success, many cancer biologists are beginning
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to accept that we need to integrate our knowledge (across scales) and start to look
at cancer in a whole new way.” [140]
Rejniak and Anderson, along with many others including Vito Quaranta, Philip Gerlee,
David Basanta, Robert Gatenby, Heiko Enderling, Anuraag R. Kansal, Jose´ Santos and A´ngel
Monteagudo, have been doing this difficult and important work of integrating our knowledge.
They have gathered knowledge gained over hundreds of years into models and simulations
that allow clinicians and computational scientists to work together to battle cancer. Many
cancer models currently exist, including: Anderson et al.’s multiscale mathematical model of
2-dimensional tumour growth [18]; Lloyd et al.’s computational framework for solid tumour
growth, which comprised models at the tissue, cellular and subcellular levels [100]; and Ramis-
Conde et al.’s hybrid discrete-continuum model which looked at tissue invasion by cancer cells
[137]. Models focus on different aspects of tumour growth (including the use of the glycolytic
phenotype [67], evolution of cell motility [68] and confined environments [69]) and employ
different modelling approaches (mathematical, [80], [137], hybrid, [141], [66], agent-based
[106], [157]).
Currently the state of the art in cancer modelling is spread across these different modelling
techniques. A recent review paper looking at cancer invasion discusses the use of both hybrid
discrete-continuous (HDC) models and immersed boundary models of a cell (IBCell). HDC
allows for cells to be modelled discretely but microenvironmental variables such as nutrients
and oxygen to be modelled using reaction-diffusion equations. The IBCell model is benefi-
cial for capturing the morphology of a tumour cell as the cells in this model are deformable
[88]. In addition to these two types of agent-based models, cellular automaton (CA) models are
also used frequently. Gerlee and Anderson created an evolutionary hybrid cellular automaton
model where the cancer cells are modelled using cellular automata to capture the behaviour of
the tissue as a whole, while using an artificial neural network for cell decisions [66]. This type
of hybrid cellular automaton model has recently been built on by Shrestha et al. who used a
similar model to look at large-scale growth of tumours [148]. Recently, CA models have been
used to look at the hallmarks of cancer [1], [25], [143] as proposed by Hanahana and Weinberg
[74], [75].
Many reviews of the field of cancer modelling exist, and readers who wish a broader
prospective are directed to the following review articles: [15], [17], [139]. Here I will out-
line four major works that have lead to the questions addressed in this thesis. These papers are
representative of a path from some of the earliest accurate cellular automata models through to
the current state of the art of CA models with respect to cancer “hallmarks”. These four works
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reflect the journey my research question took. The first paper, by Kensal et al., showed that
simple CA models are capable of achieving complex results – including accurately predicting
time of diagnosis and death. The next works, by Gerlee and Anderson, provided the foundation
of my model. They outlined the lifecycle for CA models of cancer and showed the importance
of accurately modelling oxygen around the tumour. Next, the work of Abbott et al., was the
first to include the hallmarks of cancer in the rule set of the cellular automata. Lastly, Santos
and Monteagudo provided a launching point for my research. They set out to find the rela-
tive importance of the hallmarks of cancer, and looked at the impact of removing each from
a cancer simulation. This lead me to question how removing these hallmarks in pairs, triplets
and quadruplets would impact the system. Each of these bodies of work were influential in
bringing me from an interest in the field to a specific, attainable question, and I will describe
each in detail in order to show both a representation of the field of cellular automata cancer
modelling with respect to hallmarks as well as how my research question came about.
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1.2 Simulated brain tumour growth dynamics using a three-
dimensional cellular automaton
1.2.1 Introduction
When this paper [89], by A. R. Kansal, S. Torquato, G. R. Harsh IV, E. A. Chiocca and T. S.
Deisboeck was published in January 2000, human glioblastoma multiforme (GBM) tumours
left patients with a median survival time of only eight months. Due to the confined nature of the
tumour (typically encased by the skull), GBM tumours were a good choice for mathematical
modelling as they are fairly self contained, spherical tumours.
Another positive about modelling GBM tumours, is that they are able to be accurately mod-
elled as a multicellular tumour spheroid (MTS) (an early stage tumour which is easier to model
than a full grown GBM). Modelling a GBM as an oversized MTS is possible because a GBM,
like a large MTS, is comprised of a large necrotic centre with a surrounding shell of proliferat-
ing cells. Kansal et al. developed a CA model that allows for GBMs to be modelled as MTSs
and included several novel features at the time. The model treated cell division in a new way,
used the Voronoi tessellation to study the dynamics of tumour growth in a cellular automaton
and used a varying density of lattice sites (an adaptive grid lattice). The model is able to grow
from roughly 1000 cells to a size of 1011 cells, the thickness of the proliferative rim and the
non-proliferative shell are linked to the overall tumour radius by a 2/3 power relation which
gives more biologically accurate results and the model included mutant phenotype “hot spots”
in the tumour. This was a very advanced model and a seminal paper.
1.2.2 The model
The lattice
This model uses an underlying Delanuay triangulation lattice structure, which is the dual lattice
of the Voronoi tesselation. To create the lattice a selected number of points are distributed ran-
domly in space. The triangulation is created such that no point is inside the circumcircle of any
triangle (this maximizes the minimum angle in the triangle, helping avoid skinny triangles).
Connecting the centres of these circles creates the Voronoi tesselation.
The lattice used in this model was designed with a variable grid size. The density was
allowed to vary with the radius from the centre of the tumour. Every lattice cell corresponded to
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some number of biological cells. Where the density was high, there would be fewer biological
cells per lattice cell and where it was low there would be more biological cells per lattice cell.
Lattice cells near the center had significantly higher densities than those at the edge to allow
for better resolution. Each cell in the centre of the tumour represented approximately 100 real
cells, however the cells on the outside edge of the tumour each represented close to 106 real
cells. The average distance between lattice sites is represented by ζ and is defined as:
ζ =
1
6
r
2
3 , (1.1)
where r is the radial position where it is being measured. The 23 in the exponent is intended
to incorporate a surface-area-to-volume-like relation in order to better represent the diffusion
of nutrients to the centre of the tumour.
In order to generate the points for the lattice, the random sequential addition (RSA) process
was used. The RSA method checks each generated point to ensure it is not too close to all
the other points. This was used to make sure there were no areas with extremely high density.
They also tried to closely approach the “jamming limit” of the RSA in order to eliminate the
chances of there being a low density spot. The minimum distance between points (Rs) could
vary and was calculated as
Rs = 0.146r
2
3 (1.2)
The proliferation algorithm
The algorithm is designed to grow the tumour from a few cells (approximately 1000 biological
cells) to full macroscopic size. The idealized version of the tumour is a group of concentric
spheres. The inner most sphere represents the necrotic region. This region has radius Rn which
is a function of time, t, and distance from the proliferation rim, δn. The next sphere represents
cells that are alive but in the G0 cell cycle state (a resting state of the cell cycle), and is termed
the non-proliferative region and is also defined in terms of its distance from the edge of the
tumour, δp. In order for the cells to be alive and not necrotic they must have access to nutrients
from the blood vessels surrounding the tumour so the thickness is the maximum distance the
nutrients can diffuse to. The outer, thinnest sphere, contains the actively dividing cells. Each
cell can only divide if there is space available where it will still be able to access nutrients
(again, δp).
Rt is the radius of the tumour. Since tumours are not perfectly spherical, the values of Rt and
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Rn vary depending on the radii of cells on the edge of the model. The value of these parameters
in the paper are the average of the values defined by:
Rt =
∑Np
i=1 ri
Np
(1.3)
Rn =
∑Nn
i=1 ri
Nn
(1.4)
where Np is the number of cells on the edge of the proliferative region and Nn is the number
of cells on the edge of the necrotic core.
Cells that do not lie on the very edge of the tumour are allowed to proliferate, but an al-
gorithm was needed to ensure there was no discontinuous division. The algorithm allows for
expansive growth via intracellular mechanical stress (IMS). Non-tumour cells are treated as
empty cells and can be “filled” by a cancer cell dividing into their space. They are then pushed
into the surrounding area and are not considered. Only if a cell can divide into a space where
nutrients are still available can it divide.
The four main properties being monitored are Rt, δp, δn and pd (the probability of division).
In order to find these as functions of time the simulation utilizes four microscopic parameters:
p0, a, b and Rmax. These parameters effect cell-doubling time, the nutritional needs of growth-
arrested cells, the nutritional needs of dividing cells, and the effects of confinement pressure,
respectively. The algorithm Kansal et al. used to calculate the quantities is as follows:
• Initial Setup: The cells at the center of the grid are set to proliferative, all others are
non-tumour cells.
• At each time step:
– Each cell is checked for type
– Non-tumours cells and necrotic cells do nothing
– Non-proliferative cells that are now more than δn from the tumour’s edge become
necrotic. The edge of the tumour is taken to be the nearest non-tumour cell as
calculated by:
δn = aR
2/3
t , (1.5)
where a is the base necrotic thickness measured in units (length)1/3.
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Table 1.1: Summary of time-dependent functions and input parameters
Functions within the model (time dependent)
Rt Average overall tumour radius Rt =
∑Np
i=1 ri
Np
δp Proliferative rim thickness δp = bR
2/3
t
δn Non-proliferative rim thickness δn = aR
2/3
t
pd Probability of division pd = p0(1 − rRmax )
Parameters (constant inputs to the model)
p0 Base probability of division p0 = 0.192
a Base necrotic thickness a = 0.42mm1/3
b Base proliferative thickness b = 0.11mm1/3
Rmax Maximum tumour extent Rmax = 37.4mm
– Proliferative cells are checked for division. If they will divide is a random process,
though the probability of division, pd, is dependent on the location of the cell (r).
The probability of division is calculated as:
pd = p0(1 − rRmax ) (1.6)
where Rmax is the maximum extent of the tumour.
– If a cell attempts to divide it will try to find an empty space within the proliferative
range (where nutrients are available), which is calculated by:
δp = bR
2/3
t (1.7)
where b is the base proliferative thickness again in units (length)2/3.
– If the cell cannot divide it becomes a non-proliferative cell.
• After a certain amount of the time, volume and radius are plotted as function of time.
Please see Table 1.1 for all of the time-dependent functions used by the algorithm, as well
as the real values used in the simulations.
1.2.3 Results
The simulations were run according to the above algorithm and compared to experimental
data for untreated GBMs on the basis of cell number, growth fraction, necrotic fraction and
volumetric doubling time. The parameters a, b, Rmax and P0 were chosen to fit the test case.
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The data from the simulation matched experimental data quite closely with a 25 mm sized
tumour in both the simulation data and real data at time of death. The growth fraction data
showed 9% and the simulation showed 11% and volume doubling time for the simulation was
100 days and 105 days for the real life data. The simulation was very accurate for tumours
that were essentially spherical. This does not illustrate the more realistic and complex case of
multiple distinct tumour clones. In order to simulate this case, second strain parameters were
defined to be:
p0 = 0.384, a = 0.42mm1/3, b = 0.11mm1/3,Rmax = 37.55mm (1.8)
This second strain has a faster doubling time, roughly 1.7 days as opposed to 4 days in the
previous strain. A mutation in the tumour is chosen as a randomly selected cellular automaton
cell (representing roughly 105 real cells) and is given the parameters above. This second geno-
type represents approximately 0.01% of all the cells. Gradually the second strain takes over
the tumour.
Preliminary results show that this model does fit both experimental and clinical data for
brain tumours. It also shows that for mutational strains to be dominate they need to have a
large competitive advantage, such as the quick volume doubling time shown here.
1.2.4 Conclusions
This model incorporates four parameters and predicts the composition and dynamics of ma-
lignant brain tumours. The results from the simulation match experimental and clinical data
for very idealized tumours. This model incorporates the Voronoi tessellation to create a cel-
lular automaton model and was the first model to do so. The ability for cells that are not on
the tumour border (other cells in the proliferative rim) to divide was new to modelling at the
time and allowed this model to be much more biologically accurate. Also the inclusion of
heterogeneity, by way of different parameters for different cells, was new to this model. The
group modelled very few different parameters but had relatively close to life results. There is
a balance needed between a high level of abstraction that still generates a relatively accurate
model, and a complex model which could be less accurate and has severely increased computa-
tion time and space demands. This model convinced me that a simple model of cancer growth
was capable of achieving complex results – even biologically relevant results. It gave me hope
that it would be possible to create a cancer simulation during the course of a PhD that while
simple, could still contribute to the field in a meaningful way, and provided me with the basic
modelling approach to do that – using cellular automata.
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1.3 An evolutionary hybrid cellular automaton model of solid
tumour growth
1.3.1 Introduction
This paper by P. Gerlee and A. R. A. Anderson was published in February 2007 and describes
a cellular automaton model for modelling the prevascular stage of a tumour [66]. The aim
of the work is to model this early tumour growth where growth is limited by the diffusion of
nutrients. The main goal of the model is for it to include the evolution of subclones within
the tumour. In order to effectively do this, this novel cellular automaton model equips each
cell with a “genotype” that can be mutated as well as passed on to the daughter cells at each
generation. In the model, this genotype controls the behaviour of the cell. The authors believed
they had created a model that is simple enough to be computed in a reasonable amount of time
but that is also complex enough to provide information on the dynamics of clonal evolution.
Each cell is equipped with a feed-forward artificial neural network that helps it decide what
to do at each stage in the model. This network takes environmental variables as input, pro-
cesses it and produces an output telling the cell whether it should grow, divide, die or take part
in other events. These networks are governed by connection weights and thresholds which can
be mutated to allow new cells to have different genotypes.
The microenvironment has been shown to play a big role in tumour development, influenc-
ing both morphology and phenotype. Early selective pressure due to limited nutrients could
impact the later development and invasiveness of a tumour. Tumour hypoxia (caused by lack
of oxygen in the microenvironment) has been shown to be directly linked to tumour morphol-
ogy as well as cancer cell aggressiveness. There is a known pathological link between tumour
morphology and invasive potential. The aim of this model is to allow for clonal evolution in
tumours and then to see the impact of hypoxia and the microenvironment on the morphology
and genetic make up of cancer cells during avascular growth.
1.3.2 The model
This CA model represents a cross section of the tumour and is represented on a two-dimensional
grid where each automaton cell is approximately the same size as a real cell. This is a vast im-
provement on Kansal et al. (2000) where each automata cell represented approximately 100
up to 106 real cells and shows how far computational power had come in seven years. Each
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automaton cell can be empty or filled with a cancer cell. Non cancerous cells are not mod-
elled in order to keep the model more simple and to focus on the effects of oxygen, however it
has been shown that the interactions between cancer cells and host tissue are very important.
This model also excludes direct interaction between the tumour and blood supply as it is to be
modelling avascular growth. All oxygen is supplied by the surrounding tissue, which is more
biologically accurate for avascular growth. In the model each cancer cell is an individual agent.
Each cell decides what its phenotype will be based on the surroundings and its genotype, there-
fore each cell is not just characterized by if it is a cancer cell or not, but where it is located, the
microenvironment and its genotype – again an improvement on other models.
The cell
Each cell is a computing unit that takes as input the microenvironmental factors, processes
them (determined by the “genotype” of the cell), and then develops a phenotype as the output.
Each cell has an artificial feed-forward network that takes the input, processes it and produces
the output, and the actions of each cell are based on this network, the microenvironment and
the interactions between the two. Each cell will have an individual response to stimuli in the
environment. This way, the fitness of a cell is not defined by only what type of cell it is, but
where it is located and the network it is equipped with. For example, cells with the same
genotype (network) but in different areas of the tumour might have different fitness levels. At
the same time, two cells beside each other with different genotypes can have very different
fitness levels as one might have a mutation that allows it to survive better in its environment.
The network
The neural network each cell contains is designed to be an abstract representation of cellular
behaviour and cellular pathways. There is an input layer that takes real numbers (measure-
ments from the environment), a hidden layer and an output layer that determines the action of
the cell. These layers are connected by matrices that can have different weights, representing
the signalling strength of the “receptors” (the input nodes). The hidden layer represents regula-
tory genes, it processes the information then sends this to the output layer, which is thought of
as the phenotype of the cell. This system, as a whole, represents a mapping from the genes to
the behaviour of a cell, and as an extension, altering the weights can be thought of as changing
the level of expression of one of these genes or the strength of a receptor.
There are four input nodes that take the value for the number of neighbours, the oxygen
concentration, the glucose concentration and the hydrogen ion concentration. The input vec-
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Table 1.2: Input and output nodes.
Node Function Variable
ζ1 No. of neighbours n(~x, t)
ζ2 Oxygen concentration c(~x, t)
ζ3 Glucose concentration g(~x, t)
ζ4 Acidity [H+] h(~x, t)
O1 Proliferation P
O2 Quiescence Q
O3 Apoptosis A
O4 Metabolism M
O5 Movement Mov
tor is ζ = (n(~x, t), c(~x, t), g(~x, t), h(~x, t)) where n(~x, t) is the number of neighbours, c(~x, t) is the
oxygen concentration, g(~x, t) is the glucose concentration and h(~x, t) is the hydrogen ion con-
centration. There are also five output nodes. These are the phenotypes for the cell and are:
proliferation, quiescence, apoptosis, metabolism and movement. The behaviour/phenotype for
the cell with the strongest response is chosen. Please see Table 1.2 for an overview of the
nodes, their function and the variable representing them.
Cell metabolism
The metabolic rate of cancer cells is often higher than normal cells, and frequently cancer cells
rely on anaerobic metabolism instead of the more traditional aerobic metabolism [48]. The
anaerobic pathway is 18 times less efficient at producing ATP, and since hydrogen ions are a
by-product of ATP production, in order for an anaerobic cell to produce the same amount of
ATP, it must also produce much more hydrogen [173], [175], [6]. This causes the cell’s envi-
ronment to be more acidic and this may be why cancer cells prefer anaerobic metabolism – the
increased hydrogen ions can kill normal cells.
In order to model cells utilizing different pathways, the anaerobic cells are allowed to con-
sume 18 times the glucose of normal cells and not consume any oxygen. The magnitude of
the network output is then assumed to be proportional to the cell metabolism (higher output,
higher metabolic rate). In order to model this there must be a response that corresponds to
normal metabolism and a function relating this to the network. The authors have created a
“target response” Tr and a modulation function F = F(R), which depends on the response R
of the network. To give the metabolism of each cell, F is multiplied by the base consump-
tion/production rates, and the response R is set to the highest value for the lifecycle nodes. The
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modulation function is:
F = max((k,R − Tr) + 1, 0.25), (1.9)
where k determines the strength of the modulation and the use of max(·, 0.25) makes sure
the cell has a minimal metabolism (no less than a quarter of the initial one).
Quiescent cells consume less oxygen than active cells, so their consumption is divided by
some factor q which is not very well determined yet.
Cell death
Cells can die in two ways: 1) if a cell tries to consume more oxygen or glucose than is available,
it dies of starvation; 2) if the apoptosis node in the network gets the strongest response, the cell
will die.
Cell movement
There is a value ai, which is the internal adhesion value and represents the number of neigh-
bours a cell prefers to adhere to. If the number of actual neighbours is higher than this value
(n(~x, t) ≥ ai) and the movement node gets the highest response, the cell can move.
Proliferation
If the proliferation node gets the strongest response out of the life cycle nodes, the cell can
divide if two conditions are met. The first is that there must be an open space for the daughter
cell to go to in one of the four adjacent CA spaces. If not the cell fails to divide and becomes
quiescent. The second is that the cell must be of proliferation age. Each time a new cell is
created it is randomly assigned a proliferation age between (Ap, Ap/2), where Ap is the base
proliferation age. At each time step, an internal counter Xp is incremented by F (see above)
until Xp Ap. If both of these conditions are satisfied the cell can divide.
Mutations
The number of mutations that will occur is chosen from a Poisson distribution with parameter
p and these are then equally distributed over the matrices and threshold vectors. The mutations
alter values inside the matrix and threshold vectors, which alters connection strength between
the nodes, simulating up or down regulation of receptors or genes in the cell.
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Chemical fields
In this model the researchers have chosen to focus on glucose, oxygen and hydrogen ions for
the chemical modelling. To make it simpler, they are not looking at the decay of these but rather
are looking at the production of oxygen and glucose in the boundary conditions by applying
Dirichlet boundary conditions with constant functions. This is to model the situation where
there is a tumour surrounded by blood vessels that allow for diffusion of glucose and oxygen
and take away the hydrogen ions. The simplified equations for the time evolution of oxygen,
glucose and hydrogen ions are:
∂c(~x, t)
∂t
= Dc∆c(~x, t) − fc(~x, t), (1.10)
∂g(~x, t)
∂t
= Dg∆g(~x, t) − fg(~x, t), (1.11)
∂h(~x, t)
∂t
= Dh∆h(~x, t) − fh(~x, t), (1.12)
where Di are the diffusion constants and the fi(~x, t) give the individual cell consumption or
production of the chemical i = c, g, h for the cell at position ~x at time t. The concentrations are
solved on a grid, and these concentrations are defined for each individual cell. The fi(~x, t) are
defined as:
fi(~x, t) =
0 if there is no tumour cell at that pointriF(~x) if there is a tumour cell at that point (1.13)
where ri are the base consumption/production rates and F(~x) is the modulated energy con-
sumption of the individual cell occupying the automaton element at ~x described earlier.
Cellular automaton
The grid for this model is an NxN grid with a grid constant d that represents the spacing be-
tween cells. The grid points are labelled by a coordinate, ~x = d(i, j), i, j = 0, 1, ...,N − 1. The
partial differential equations mentioned above are discretized using standard five-points finite
central difference formulas with space step d and time step δt. The chemical concentrations are
solved at each time step and all the cells are updated.
At each time step for each cell (each is updated in a random order):
• the input vector is calculated from the environment
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• response is calculated from the network
• the cell consumes nutrients as is required
• cell carries out end point decision (proliferation, apoptosis, quiescence)
If a cell dies via apoptosis, the grid space where the cell was becomes empty. However, if
a cell becomes necrotic, the grid space remains filled by the cell.
Parameters
The parameters can be split up into three main areas in the model: cell behaviour, tissue struc-
ture and modelling parameters. One of the most important is the original cell structure because
these make up the seed cells. The features the group incorporates into the cells to make them
more closely resemble cancer cells are:
• cells perform apoptosis if the oxygen concentration falls below a certain threshold
• cells die if the glucose concentration falls below a certain threshold
• the cell will not divide if there is no space for the daughter
• cells perform apoptosis if the acidity is above a certain threshold
• cells switch to anaerobic metabolism if the oxygen concentration falls below a certain
threshold
• cells are allowed to move if the number of neighbours exceeds the internal adhesion
value
The real values for these thresholds can be found in the paper. After non-dimensionalising
the equations and setting all the parameter values from various references, the group made the
grid of size N = 400 which allows simulation of a tumour with radius 200 cells, which in three
dimensions would be a tumour approximately 8x106 cells.
1.3.3 Results and discussion
Due to the complexity of the model, the group decided to only investigate the dynamics of a
subsystem of the model consisting of the effects of oxygen. Using this “minimal” system they
hoped to see the effects of background oxygen concentration on the system.
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For the lowest oxygen concentration they tested (normal levels divided by 10), cell death
emerged early as diffusion could not get oxygen to the centre of the tumour. Only cells on the
boundary were able to get oxygen leading to a fingering morphology. Cells had to compete
with neighbours for oxygen which lead to this morphology where the proliferating cells were
on the tips of the fingers and all other cells were necrotic or quiescent. This growth is like a
race among the cells for oxygen.
With an increase in oxygen concentration (normal levels divided by 2.5), a slightly fingered
morphology occurred. The tumour grew larger before the centre became hypoxic, after which
point the growth was dominated by a proliferating rim on the outside of the tumour. For normal
oxygen levels, hypoxia occurs late and the tumour grows as a mostly circular tumour with a
small proliferating rim.
In all simulations the tumour begins as mostly quiescent cells and a thin rim of proliferating
cells. This breaks down as oxygen cannot get to the centre of the tumour and cells begin to die.
If there is enough oxygen, the cells leave a homogeneous wave of dead cells behind them as
the proliferating edge grows. With less oxygen, this is not possible, as the proliferating cells
begin to compete for resources. If a cell divides too slowly it may get trapped in the tumour
where it will not have access to oxygen. Also, the tips of the fingers represent the surviving
cells that have the most exposure to oxygen, but since their competition are the other living
cells on other finger tips, these cells differentiate and the tumour is filled with many dominate
subclones. When there is more oxygen, living cells are near each other and compete, which
gives rise to only a few dominate subclones as they take over the surrounding cells. With the
fingered morphology, there can be a different clone for each finger.
Cells in low oxygen environments will sacrifice normal consumption for a low proliferating
age (the two are linked through the response modulation). Proliferation age is under stronger
selective pressure, and although a high consumption increases the possibility of death by star-
vation, this appears to be less important than the advantage of a faster growing cell due to a
younger proliferating age.
Overall, the results match those of other models and experiments which have showed that
low oxygen concentrations created more fingered morphology and more aggressive popula-
tions [19], [18], [130]. The hypoxic environment creates selective pressure and the cells with
slight growth advantages due to mutations tend to create dominate subclones. Low oxygen
concentration also gives rise to phenotypes with a smaller apoptotic potential, in that on aver-
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age cells in low oxygen concentrations tend to be less likely to die from apoptosis. Avoiding
apoptosis is a hallmark of cancer cells [74].
1.3.4 Conclusions
This paper demonstrated that the base level of oxygen affects both the growth dynamics and the
evolutionary dynamics of the tumour. When there is low oxygen levels a fingered morphology
emerges, containing phenotypes that are very far evolved from the original tumour cells. These
are also more aggressive compared to the tumour in normoxic conditions which grows with a
round morphology. The main points are:
• lower oxygen concentrations cause fingered morphology
• fingered morphology tumours have more aggressive cells as they compete for oxygen at
the tips of the fingers
• lower oxygen concentration also results in more diverse subpopulations because cell
clones on different fingers cannot compete directly with each other
• there is higher heterogeneity in populations in harsh growth conditions
• harsh environments give rise to a lower variant in tumour size
• evolution in harsh environments is more directed towards aggressive phenotypes as op-
posed to just larger cells
From this, one can infer that cutting off the blood supply to a tumour could be very detri-
mental to the patient. While the growth of the tumour might be slowed, the cells that do remain
are likely to be very powerful cells. They will be strong enough to survive in hypoxic condi-
tions and possibly will be embedded in normal tissue if very thin fingers have grown.
Shortly after this paper was published, Gerlee and Anderson published a second paper, A
hybrid cellular automaton model of clonal evolution in cancer: The emergence of the gly-
colytic phenotype [127]. This second paper shows a model that is designed to determine the
microenvironmental conditions that lead to a glycolytic tumour. It is a continuation of the
model presented in their earlier work, however it uses the full version of the model unlike the
previous paper. It also includes information on the extracellular matrix which is new to the
model.
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Some cancer cells exhibit an anaerobic phenotype while others have a more typical aero-
bic phenotype. During anaerobic metabolism, oxygen is not used to convert glucose to ATP,
but rather glucose is converted into less ATP with a by-product of lactic acid created. The
anaerobic phenotype is much less efficient and the excess creation of acid can be detrimental to
cells. However, certain cancer cells utilize this anaerobic metabolism and seem to thrive better
because of it. This paper tries to determine under which conditions the glycolytic phenotype
emerges and is successful. Using a model that is on the level of a single cell, a feed-forward
neural network in each cell allows each individual cell to interact with the microenvironment
and grow accordingly. This continuation from the paper above utilizes the full abilities of the
previous model and is extended to include the interaction with the extracellular matrix (ECM).
The model focuses on tissue oxygen concentration and extracellular matrix density, varying
these two parameters to see what combination creates the glycolytic phenotype.
It was found that low oxygen concentrations create tumours with a branched, fingered mor-
phology. A dense matrix was found to create less fingered, more compact tumours. However,
when both conditions were present in the environment (low oxygen concentration and dense
matrix), the tumour was found to switch to the glycolytic phenotype. Therefore, the glycolytic
phenotype emerges from a complex interaction between cancer cells, the microenvironment
and the surrounding tissue.
These papers together provided me with a skeleton of how I could create my cellular au-
tomata model. The provided implementation details that were helpful in creating my own
model, especially the lifecycle they provided. They also showed the importance of modelling
oxygen in the system, which later led me to pair my cellular automata model with a lattice
Boltzmann model of fluid flow. Lastly the authors provided a standard to shoot for, as they
have continued to model in this area and regularly produce interesting papers that look at a
variety of issues surrounding cancer growth.
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1.4 Simulating the hallmarks of cancer
1.4.1 Introduction
This paper [1] is one of the earliest papers to use cellular automata to model cancer hallmarks,
specifically coding the automata rules by using the concepts from the Hanahan and Weinberg
paper, the Hallmarks of Cancer [74], [75]. It was written by Robert Abbott, Stephanie Forrest
and Kenneth Pienta, published in the journal Artificial Life in 2006 and looks at the “dynamics
and interactions” of the Hanahan and Weinberg hallmarks.
Abbott, Forrest and Pienta created a computer simulation of cancer growth titled Cancer-
Sim, which looks at the interactions of cell phenotypes. They were especially interested in
finding the “pathways to cancer” - the order that hallmark mutations are sustained during the
progression from healthy cell to cancerous cell. They found that some mutations have precon-
ditions – other mutations that must occur before or concurrently – in order to be advantageous
to the tumour. They also found that the order in which mutations occurred in their model was
different than those pathways proposed by Hanahan and Weinberg as well as those predicted
in an ordinary differential equation model of tumour growth.
The authors point out that progress on “the war on cancer” has been generally slow. They
also note that research in cancer is often very specific, looking at individual cellular pathways
or components, which means success in these research areas often only impacts a small, spe-
cific group or type of cancer. Hanahan and Weinberg on the other hand present a more general
view of this group of diseases, distilling all cancers down to a set of six phenotypic changes
they refer to as the hallmarks of cancer.
This general set of hallmarks allows for a more unified understanding of cancer progres-
sion, however the authors realize the need to not just understand individual hallmarks but also
their dynamics in a cell or group of cells. They state that the effect of a mutation is often
contextual in that it depends on nearby cells, the environment and the patient. This creates a
disease with many different populations (different both genetically and phenotypically) com-
peting to survive.
Knowing cancerous tumours have a heterogenous makeup of cells, the authors were inter-
ested in how this heterogeneity came to be and what pathways cells took to get there. Specifi-
cally, they were interested in:
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• the relative frequency of different mutational pathways
• how long different pathways took to emerge
• the dependence of pathways on various parameters
They ultimately wanted to determine how much of cancer could be accounted for by the
hallmarks of Hanahan and Weinberg. They hypothesized that if a model of individual cell be-
haviour, as described by the hallmarks, could not give rise to what is seen in vivo in a cancerous
tumour than either the hallmarks are incomplete or the model is incorrectly implemented. If,
however, the hallmarks and individual cell behavior could lead to whole tumour behavior con-
sistent with reality then other phenomena arising in the model could generate hypotheses about
cancer in a more general sense than often occurs in traditional cancer research.
1.4.2 Methods
Overview
CancerSim is an abstract model of cancer growth on the cellular level. The model is contained
on a 3D Cartesian array which represents a tissue volume of 0.1 mm3 growing over a time frame
of approximately 60 years. A variety of parameters (many mentioned below) are changeable
and cells differentiate over time by random mutation. Below, the methods used for modelling
the hallmarks, implementing the cells and implementing the lifecycle are briefly described.
Hallmarks
Hanahan and Weinberg initially proposed six hallmarks: self-sufficiency in growth signals, ig-
norance of anti-growth signals, invasion and metastasis, replicative immortality, induction of
angiogenesis and resistance of cell death [74]. Later, in 2011, they added two new “enabling
characteristics”: genome instability and mutation, and tumour-promoting inflammation. They
also added two emerging hallmarks: deregulating cellular energetics and avoiding immune de-
struction [75]. For a complete overview of all these hallmarks and characteristics, please see
the exposition in Section 2.2. Here I will only explain those hallmarks modelled in CancerSim.
The first hallmark described is a cancer cell’s ability to grow regardless of growth signals –
signals needed by healthy cells to initiate mitosis or cell division. To model this ability, healthy
cells can only undergo mitosis while they are within a predefined spatial boundary. The authors
think of this as the area where growth factor concentration is high enough to sustain growth.
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Cells with the sustained growth hallmarks are able to divide even when outside this boundary.
When cancer grows, the local blood supply is often not set up to handle the extra cells
and once the early tumour reaches 1 - 2 mm in size it begins to die from lack of oxygen and
nutrients [60]. Normal healthy cells cannot induce the creation of new vasculature (called an-
giogenesis), however this death process in a small tumour can activate angiogenesis and cause
new vasculature to grow towards the tumour, infusing it with fresh oxygen and nutrients. This
ability of cancer cells to induce angiogenesis is modelled similarly to the self growth hallmark
in CancerSim. Cells within a certain boundary are seen to have enough nutrients, while those
outside of it do not. Those without enough but with the sustained angiogenesis hallmark acti-
vated can “induce angiogenesis” which just means (in the model) that those cells now do have
enough nutrient even when outside the predefined nutrient boundary.
Along with needing signals to divide, healthy cells also receive signals to stop growing,
allowing them to enter a mature, post-mitotic stage. One of the ways a cell receives this sig-
nal is through contact inhibition, which turns off growth for a cell when it is surrounded by
many others. Cancer cells, in contrast, ignore this contact inhibition and will continue to grow,
potentially causing overcrowding and overgrowth. In CancerSim, a cell on the grid has 26
neighbours (needing only to touch by at minimum a corner to be considered a neighbour). If
all 26 neighbour slots are filled with a cell, the center cell will stop growing due to this “contact
inhibition”. Cells with the ignore growth inhibition hallmark will attempt to grow anyways,
entering into a battle for survival with one of its neighbours, winning it with some probability
of success that is a tuneable parameter.
Healthy cells also have a mechanism for determining cell damage and if the damage is too
great they can induce apoptosis (programming cell death to prevent the damage from being
passed on to daughter cells). Cancer cells also manage to avoid this check, often dividing with
many mutations. To simulate this, all cells about to undergo mitosis in CancerSim are checked
for genetic damage. Damage is detected with a rate of n/e where n is the number of mutations
the cell has sustained and e is a tunable parameter. Cells without the avoid apoptosis hallmark
are killed if damage is detected, while cells with the hallmark completely avoid this mecha-
nism. The n/e probability means that death by apoptosis is more common in cells with more
genetic damage (mutations).
Yet another barrier to cancer is a cell’s limited replicative potential. Even in the presence
of growth factor, a cell cannot grow indefinitely. Cells have a limited number of replications
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(approximately 50 - 70 in humans and differing in other organisms) that, once reached, stops
the cell from replicating further. The mechanism controlling this is the telomere – a short bit of
DNA on the ends of chromosomes that shortens with each division, eventually becoming too
short to allow for division [74]. Cancer cells can extend their telomeres to effectively become
immortal [74]. This is modelled by a cell variable that tracks telomere length / number of di-
visions. Each division decreases this number by one, and when it reaches zero the cell is no
longer allowed to divide. If the cell has acquired a mutation activating the limitless replicative
potential hallmark, the simulator effectively ignores this greater than zero requirement.
While not identified as a hallmark, Hanahan and Weinberg have classified genetic instabil-
ity as an “enabling characteristic” of cancer. The authors decided to include this attribute of
cancer in their model. It is known that tumours are made up of a variety of cell phenotypes
with all different mutations and it appears genetic instability allows for acquiring of changes
that can be beneficial and confer a selective advantage. This means genetic instability can
assist in generating this heterogeneous group, although the exact mechanisms of how are rela-
tively unknown. In the model, cells that are “genetically unstable” are said to have a “mutator
phenotype” and gain more mutations with increased likelihood.
The model
CancerSim is an agent based (a type of model which simulates the actions of autonomous
agents), three-dimensional highly abstract model of very early cancer growth implemented in
C++. All cubes in the 3D space can either be empty or filled with a cell. Along with the cancer
cells, CancerSim also models vasculature, which can pass through any 3D cube, whether it has
a cell or not. Both the vasculature and the cancer cells grow according to internal rules, in a
roughly cellular automata fashion.
At the time of publication the authors were able to feasibly model roughly 1,000,000 cells,
which corresponded to approximately 0.1 mm3. While most tumours are not recognized by
traditional methods until they are closer to 1 cm3, it was not computationally feasible to model
that many cells.
CancerSim starts with 1 single cell in the center of the simulation. At each cycle through the
simulation the cell can either die via apoptosis, replicate or signal angiogenesis. The simulation
ends when any one of three conditions are met:
• All cells die from old age
1.4. Simulating the hallmarks of cancer 23
• 90% of the population is cancerous
• Some predefined number of steps has passed (the simulation could run forever if cells
become immortal but healthy cells continue to grow as well, preventing cancer from
completely taking over)
In order to model many cells in a reasonable amount of time, the authors chose to make
each cell a highly simplified version of the biological cell, where the “genotype” is a boolean
vector where each bit represents a phenotypic hallmark which is either on or off for that cell.
Some state info, such as the length of the telomeres or the nutrient or oxygen around the cell,
are stored in the cell along with this genotype vector. During the simulation, each cell goes
through a rough version of the biological cell cycle. The cell enters G1 phase (a time of cell
division when the cell grows and creates building blocks needed for DNA replication) if there
is space around it for it to divide into. If the cell is successful in dividing, the daughter cell
has all of the same hallmarks, unless a mutation occurs. Mutations occur with some parameter
probability. At the G2 check phase (a point in the cell cycle when the cell makes sure it is
ready to divide) apoptosis could occur, again based on some probability set as a parameter.
Once division is over, the cells occupy the original space and one new neighbour space, and
both are in the M phase of the cycle.
The authors included a highly simplified but quite elegant model of the vasculature sur-
rounding tumour growth. Initially the simulation has 1 cell in the center, and that simulation
cube also has a capillary. As cells grow, they get oxygen and nutrient from nearby vasculature
and it diffuses towards the cell declining as it gets farther away according to the power law.
When a cell has too little oxygen or nutrient it can signal for angiogenesis. This causes a new
capillary to be added in a cell adjacent to the nearest existing capillary. This simple growth rule
always creates a continuous vasculature with branches. While branches can occur anywhere,
which is not the case in vivo, it creates fractal structures that look very similar to those seen in
nature. Cells can only initiate this process when inside the predefined vasculature boundary,
unless they have the angiogenesis hallmark activated.
To update the cells, instead of doing so with each time step (which would be computation-
ally expensive when the vast majority of cells would not qualify for an update at every time
step), CancerSim uses an event queue. Each cell has a future event scheduled during the current
event for some time point in the future. At every iteration of the simulation the nearest event
in time is processed.
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A variety of parameters are required to run a model such as this. However, since the model
presented here is so abstract, many parameters do not have a “real life” counterpart. This makes
setting up the model challenging. All hallmarks had the same probability of getting mutated,
however there were parameters associated with most hallmarks that could vary. With the wrong
parameter a hallmark could basically become useless, but could also become extremely pow-
erful, almost ruling out the other hallmarks. In order to find the best possible set of parameters,
the authors did an 8-dimension parameter sweep 3 times with 1458 different parameter settings
(a total of 4374 runs). This resulted in a set of parameters they published for future modelers.
Lastly, the authors did supply a rough visualization tool for the model. It represents the
tumour in 2D but is moveable, showing each cell as a square. Since squares pack together
completely one can only see the exterior surface of the tumour, which is useful for rendering
speed. However, if desired, a user can select to see inside the tumour.
1.4.3 Results
Initially the authors ran 100 simulations with the set of parameters they discovered in their pa-
rameter sweep, only varying the random number generator seed. They were interested in what
order the mutations appeared – the order often being referred to as the “pathway to cancer”.
Hanahan and Weinberg stated that “virtually all cancers must acquire the same six hallmark
capabilities” which the Abbott et al. model does, however the pathway to this end state could
be varied. In fact, even if every cell acquired all 6 mutations, there would still be 720 different
possible pathways. The authors were interested in how the cancer arose and what combinations
of hallmarks were dominant at the end of growth (a dominant pathway is one shared by 50%
or more cells in the tissue at the end of simulation).
The authors noticed many interesting things about the pathways. By varying parameters
they noticed dominant pathways would arise with different probabilities based on the initial
base mutation rate. A low mutation rate allowed for more ecological dynamics. If the mutation
rate was low, the initial, or close to initial, mutation would dominate as long as it was relevant.
Once it was no longer as advantageous, it would die off and a new mutation that conferred
more advantages at that particular growth phase would begin to take over. High mutations
rates instead made it so a single mutation had less of an overall impact, and different mutations
could arise more easily.
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Since low (and more biologically likely) mutation rates seemed to create a tumour with a
dominant pathway, the next question was whether a particular pathway repeatedly dominated.
In one set of 100 runs, 96 of the runs finished with cancer and 90 of those had a dominant
pathway. More interesting than that is the fact that all but one of those was formed from some
permutation of the same 4 hallmarks, and only 7 different dominant pathways existed at all! In
fact, one particular pathway dominated in 48% of the cancerous runs. Another interesting re-
sult that was sustained angiogenesis hallmark was not present in any of the dominant pathways.
Many angiogenic cells were produced, however after they assisted in getting new vasculature
set up they were not particularly advantageous and did not become the dominant group. An-
other hallmark not very common was genetic instability, which in CancerSim is only weakly
selective. It does not convey any advantageous ability except the ability to potentially get more
hallmarks, so it does not assist well early on.
Conversely, evade apoptosis was in every dominant pathway. It never occurred first but
became advantageous early on when cells had accumulated damage and would be susceptible
to apoptosis. Limitless replication usually occurred first. This surprised the authors as they
thought an initial telomere length of 100 would mean cells would not be under much pressure
to avoid becoming senescent. However the authors hypothesized that since cells with muta-
tions have a high turnover as they are being targeted by apoptosis, then having the opportunity
to replicate many times could be advantageous.
Lastly, the ignore growth inhibition mutation was near the end of the pathway, as it be-
comes advantageous once other cells have taken up most space.
In addition to the aggregate data from multiple runs, the authors also describe one particular
run as an example of how mutations come and go early on before they are advantageous, and
then how certain mutations eventually take over the growth. This is an enlightening walk
through a possible progression of cancer and interested readers are pointed to the paper to read
more [1].
1.4.4 Discussion
The authors point out that the pathways to cancer they discovered were different than those
Hanahan and Weinberg proposed. Counter to CancerSim, Hanahan and Weinberg had insen-
sitivity to anti-growth signals early on with limitless replication towards the end. The authors
point out a few possible reasons for this discrepancy:
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• The phenotypes may have been modelled incorrectly: the authors made many simplifi-
cations and assumptions that may have been incorrect
• The parameters could have been incorrect: the parameters have a large impact on how
powerful each hallmark is, and if they were incorrectly chosen or not biologically rele-
vant that could change the outcomes very much
• Hanahan and Weinberg’s pathways could have been incorrect or insufficient: perhaps the
six hallmarks are not enough to model cancer, or the pathways found were incorrect
The authors do point out that another model, an ODE model of cancer pathways [152], also
found a different pathway and so perhaps modelling and implementation details are not the
problem (as these were implemented very differently).
For future work, the authors suggested perhaps adding cancer stem cells to the model. It
has been hypothesized that certain cancer cells have the ability to regenerate a whole tumour
if it is almost completely destroyed, or if those cells migrate to a new location. If this is true,
these cells would need to be destroyed to eradicate cancer. They also recommend breaking
down the hallmarks into steps and modelling those individually, and adding a model of tissue
invasion and metastasis.
The authors recognize that this is an early version of a highly abstract model, however they
still found some interesting phenomena from studying it.
• Discrepancy between Hanahan and Weinberg’s results and their own: There are many
reasons this could be, pointed out above, however one possible reason seems to have
been left out. Perhaps the differences are due to a relatively small number of runs. Only
100 runs were studied to find those pathways. Since there are more than 200 different
kinds of cancer itself, all of which have different tumours with potentially different cell
groups, it is conceivable certain cancers have certain dominate pathways, and others
have different ones. It is possible both Hanahan and Weinberg and Abbott, Forrest and
Pienta could have found a pathway to cancer. Perhaps factors like tissue location, age,
environmental damage, etc, also impact the pathway, which could explain why different
types of models and research result in different pathways.
• The role of limitless replication mutation: This appears early in their simulations as cells
that have acquired mutations turn over quickly. They believe this signals a complication
in cancer treatment. Obviously cancer cells need to be killed, but the act of killing
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them might select for stronger cells. This has been seen in vivo. The childhood brain
cancer, meduloblastoma, has an 80-90% survival rate when found early. It is treated
with everything possible. If then the cancer ever recurs it has a nearly 100% fatality
rate [23]. This is because any surviving cells that repopulate a tumour are most likely
immune to the earlier forms of treatment, since they survived the first time.
1.4.5 Conclusions
This paper was an interesting first step in the area of modelling the hallmarks using an agent-
based model. The large parameter sweep set the stage for future models (such as those by
Santos et al., described below [143]) and provided me with many needed parameters. The idea
of looking at individual hallmarks and how they built up to the whole tumour using a model
was quite inspiring to me, and I believe has great potential for learning more about how cancer
operates in general. Since cancer is such a varied and complex disease, anything we can know
that transcends location and type could be quite beneficial for large scale treatment, diagnosis
or prevention. Abbott, Forrest and Pienta began a research trajectory that I hope to continue.
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1.5 Study of cancer hallmarks relevance using a cellular au-
tomaton tumor growth model
1.5.1 Introduction
The last paper I will review in this introduction to the field is by Jose´ Santos and A´ngel Mon-
teagudo. It was published in 2012 in Lecture Notes in Computer Science, after it was presented
in the conference Parallel Problem Solving in Nature [143]. The authors were motivated by
both the previously mentioned paper by Abbott et al. [1] and the paper Computational anal-
ysis of the influence of the microenvironment on carcinogenesis by Basanta et al. [25]. The
paper aims to identify the relative importance of each hallmark on overall cancer growth, and
attempts to do so by simulating cancer growth with all hallmarks present, all but 1 hallmark
present, and only 1 hallmark present at a time, with varying parameters. They use a 3D cubic
lattice which is initially empty space, and begin with 1 healthy cell. Following closely the
model shown by Abbott et al., they allow for that single cell to begin the whole system, us-
ing an event queue to track mitotic events. The emergent behavior of the system is that of a
cancerous tumour when the parameters are chosen in such a way to allow for cancer to grow.
They use parameters similar to both Abbott and Basanta, and do a number of experiments on
the growing system.
The authors remind us that Hanahan and Weinberg point out that while some hallmarks
have helped identifiy potential therapeutic targets, they have not been entirely successful as
cancer is adept at developing resistance to drugs which only target one property of cancer.
They say that therefore, perhaps simultaneous targeting of more than one hallmark would be
more beneficial [74], [75]. This lead Santos and Monteagudo to wish to identify which of the
hallmarks are most critical to tumour growth. While the paper has no statistical proof of the
significance of their results, I found the idea very interesting and this paper was the most influ-
ential on my ultimate choice of thesis question.
1.5.2 Methods
As mentioned above, the methods are closely related to those described previously from Abbott
et al. [1]. Each cell in the model lives on a cubic lattice and has a “genome” that is a collection
of hallmarks and cell specific parameters.
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The hallmarks considered
Similar to Abbott et al., Santos and Monteagudo did not model every one of the hallmarks
introduced by Hanahan and Weinberg [74], nor each of the emerging hallmarks or enabling
characteristics introduced in their updated paper, The hallmarks of cancer: the next generation
[75]. They chose not to include hallmarks that are more relevant during later growth phases,
such as mitosis and tissue invasion or tumour-induced angiogenesis. They also did not con-
sider reprogramming of cell energetics, tumour promoting inflammation or evading immune
destruction. The hallmarks incorporated into the cell’s genome in this model include:
• Self Growth (SG): Cells with this hallmark are allowed to grow outside the predefined
boundary of “growth factor”, which is present in 85.7% of the total simulation growth
space volume.
• Ignore Growth Inhibition (IGI): Typically, cell growth stops once the neighbouring space
is full. Cells exert a pressure on neighbouring cells that causes them to stop growing, a
way of signalling that the space is full and no more growth is needed. Cancer cells are
often able to ignore this signalling and continue to grow, pushing other cells out of the
way to make room.
• Evasion of Apoptosis (EA): Cells with this hallmark are able to completely avoid the
cell mechanism of self death that is sometimes initiated in response to overwhelming
cell damage.
• Effective Immortality (EI): The authors pose a limit on the number of times a healthy
cell can divide in their model (ranging from 35 to 100). This represents some of the
biological activity of telomeres, which shorten with every cell division and stop division
once they reach a certain size. In this model, cells with the EI hallmark are able to
continue to divide regardless of whether they have reached their “limit”.
• Genetic Instability GI: Seen as a reason for the high number of mutations in cancer,
genetic instability allows for accumulation of mutations (and possibly hallmarks) at an
increased rate. Cells with this hallmark in the model have an increased base mutation
rate, meaning they can accumulate hallmarks more quickly.
Event model
The driving force of the model is cell mitosis, which for each cell is kept track in one large
event queue. The initial starting cell has a mitotic event scheduled for 5-10 time steps in the
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future (representing the different cell division lengths, which Santos and Monteagudo say can
range from 15 - 24hrs) and after that each cell has an event scheduled and the model goes so
long as events are currently scheduled. The cellular automata on the model can exist in 2 states:
alive or dead. When they are alive, they can also be going through mitosis, but that is for a
short period of time taken up during 1 event, not a state the cell remains in for any more than 1
moment. When an event is popped from the queue, there are a set of tests that take place:
• Random Cell Death Test: It is possible that any cell could die randomly, based on a given
probability (provided in the paper and varied for different runs of the simulation)
• Genetic Damage Test: If the cell has sustained any damage, there is a chance for random
death. This chance increases with the number of mutations. Cells with the EA hallmark
will not be killed regardless of the outcome of this test
• Mitosis Tests: A collection of tests which all must be passed for a cell to divide
– Growth Factor Test: The cell must either be within range of growth factor or have
the SG hallmark activated
– Ignore Growth Inhibition Test: The cell must either have empty space, or have the
IGI hallmark activated
– Replicative Potential Test: The cell must either have some “telomere” left (variable
keeping track of number of remaining divisions must not be at zero) or have the EI
hallmark activated
• If mitosis occurs: Mutations can possibly be sustained by the parent or daughter cells and
the two cells both have mitotic events scheduled for the future and added to the queue
• If no mitosis occurs: The original cell has another mitotic event scheduled and added to
the queue
It is important to note that Santos and Monteagudo have followed the rule of Abbott [1]
and stipulated in their model that once a hallmark has been activated, no other mutations can
inactivate it.
1.5.3 Results
The authors tracked total healthy cell and cancerous cells numbers, as well as the number of
cells with each hallmark activated, over three different experiments: growth under different
parameter values including high and low rates of mutation and the parameter set presented by
1.5. Study of cancer hallmarks relevance using a cellular automaton tumor growth model 31
Abbott et al. chosen to “facilitate the appearance of cancer cells” [1]; growth numbers when
one hallmark is missing from the simulation; and growth numbers when only 1 hallmark is
available for activation in the simulation. The numbers presented were all the average of 5
runs. The execution and results of each are described in more detail below.
Hallmark accumulation for different parameter sets
The authors used default parameters (provided in the paper) with a mutation rate of both 100
and 1000 (during any mitotic event, there was a 1/m chance of developing a mutation) and
tracked the total number of healthy cells, cancerous cells, and cells with each type of hallmark
activated. They found that with m = 1000, the cancerous cells did not “take off” and healthy
cells dominated the growth. With m=100, cancerous cells quickly outnumbered healthy cells,
and the evades apoptosis (EA) hallmark was most dominate in the group. The second most
common hallmark was ignores growth inhibition (IGI). The authors believe with high muta-
tion rates cells need the EA hallmark in order for any cancerous cells to survive, since they
quickly accumulate enough hallmarks to greatly increase their chances of dying from apopto-
sis. Also, the authors think IGI becomes important as it allows growth to continue once the
space is almost full. With the lower mutation rate, Self Growth (SG) was more dominant than
either EA or IGI. This makes sense since with lower mutation rates, cells would be less likely
to be killed by apoptosis and therefore not need to avoid it as much, and cells might be less
aggressive and so happy to grow slower so long as they can continue to expand outward (an
ability conferred by SG).
When the authors used the parameter set provided by Abbott et al. in [1], they found other
hallmarks to dominate. The parameter set lowered the telomere length from 100, to 35, and
changed m to be 100,000. This time in the simulation, cancer cells never dominated (up to
time step 5000) however they did steadily increase in number. The most dominant hallmark
was effective immortality (EI). Other hallmarks present in large number at time 5000 were EA
and SG. The other hallmarks were present in such small amounts that they are not detectable
on the graph presented. Due to the drastic decrease in max telomere length (100 to 35), it is
not surprising that EI would dominate to such a large degree.
Next, the authors wanted to investigate the relative importance of each hallmark, and so
performed the same growth experiment (growth to 1000 time steps for m=100) with each hall-
mark missing. They looked at the total number of cancer cells that managed to grow with the
hallmark missing and infered importance based on the decrease in cancer cells from the base-
line, that is, all hallmarks being available for activation. For m=100 (a high mutation rate),
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they found the most critical hallmark to be EA. This again is not surprising since with a high
mutation rate cells would be highly susceptible to apoptosis, so avoiding it would be highly ad-
vantageous. The next most important was IGI. The authors suggest that once time hits roughly
200 time steps space is mostly full, and so without IGI cells cannot continue to grow (except
on the very outer limits, and only there until they run out of growth factor). A close third in
relevance at this mutation level was genetic instability (GI). Without it cells would have fewer
mutations over all and therefore less hallmarks. Since a cell needs at least 1 hallmark activated
to be considered cancerous, it is not surprising that without GI there are less overall cancer cells.
Using the same set of parameters they investigated what happened when only 1 hallmark
was available for activation. In this case they found that again EA and IGI were most relevant
to the simulation. Now however GI is completely insignificant, as the only real benefit it con-
fers is the ability to accumulate hallmarks faster and in this experiment only 1 hallmark could
exist in the system at a time.
Lastly, they repeated the one-hallmark-missing and one-hallmark-present experiments with
the parameter set given in Abbott’s model [1]. Now that the mutation rate was much slower
and the telomere length much shorter, the only hallmark that causes cancer growth when only
one is included is EI. This effect is even more pronounced than when only one hallmark was
present in the m=100 parameter set. This parameter set is chosen to help facilitate cancer, and
yet the simulation has removed almost everything that defines cancer, so it is not surprising
that the simulation fails to produce cancer in almost every instance when all but one hallmark
is removed. With these parameters however the impact of removing any one hallmark seems
to be fairly uniform. Aside from removing EI (which basically obliterates any cancer growth
whatsoever), removing any hallmark has as small impact on the total number of cancer cells
compared to any other. This again shows the huge power imbalance in the hallmarks due to the
choice of parameters.
1.5.4 Conclusions
The authors set out to determine the relative importance of each hallmark included on overall
cancer growth. It was shown that different parameter sets change the relative importance. They
concluded by saying that “the simulations can help to analyze what are the most relevant hall-
marks which can be targeted in each multicellular system simulation”. While this slightly over
states the contribution of the paper, a side effect of their parameter choice emphasizes an even
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bigger contribution.
While the paper lacked any statistics (so one can’t say if one hallmark is really more im-
portant statistically), it did show plainly that the choice of parameters had a huge impact on
relative importance. It was not at all surprising that the only hallmark that made any impact
on the system when telomere initial lengths were shortened to 35 was EI, since with telomeres
that short, cells without it would quickly be stunted. A lot of the results in this paper could be
artifacts of parameter selection. Aside from the over-dependence on EI, IGI also played a large
role. This may have been for two reasons. One, the simulation was almost completely full of
growth factor (85.7% of the space had growth factor), and so the relative roll of self growth
(SG) may have been artifically down played, making IGI look more important as the real fight
for growth space was within the tumour. Secondly, in real systems oxygen availability has a
big impact on growth. Often the centre of a tumour dies from a lack of oxygen and actively
proliferating cells are only on the very rim where oxygen is available. This would greatly de-
crease the importance of IGI as cells on the boundary would automatically have space. It might
also increase the importance of SG as cells might reach the boundary faster.
However, the fact that many of the results could be artifacts of parameters is a great result in
and of itself! Since the authors are trying to model a generalize tumour, using the hallmarks of
cancer which are common across almost all cancers, it is extremely challenging to pick specific
parameters. They cannot use ones from any specific cancer without impacting the generaliza-
tion of the model. This has a direct application in medicine. Different cancers from different
patients, in different parts of the body and different tissues, may all have different “parameter
sets”. For example, the cells may have different division rates, mutation rates, division maxi-
mums, etc. Because of this their treatment may need to be altered, as we can see that different
parameters expose a different “Achilles heel” in cancer growth.
While this paper had some shortcomings, it was an introduction to this idea and the authors
have since expanded it to look at other properties of cancer growth including stem cell abilities
[114], [115]. Of all the papers, it excited me most as I have always found the hallmarks of
cancer to be fascinating and have wanted to create a broadly applicable model of cancer. I
also noticed that Santos and Monteagudo said they wanted to find the relevance of hallmarks
because Hanahan and Weinberg had noted cancer’s ability to develop resistance to a particular
treatment, and therefore multiple treatments should be used. I found it odd that the authors
stopped at knocking out just one hallmark, and thought investigations were needed to see the
impact of knocking out multiple hallmarks together. Using the hallmarks as part of the cellular
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automata rules seemed brilliant, and excited me to create my own model based on the work
of both Abbott et al. and Santos et al. which had more hallmarks, relevant oxygen, and an
investigation of targeted combination knockouts.
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1.6 Overall conclusions
These four works offer a brief but fairly representative look at the history of cancer modelling,
from the perspective of the modelling approach I will be employing in this thesis. The initial
paper, Simulating brain tumour growth dynamics using a three-dimensional cellular automa-
ton by Kansal et al. shows the early promise of cancer modelling. Their model used only four
varying parameters (cell-doubling time, nutritional needs of growth-arrested cells, nutritional
needs of dividing cells, and the effects of confinement pressure) and was able to model a simple
real life case, matching tumour doubling time and size of the tumour at death almost exactly.
They were the first model to allow cells not on the boundary to divide which gave the model
another element of realism previously missing. In addition to this, they allowed cells to have
different parameters, modelling a heterogeneous tumour type, yet another unique feature of the
Kansal et al. model. This model was basic in its chosen parameters but well thought out and
the best for the time in its abstraction. It set the stage for many future models and solidified the
theory that a simple, well abstracted model could get biologically relevant results.
Gerlee et al.’s work initially sparked my interest in this area, actually putting me on the path
for this thesis. They set out to model early tumour growth, at the prevascular growth stage, in-
corporating fairly advanced “genotypes” for each cell that could be passed on to daughter cells
with each division. This model was simple enough that it was computationally feasible at the
time (2007) but complex enough to actually provide some insights into the interesting concept
of clonal evolution. To study this clonal evolution, Gerlee and Anderson specifically looked
at the impact of nutrient diffusion, finding that lower oxygen concentrations caused fingered
morphology and more aggressive cells. It sparked thoughts on the interesting idea of tumour-
induced angiogenesis (the development of new blood vessels caused by tumour growth). It was
known that angiogenesis gave a tumour fresh oxygen and nutrients as well as a network with
which to travel through the body. One would assume this could only be detrimental. However
this model revealed that low oxygen to a tumour could possibly select for a more aggressive tu-
mour, which could be even more dangerous than an oxygenated one. Many more models were
put forth after this investigating the impact of oxygen, vascularization, etc, and encouraged me
to study in more detail the impact of oxygen availability on cancer growth.
Building on this model, Gerlee and Anderson published another paper looking at the im-
pact of nutrient availability, specifically looking at what kind of microenvironmental conditions
would lead to a glycolytic tumour (one in which many cells are getting energy via anaerobic
glycolysis). They introduced elements of the extracellular matrix on top of what was already
36 Chapter 1. Introduction and Literature Review
included in the previous model. The results of this model gave a rough framework for what
kinds of microenvironmental conditions (meaning properties like oxygen availability, acid and
glucose levels, and density of the extracellular matrix) lead to what properties in the tumour
(such as glycolytic or not, how quickly a necrotic core appeared, how soon a quiescent rim
appeared, etc). This model encouraged me more to study the impact of oxygen, and the gly-
colytic phenotype related well to the emerging hallmark of cancer reprogrammed metabolism,
which I have incorporated into my model.
The last two papers, Simulating the hallmarks of cancer by Abbott, Forrest and Pienta [1]
and Study of cancer hallmarks relevance using a cellular automaton tumour growth model
by Santos and Monteagudo [143] introduced me to the idea of modelling Hanahan and Wein-
berg’s hallmarks of cancer [74], [75] in order to learn about the growth dynamics of early
tumour growth. Using the hallmarks to model the tumour allows one to model the most basic
principles that are shared by almost all tumours, hopefully giving unified results that are appli-
cable to a variety of cancer types.
Abbott, Forrest and Pienta published their model in 2006 and looked at “pathways to can-
cer” - the order that hallmarks were acquired during progression from healthy cell to cancerous
cell. They came up with many simple abstractions that allowed them to model 5 of the 6 hall-
marks of cancer, as well as genetic instability, using cellular automata. They also included a
simple but elegant model of tumour-induced vasculature that is similar to what I used in this
model. They chose and validated a set of parameters for modelling hallmarks that Santos and
Monteagudo [143] have used and that I have also used as a jumping off point in the following
models.
Overall, these works present a historical and informative look at the progression of cancer
models in the last 15 years. All have influenced the model presented throughout this thesis
in some way and were unique papers in the field. These papers greatly excited me and gave
me the question I posed in this thesis: how do cancer hallmarks impact overall growth in a
simulation with accurate oxygen modelling? I appreciate their contribution and hope to have
even a small amount of the impact they had in the future.
Chapter 2
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2.1 Introduction
I have created a highly abstract cellular automaton model of early cancer growth with a dy-
namic binary fluid model of oxygen flow in blood that investigates the impact of knocking out
pairs of “cancer hallmarks”. As of 2009, cancer was the leading cause of death in Canada [154]
and the second leading cause of death in the United States [39]. While much time, money and
research are dedicated to cancer, the statistics are still grim, with little to no progress in some
cancers – for example, there has been no significant improvement in 5 year survival rates of
pancreatic cancer since 1971 in England and Wales, with similar numbers in North America
[38].
While the traditional reductionist approach to studying cancer has been successful in target-
ing some forms of the disease, new approaches are needed that can study cancer across scales
[140]. In silico modelling of cancer is a nascent approach available to attack this problem.
Specifically, multiscale in silicio modelling is a powerful tool for cancer simulation as it allows
modelling at the cellular level as well as at the fluid level in order to accurately model oxygen
flow. The availability of oxygen is one of the most critical factors in whether a tumour remains
in the relatively safe avascular growth phase or switches to the more deadly vascular growth
phase. A small, avascular tumour (approximately 1-2mm) cannot support its own growth and
will begin to die unless new vasculature is developed to deliver oxygen and other nutrients [60].
If angiogenesis (the development of new vasculature) does occur, the tumour will have a di-
rect supply of oxygen and nutrients, allowing almost exponential growth, and providing a direct
route through which to spread in the body. Since oxygen availability is one of the key factors in
whether the tumour becomes vascularized, modelling both scales (cellular level and fluid level)
provides a more realistic model. Many cancer models currently exist, including: Anderson et
al.’s multiscale mathematical model of 2-dimensional tumour growth showing harsh microen-
vironments can produce fingering outlines and aggressive subclones (often seen in vivo) [18];
Lloyd et al.’s computational framework for solid tumour growth, which comprised models at
the tissue, cellular and subcellular levels [100]; and Ramis-Conde et al.’s hybrid-discrete model
which looked at tissue invasion by cancer cells, modelling the cells discretely and the spatio-
temporal interactions of variables using PDEs [137] but many do not have a strong focus on
oxygen modelling beyond simple diffusion [18], [137], [106].
Models focus on different aspects of tumour growth (including the use of the glycolytic
phenotype [67], evolution of cell motility [68] and confined environments [69]) and employ
different modelling approaches (mathematical [101], [80], [137], hybrid [54], [141], [66],
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agent-based [157], [172], [106]). Readers who wish to know more are directed to the fol-
lowing review articles: for a review of three hybrid models and how they can be used to bridge
scales and relate to one another, see [15]; for more on the field of integrative mathematical
oncology, see [17]; lastly, for a review of hybrid models, see [139]. One type of agent-based
model that has gained popularity uses cellular automata to model the states, and state transi-
tions, of individual cells [135], [150], [89], [133]. These models have been used to look at the
hallmarks of cancer [1], [25], [143] as proposed by Hanahan and Weinberg [74], [75].
Today, survival rates for cancers vary widely, as different cancers are approached in dif-
ferent ways. For example, the 5 year survival rate as recorded from 2003-2009 in the United
States for prostate cancer, breast cancer, colon cancer, lung cancer and pancreatic cancer were
99.2%, 89.2%, 64.9%, 16.6% and 6% respectively. While different cancers are approached dif-
ferently (surgery, radiation, chemotherapy, brachytherapy, etc) and have different survival rates,
Hanahan and Weinberg proposed that almost all cancers actually share six common phenotypic
changes: self sufficiency in growth signals, insensitivity to anti-growth signals; avoidance of
programmed cell death; limitless reproductive potential; sustained angiogenesis; and tissue in-
vasion and metastasis [74]. More recently, in 2011 they updated this list to include two new
hallmarks: deregulated metabolism and evading the immune system [75]. They also proposed
two “enabling characteristics” of cancer: inflammation and genetic instability. These general
hallmarks and characteristics of cancer have been investigated as potential treatment targets for
cancer since a drug targeting these issues might be successful with multiple types of cancer
[75].
Both Abbott et al. and Santos et al. have developed models looking at these hallmarks [1],
[143]. Abbott et al. (as discussed extensively in Section 1.4) primarily focused on looking at
the order in which hallmarks were acquired in the growing tumour. Abbott’s results differed
from the pathway to cancer proposed by Hanahan and Weinberg, as did the results of an ordi-
nary differential equation model looking at the pathway to cancer [152]. Abbott’s model was
an agent based model that simulated the progression of cancer from a single healthy cell to a
tumour with at least 90% cancer cells. They found that hallmarks that confer an advantage to
all cells (such as sustained angiogenesis which creates blood vessels carrying oxygen into the
tumour which all nearby cells can benefit from), do not dominate a cancer clone, whereas hall-
marks such as limitless replication appear early and dominate as they turn over very quickly.
Santos et al. (also discussed thoroughly in Section 1.5) built on the work of Abbott by
using a similar modelling approach, but instead of looking at pathways to cancer focused on
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the impact of removing different hallmarks on tumour growth. They investigated how critical
to growth each hallmark was by removing it from the system and comparing the total number
of cancerous and healthy cells present without the hallmark present, to growth totals with all
hallmarks present. They used a cellular automaton model which determined cell division and
apoptosis based on internal rules and acquired hallmarks. They found that with high mutation
rates, the most critical hallmark is avoids apoptosis, while in tumours with little room to grow
the ignore growth inhibition hallmark proved most impactful on overall growth. In addition
they found when cells had reached their proliferation potential the impact of limitless repro-
ductive potential (called effective immortality in their paper) became great.
I have used similar model parameters and methods as those outlined in Abbott et al.’s work
to build upon Santos et al.’s hallmark relevance study. I have created a high level abstract
model of early tumour growth. This model uses cellular automata to model individual cancer
cells, and uses various rules to model the hallmarks as outlined by Hanahan and Weinberg. In
this model I have implemented five of the six original hallmarks as well as three of the four
newly introduced hallmarks and enabling characteristics. This thesis specifically focuses on
those relevant during initial tumour growth, not metastasis, as this early tumour growth is crit-
ical to patient survival. In general, finding and treating cancer during the early phase (before it
metastasizes) increases the chances of patient survival [10], [11], [36], [37].
Using this model I have investigated the impact of knocking out hallmarks (in pairs, triplets
and quadruplets) on overall tumour growth. These investigations have lead to the conclusion
that attacking multiple avenues of tumour growth is often the best way to treat the tumour.
Moreover, the results show that only certain combinations of “hallmarks” are more advanta-
geous than their singular counterparts. This research shows that some combinations are not
additively better, and in fact are worse, than individual treatments. It also shows that in silico
modelling is a useful tool in determining what hallmark combinations are most useful for halt-
ing cancer growth in a high level scenario.
Henderson and Samaha stated that “in the most general sense, combinations of therapies,
whether drugs and/or other modalities, will always play an important role in the management
of diseases for which there exists no single specific and totally effective treatment” [78]. Com-
bination treatment involves pairing multiple drugs with the hope that two in combination will
not just be an additive advantage but a multiplicative one. Targeted therapy involves identi-
fying key pathways or molecules involved in cancer progression and creating drugs to target
these entities. This model simulates targeted combination therapy as we remove key cancer
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properties in pairs, triplets and quadruplets and compare cancer growth rates to tumours with
all hallmarks active. We hypothesize that knocking out pairs of hallmarks will not necessarily
have just a slightly greater effect than knocking the hallmarks out separately but rather will
sometimes have an even greater, potentially multiplicative, combined impact.
2.2 Cancer Hallmarks
2.2.1 Introduction to the hallmarks of cancer
Hanahan and Weinberg noticed over the years that cancer research had created such a large
body of knowledge that it was almost beyond measure [26]. They recognized the benefit of
being able to distil this knowledge into a small number of underlying principles describing
this broad disease category, and attempted to begin that endeavour by putting forth what they
called The hallmarks of cancer [74]. They stated that these hallmarks were “rules that govern
the transformation of normal human cells into malignant cancers” and they believed they ap-
plied to all, or at least almost all, cancers [74].
Cell biology teaches that mammalian cells share similar machinery for common cell pro-
cesses such as proliferation and death, so the idea of a common transformation step (or set of
steps) to cancer seems plausible. Cancer often appears in stages; a series of intermediate steps
transforms normal tissue into an invasive cancer [170]. Cancers are found to contain multiple
aberrations, likely because of these progressive changes.
This stepwise process has been speculated to be similar to Darwinian evolution [74]. A cell
sustains a small mutation and if it confers strength to the cell, it gets passed down to daughter
cells. It can get added to by more advantageous mutations until a select group of changes is so
powerful as to allow for an overpowering of normal cells by this stronger population.
A major barrier to the study and treatment of cancer is that cancer itself is actually a col-
lection of over 160 different diseases. The question remains: what are their similarities, if any,
and how can we use them to treat more cancers more efficiently?
Hanahan and Weinberg proposed that the large array of cancer types and genotypes is
actually the impact of six essential changes to the cell [74]:
• Self sufficiency in growth signals
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• Insensitivity to anti-growth signals
• Evasion of programmed cell death (apoptosis)
• Limitless replicative potential
• Sustained angiogenesis
• Tissue invasion and metastasis
Cells have built in defenses to all of these and cancer is the successful breakdown of these
defense mechanisms. The number of defences that need to be broken down could be why
cancer is somewhat rare, usually only appearing once per life time and later in life. Clearly the
idea of a set of six common cancer abilities is appealing to researchers. Many drugs attempt
to stop one or more of these “hallmarks” and over time it has become apparent that the idea of
Hanahan and Weinberg has strong merit [56], [21]. Since so much treatment and research is
based on these six abilities, I have chosen to use them as my basis for modelling cancer. They
are arguably what defines cancer, and therefore they form how cancer is programmed in my
model. Below I will outline each hallmark and describe a bit about the biology of it as well as
how it is represented in my model simulation.
2.2.2 Self-sufficiency in growth signals
Normal cells are generally in a quiescent state where they are functioning but not actively pro-
liferating. In order for a cell to become mitotically active (divide), it needs mitogenic growth
signals, which stimulate it to move from the quiescent state to a dividing one. It is believed in
fact that normal cells cannot divide in the absence of growth signals.
Normal, healthy tissues regulate the creation and release of growth signals very carefully,
balancing the number of actively dividing cells so no area is overburdened with resource re-
quests. Cancer cells de-regulate these signals. In fact, self-sufficiency in growth signals is said
to be the most fundamental trait of cancer cells [75].
The signals involved with cell proliferation are often bound by cell-surface receptors, which
in turn are often involved in even more pathways, including cell-survival and energy metabolism.
Altered regulation of the proliferation pathway, particularly upstream enzyme modulators, can
initiate a cascade of detrimental changes that may present themselves later in the cell’s life
cycle. The full set of events governing the creation and release of these signals is poorly under-
stood due to a variety of issues making experimentation difficult. These issues include temporal
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and spatial regulation of the signals, the complexity of the networks involved and the highly
localized and specialized mechanisms involved.
Interestingly, the deregulation of these signals in cancer is much better understood [176],
[131]. Cancer cells can sustain their growth through a variety of mechanisms including:
• sending growth signals to surrounding cells which reciprocate by releasing even more
growth factors.
• increasing their own cell-surface receptors for growth signals so that basal levels of signal
can have an enhanced effect.
• activation of growth pathways downstream of signal reception, which enhances prolifer-
ation but also reduces their dependency on external stimuli.
• interference with negative feedback loops which normally lessen signals and therefore
assist in maintaining homoeostasis. Hanahan and Weinberg have predicted that “compro-
mised negative-feedback loops” will be found to be “wide spread among human cancer
cells” [75]. They also believe cancer cells may use this ability to disturb feedback loops
to gain resistance to drugs which target cell cycle signalling.
Interestingly, very high levels of some oncoproteins (proteins created from an oncogene, a
gene with the potential to cause cancer that is often mutated in cancers) such as RAS (a family
of proteins which are involved in cell growth) and MYC (a regulator gene that is involved in
cell cycle progression and apoptosis) are implicated in cell senescence, a cell state that is viable
but non-proliferative [75]. This is counter-intuitive to the thought that high expression of sig-
nalling proteins would lead to increased growth. It is hypothesized by Hanahan and Weinberg
[75] that cells may have built in safety mechanisms to avoid excessive growth and therefore
induce senescence in cells with high levels of oncoprotein. Furthermore they postulate that
cancer may be involved in a delicate trade-off between increased signalling for fast growth and
not growing so fast as to activate these safety mechanisms. It is also possible that cancer cells
could somehow be deactivating these safety mechanisms.
Many cancer hallmarks have an impact on more than just the cancer cell itself, and self
growth is no different. Indeed, cancer’s ability to “co-opt” neighbouring normal cells by stimu-
lating them as well, helps create a rich tumour microenvironment where cancer cells can thrive
and be supported by normal cells. Signal changes, including in growth factors, can conscript
normal cells as active agents in a tumour’s growth.
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In order to model this hallmark, I have set up healthy cells to only be able to divide within
a certain area of the total growth environment. Healthy cells can only divide up to some pre-
defined boundary (which is a gradual boundary), which is akin to an area with growth factor
present. In certain areas (outside the boundary) there is not enough growth factor to signal
proliferation, and therefore healthy cells become senescent in this area. Cancer cells however
can obtain the sustained growth (SG) mutation, allowing them to actively divide outside of
the predefined boundary, modelling the ability to initiate growth themselves via a variety of
mechanisms. My model is a high level model, modelling a general solid-mass tumour, and
so no specific pathways or proteins are involved. Rather the use of the boundary models self-
sufficient growth via any means the cancer cell may be using.
2.2.3 Evading growth suppressors
Coupled with a tissue’s tight regulation over growth inducing mechanisms, tissues also have
strong negative regulation over cell growth, actively suppressing it as opposed to passively not
taking part due to the absence of growth promoting factors. The genes which do this are often
referred to as tumour suppressor genes (genes that when damaged and lose function often al-
low cancer to grow) and many have been identified via gain- or loss-of-function experiments
in mice [75]. These genes can actively limit cell growth and proliferation through a variety of
mechanisms including stopping the cell cycle and cell-cell contact inhibition.
One tumour suppressor gene often discussed and referred to as “the guardian of the genome”
is TP53 (tumour protein p53, often abbreviated p53). Cells have built-in stress and abnormality
sensors that p53 can utilize to detect unfavourable conditions or cell damage. If p53 detects
such things, it can pause the cell cycle and stop division until the damage has been fixed and/or
the conditions have changed for the better. If dire circumstances are detected, or extreme cell
damage is found, p53 can actually initiate apoptosis (the process of programmed cell death),
preventing such damage from being passed on to daughter cells [98].
Similar to the internal guardian p53, the RB gene product (pRb) processes both internal
and external signals to ensure the extracellular and intracellular environment is sufficient for
growth and division. It can repress the cell cycle if conditions are not as they should be [79].
Both p53 and pRb are part of complex networks with much built in redundancy [75].
Damage to either of these pathways, including but not limited to pRb and p53 themselves,
can allow a cell to circumvent the anti-proliferative cell mechanisms. In fact, the TP53 gene is
2.2. Cancer Hallmarks 45
found to be mutated in 50% of all cancers.
In addition to the functioning of cell cycle regulators, cell growth is also negatively con-
trolled by the pressure exerted on cells by other cells. When cells grow together the cell-to-cell
contact has an inhibitory effect on growth. This mechanism, called contact inhibition, is often
turned off or perhaps ignored in many cancer cells. An example of a gene involved in this
pathway is the NF2 gene, the loss of which triggers human neurofibromatosis, a disease which
deposits tumours throughout a patient’s body. The gene product of NF2, Merlin, strengths cell-
cell adhesion and also sequesters growth factors, limiting cell growth.
In order to model cancer’s ability to stop responding to anti-growth signals, I have imple-
mented a space requirement for growth. This models one of cancer’s anti-growth avenues –
avoiding contact inhibition. In my model, healthy cells stop actively growing once there is no
more space available adjacently or diagonally on the lattice. Cancer cells in this system can
have the ignore growth inhibition (IGI) hallmark activated which allows cells to grow even
without space (thereby modelling the impact of mutations which cause a cell to ignore contact
inhibition). These cells have a “competition” factor (c). If a cell with the IGI hallmark attempts
to grow and is out of space, they compete with cells around them and can potentially take over
the space another cell is occupying in order to grow. Each time a cell competes (done once
every attempt to divide without space), the cell has a 1/c probability of successfully gaining the
space, where c is the competition factor provided in Table 3.1.
2.2.4 Resisting cell death
Apoptosis, or programmed cell death, is a normal process in animal tissue. Apoptosis assists
in the balance of healthy alive cells with dead or dying cells, keeping cell populations in check
and dealing with damaged or old cells. Apoptosis involves controlled death of the cell, includ-
ing breaking up the cell whose individual pieces/components subsequently get removed from
the area. In addition to helping maintain balance, it is also a safety mechanism which prevents
damaged cells from passing on damage to future generations of cells [103], [58].
Apoptosis has been found to be triggered by different events, many of which are common
during the progression from normal, healthy cell to cancerous cell, such as high levels of onco-
gene expression and DNA damage. Although it is known that DNA damage and oncogene
overexpression can lead to cancer which should trigger apoptosis, it has also been found that
cancer cells sometimes manage to avoid apoptosis [75].
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The machinery involved with apoptosis includes upstream regulators and downstream ef-
fectors [4]. The regulators both listen for extracellular death-inducing signals and intracellular
signals of problems. When apoptosis is induced, normally latent proteases (an enzyme that
breaks down proteins) are activated and begin a cascade of proteolysis (protein breakdown)
which disassembles the cell. The cell lysate (fluid made up of the content of the broken down
cell) is then consumed by neighbouring cells or phagocytic cells (cells which consume and kill
other cells, often involved with the immune system) [75].
Various cell conditions leading to apoptosis have been identified, with one of the most no-
table being DNA damage [87]. Major DNA breaks or chromosomal abnormalities are sensed
by tumour-suppressor TP53 which can in turn activate apoptosis if the damage cannot be fixed.
While cancer cells evolve many mechanisms to avoid apoptosis, one of the most common is
loss of TP53 function (found to be gone in 50% of all cancers). This allows a cell to build up
DNA damage unchecked which can lead to additional mutations and passing down of damaged
DNA.
I have chosen to model the apoptotic pathway primarily as a sensor for DNA damage. Once
a healthy cell has sustained any mutations (in this model meaning its rules have been altered
from the healthy cell version), it is possible for it to enter the apoptotic state and be killed via
apoptosis. Since apoptosis can be activated due to genetic damage, the chances of a cancer
cell dying via apoptosis increases with each subsequent mutation (in this model). A cell has an
m/a probability of being killed by this mechanism, where m is the number of mutations already
sustained, and a is an apoptosis chance variable contained in each cell (see Table 3.1 for exact
parameters). Cells with a mutation in this mechanism cannot die by apoptosis, regardless of the
number of mutations acquired. This avoids apoptosis mutation is referred to as AA throughout
this thesis.
2.2.5 Enabling replicative immortality
Most normal healthy cells have a limit to how many times they can divide before they enter a
viable but non-proliferative state called senescence. Healthy cells that manage to avoid senes-
cence often instead enter a crisis state, ending with cell death. In contrast, cancer cells seem to
require unlimited replication to grow to a tumour of microscopic size. In culture when cells are
propagated, leading to senescence, and then for some to crisis, many of the cells die. At this
point it occasionally happens that a cell line comes up displaying this unlimited replication,
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effectively becoming immortal, continuing to grow without hitting senescence or crisis.
It is believed cells have a feature which only allows them a certain number of replications –
telomeres. These are segments of DNA made up of multiple repeating 6-nucleotide segments
capping the ends of chromosomes. Chromosome replication is not a perfect process and al-
ways results in the loss of some material at the ends of chromosomes. Telomeres protect the
“necessary” DNA by themselves being shortened at each replication. Eventually however they
become too small to effectively protect the DNA and at this point it is believed senescence can
be triggered.
Telomerase is a DNA polymerase that builds these telomeres. Normally it is not active in
healthy cells, however it is found to be turned on in approximately 90% of suddenly immortal
cells [75]. Telomerase then can continuously extend the ends of DNA making it so they never
reach a size small enough to trigger senescence or crisis. Accordingly, the presence of telom-
erase is correlated with resistance to both of these fates [75]. It is believed both of these events
are natural barriers to cancer. Rogue cells may develop mutations, be growing out of control
of the body’s signalling, and begin rapid division. These cells can be abruptly stopped when
their full replicative potential is reached, causing them to not be able to divide further and not
make it to a macroscopic tumour. Cells which manage to activate telomerase however keep
their telomeres long enough to avoid senescence and crisis and therefore forever pass on their
mutations. As such telomere shortening is thought to be one of the barriers cancer cells must
defeat to progress into a dangerous tumour [75].
One particular example supporting this hypothesis is the work of Artandi and DePinho who
found that mice genetically predisposed to certain cancers had weakened tumorigenesis when
born without telomerase [20]. The early shortening of telomeres may have pushed the cells
into senescence more quickly, and the lack of telomerase would prevent immortalization of the
cells.
The exact roll of telomerase and telomeres in cancer is complicated by evidence that a lack
of telomerase may sometimes encourage neoplastic progression (abnormal growth, a charac-
teristic of cancer) [92], [76]. As chromosomes shorten, they risk being involved in “breakage-
fusion-bridge” cycles, whereby chromosome ends lacking telomeres fuse together. During cell
division these fused chromatids form a bridge and then are ripped apart, but often not at what
would be the correct place, where they fused. The resulting chromosomes are uneven and the
two daughter cells have improper chromosomes. This often leads to large scale rearrangement,
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such as deletions and amplifications of DNA, potentially activating oncogenes or silencing tu-
mour suppressors. In this case the lack of telomerase has enhanced a cancer cell’s mutability
and possibly fitness. Over time these cells may activate telomerase thereby immortalizing these
potentially dangerous mutations. In fact, pre malignant legions in the human breast have been
found to have normal levels of telomeres as well as chromosomal aberrations while malignant
lesions had telomerase activity and fixed aberrant karyotypes presumably from earlier in the
cancer’s progression [138], [42].
We have included in our model the ability for a cell to become immortal. Every cell is
equipped with a “telomere” variable that decreases by one with every cell division. This vari-
able limits healthy cells to 60 cell divisions. Normal healthy cells go through roughly 25 to 70
divisions [74] and other models have chosen a number to lie in this range [153]. Some simu-
lations chose a higher initial telomere length (100 in both [143] and [1]) however it was found
that in models higher initial lengths cause rapid cancer development, while a number closer to
55 causes later cancer onset [153], suggesting the number of cell divisions allowed in reality
has been optimized (perhaps via evolution) to reduce cancer occurrences. We chose a value
that would not lead to rapid cancer development but would be more similar to reality. Cells can
acquire the ignore telomere hallmark which allows them to effectively ignore this limitation
and not be bound by their telomeres. This replicates the biological activity of telomerase which
continues increasing telomeres after they are shortened, preventing their length from impeding
growth. Cells with the ignore telomeres (IT) hallmark activated can divide forever, regardless
of telomere length, so long as all other required conditions are met (oxygen, nutrients, space,
etc).
2.2.6 Inducing angiogenesis
Vasculature, the system of blood vessels in the body, serves two major purposes to cell groups:
delivering nutrients and oxygen, and removing waste products and carbon dioxide. Both
healthy and cancerous cells depend on and need this system. Typically, vasculature is quite
stable. It is originally developed during embryogenesis, when the processes of vasculogenesis
(the birth of new endothelial cells and their development into tubes) and angiogenesis (sprout-
ing) occur. After embryogenesis is complete, angiogenesis is only turned on transiently during
wound healing and as part of the female reproductive cycle. A key early development in tumour
growth is the activation of this normally quiescent angiogenic process, causing new vasculature
to sprout towards and even into tumours [74], [75]. This is extremely dangerous as it not only
provides the tumour with fresh oxygen, nutrients, and waste removal, but also gives it a system
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to use to travel through the body.
It is believed that the process of angiogenesis is regulated by counteracting factors that in-
duce or oppose angiogenesis. Vascular endothelial cells have surface receptors which can bind
inhibitory or stimulating cell surface receptors – one of the most well known of which is the
angiogenesis inducer vascular endothelial growth factor A, or VEGF-A [75].
The VEGF-A products are involved in the process of new blood vessel sprouting in at least
three different situations: embryonic and post natal development, homoeostatic survival of en-
dothelial cells and disease situations. The VEGF pathway is complex and involved in a variety
of situations, and it can be upregulated by both hypoxia (lack of oxygen, common in tumour
growth) and oncogeneic signalling. Even more situations can impact this pathway, such as se-
questration (biological accumulation of a compound) and subsequent activation and release of
inactive VEGF ligands by matrix degrading proteases and upregulated pro-angiogenic factors
such as fibroblast growth factor (FGF) [75].
When angiogenesis is induced in tumours it often results in poorly set up vasculature with
issues such as leakiness, erratic blood flow and excessive and convoluted branching. While this
process was previously thought to occur later in tumour development, such as once the tumour
was rapidly growing and macroscopic in size, research in the past two decades has found it can
begin as early as the pre-malignant microscopic stage of growth [136].
Tumours exhibit widely varied tumour-induced vasculature, even within the same organ.
For example, adenocarcinoma of the pancreatic ducts is hypovascularized [124], while pan-
creatic neuroendocrine carcinomas can be densely vascularized [53]. The variety of tumour
induced angiogenesis seen suggests that angiogenesis is initially switched on, but complexly
regulated and impacted throughout tumour growth. While the mechanism of angiogenesis
switch activation can vary, the net result is a common inductive signal (e.g. VEGF). In some
cases oncogenes activate angiogenesis (such as RAS and MYC). These also can stimulate
proliferation which means other unique hallmarks (such as sustained growth) can possibly be
activated by the same rogue players.
Since it is believed angiogenesis is at least initially switched on in tumour growth, and this
model aims to simulate early tumour growth, we have included this hallmark. In the simula-
tion, angiogenesis is modelled at a very basic level. Cells that have the induce angiogenesis (A)
hallmark activated are thought to be on the path of new vasculature. In the simulation, every
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lattice location has an associated oxygen value that changes over time based on consumption
and supply, and is modelled using lattice Boltzmann methods (LBM) (for a full explanation of
this, please see Section 3.3). At each division a cell checks if it has enough oxygen to survive
by checking with the lattice Boltzmann simulation, for how much oxygen is present where it
is located. The lattice Boltzmann model simulates the flow of oxygen in the blood around the
tumour and how it diffuses towards cells. If a cell does not have enough oxygen it either be-
comes quiescent or dies (depending on how much oxygen is present). However, if it is on the
path of vasculature because it is inducing angiogenesis, it is getting oxygen directly from the
vasculature so it does not require enough oxygen in its lattice cell as calculated by the LBM.
Neighbours of cells on the vasculature also benefit from this via diffusion from the new vascu-
lature and are able to survive in places there would not otherwise be enough oxygen.
In this model angiogenic cells also have a higher chance of being killed by the immune sys-
tem, as immune-associated cells travel via the vasculature. Angiogenic cells and their neigh-
bours have a (ai) ∗ (1/i) chance of being killed by the immune system at each replication step,
where ai is the angiogenesis immunity parameters and i is the immune death likelihood param-
eter (Table 3.1).
2.2.7 Emerging hallmarks and enabling characteristics
Hanahan and Weinberg describe the hallmarks of cancer as “acquired functional capabilities
that allow cancer cells to survive, proliferate, and disseminate” [75]. They are acquired over
time by a variety of distinct mechanisms in many different tumour types. In order to acquire
these hallmarks, Hanahan and Weinberg have identified two “enabling characteristics”: ge-
nomic instability and tumour promoting inflammation. The most prominent of the two, genetic
instability, is included in this model and described below.
Other research has found cancer cell attributes that seem similar to hallmarks, in that they
are perhaps attributes allowing cancer cells to survive, proliferate and disseminate [45], [121].
Of the attributes noted, two seem particularly well suited to potentially be hallmarks. The first
is the fact that many cancer cells are found to have reprogrammed metabolism, increasing their
use of glycolysis, a less efficient form of energy generation. Secondly, tumour cells have been
observed to somehow avoid destruction by the immune system. These two attributes have been
deemed “emerging hallmarks” by Hanahan and Weinberg and are also discussed in greater
detail below [75].
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Genetic instability
Cancer cells acquire the above mentioned hallmarks in large part because of successive changes
to the genome of neoplastic cells [75]. Some mutational changes will confer an advantage to
the cell, allowing it to grow and dominate in an environment. Therefore, the many steps from
normal cell to cancerous cell, and the subsequent stages of tumour growth, can be viewed as the
successive accumulation of favourable chance mutations each creating a new cell clone group.
However, not all clonal expansions need be caused by mutations, as research has shown that
epigenetic changes (genetic influences that are not related to the actual sequence of DNA) can
also impact gene expression [29], [86].
Many innate cell systems are able to detect and repair DNA damage; consequently, the
number of spontaneous mutations in a cell generation tends to be low. Cancer cells however
often have higher than normal mutation rates, which can be achieved in a variety of ways.
There can be an increased sensitivity to mutagenic agents or breakdown in any of the genetic
maintenance machinery or pathways. Also, a disturbance in the cell machinery that detects
and fixes mutations (for example, TP53, mentioned earlier) can lead to an increased mutation
rate. The process of detecting and fixing DNA damage is complex, and so has a lot of potential
places breakdowns can happen, such as:
• Machinery that detects damage and activates repair pathways
• Machinery that repairs DNA
• Machinery that eliminates a cell if too much damage is acquired
• The pathways involved with the inactivation and interception of mutagenic molecules
Other cell components can be included in the list of “caretakers” that watch over the
genome. As mentioned above, the loss of telomeres leads to increased chromosomal mutations
and instability, another avenue for rapid mutation accumulation. Korkola and Gray found that
there may even be certain areas of the genome where aberrations are likely to lead to neoplastic
growth, an interesting observation made after seeing recurrence of specific amplifications and
deletions at certain sites in breast cancer [95].
In the future, the current development of more efficient and affordable sequencing tech-
nology should allow full sequencing of tumours, which may show even more the impact of
genetic instability. Already early research has shown that there are distinctive patterns of DNA
mutations across different tumours [75]. More knowledge in this area should help explain the
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prevalence of the apparently random mutations across cancer cells and may reveal some logic
and causation behind some of these changes.
Currently it is known that the genetic changes in cancer vary across tumours, tissues and
types, however one thing that is agreed upon is the vast array of cell maintenance and repair
mechanisms that can be damaged as well as the prevalence of copy number changes to genes in
cancers. These wide spread changes point to genome instability as an enabling characteristic
of cancer in general, and possibly one that is causing the acquisition of cancer hallmarks [75].
Working with this belief, that genome instability could cause cells to acquire some hall-
marks, we have added it as an enabling characteristic in this cancer simulation (for simplicity,
all hallmarks, enabling characteristics and emerging hallmarks and simply referred to as “hall-
marks” throughout this thesis). While there are many different pathways and mechanisms that
can be impacted in cancer growth and can cause genetic instability, the end result is a geneti-
cally unstable cell which has a higher likelihood of mutation. We model this characteristic with
the genetically unstable hallmark (GU) that when active increases the probability of mutation
in each mitotic event by a factor of (1/gif) where gif is the genetic instability factor param-
eter. Modelling it in this way allows for hallmarks to still be acquired spontaneously due to
any number of factors, but also allows cells to accumulate mutations more quickly if they are
“genetically unstable”.
Reprogramming energy metabolism
Cells need to be able to generate energy to sustain themselves and proliferate. Typically,
healthy cells perform aerobic metabolism, where they take glucose in the presence of oxy-
gen and convert it into adenosine triphosphate (ATP - a molecular unit for energy in the cell)
and carbon dioxide in the mitochondria. If cells are in an anaerobic environment (one with
little oxygen), they preferentially upregulate glycolysis, a form of energy production which
uses very little oxygen and creates much less ATP. Glycolysis is considered to be less effective
then aerobic metabolism (as approximately 18x less ATP are generated by glycolysis relative to
aerobic metabolism). However, cancer cells often seem to reprogram their glucose metabolism
to rely largely on this mechanism. This was first observed by Otto Warburg, and has since been
termed “the Warburg effect” [173], [175].
This effect has been observed repeatedly in the years since, although it seems counter-
intuitive since glycolysis produces so much less ATP. Cancer cells seem to have ways to com-
pensate for this. One such method is the increased intake of glucose into the cell, and increased
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utilization of it. This has been found by positron emission tomography and reported by various
studies and reviews [109], [50], [82].
It has been shown that glycolysis in cells is associated with both activated oncogenes and
mutant tumour suppressors. In addition, tumours often exist in a hypoxic environment (one
with low oxygen) and hypoxia is an activator of the glycolytic pathway. The cells response to
a hypoxic environment can both up-regulate glucose transporters to increase glucose uptake,
and increase creation of enzymes involved in the glycolytic pathway.
Although there is evidence for hypoxia, oncoproteins and tumour suppressors activating
this pathway, the reason why it would be advantageous to the cell is still somewhat unknown.
One hypothesis by Potter [134] which was recently reviewed by Vander Heiden et al. [168]
suggests that by switching to this pathway, cells use some of the intermediate molecules cre-
ated during glycolysis for other important biosynthetic pathways - such as creating molecules
and organelles needed for new cells. Since cancer divides so rapidly, it would be advantageous
to have more available building blocks for the process. Supporting this hypothesis is evidence
of Warburg-like metabolism in rapidly-dividing embryonic tissue.
An interesting symbiosis within cancer tumours has also been observed with respect to en-
ergy metabolism. Some tumours have been found to contain two subpopulations - one which
relies on glycolysis for energy and secretes lactate as a waste product, and a second which
relies on lactate as their main energy source. This behaviour of coordinating metabolism be-
tween lactate-secreting and lactate-utilizing cells is not unique to cancer cells and indeed is
used in operating muscle cells [75]. In addition, the oxygenation of a cancer cell varies across
the tumour and over time, most likely as a result of poorly orchestrated tumour vasculature,
and so having cells that operate efficiently in both normoxic and hypoxic environments could
be advantageous.
Hanahan and Weinberg were unsure whether altered energy metabolism was independent
and necessary enough to be listed with the other six hallmarks when they published the next
generation [75]. On the one hand, it has been observed to be as wide spread as many other
cancer traits, but on the other, it appears it may be programmed by proteins that already are
involved in programming hallmarks. Due to the ubiquity of reprogrammed metabolism in can-
cer tumours, but the lack of clarity in whether it is independent from other hallmarks, Hanahan
and Weinberg have given it the same designation as evading immune destruction – that of an
“emerging hallmark” [75].
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While the independence of this emerging hallmark is unknown, its prevalence in cancer
is not, and as such I have chosen to include it in this high level model of cancer. In this
model, cancer cells can get a mutation allowing them to switch to the “glycolytic phenotype”.
These cells do not require oxygen present in their environment, and so can survive in poorly
oxygenated environments. This model does not look at the impact of energy requirements or
metabolism by-products but is specifically interested in the role oxygen plays in early tumour
growth, and as such the modelling of the glycolytic phenotype only confers the ability for cells
to survive in low oxygenated environments.
Evading immune destruction
Listed as an “emerging hallmark” in the updated cancer hallmarks paper, the ability for cancer
to seemingly evade destruction by the immune system is an unresolved issue that appears to
play a big role in cancer growth [75]. It has long been believed that the immune system is
like a constant surveillance system, watching the body for signs of foreign cells or incipient
cancer cells, eradicating them if they are found. By this logic, cells that manage to grow into
full macroscopic tumours must have somehow avoided detection or destruction by that same
system.
One piece of evidence in the argument that the immune system is involved in the early
detection and eradication of cancer cells is the fact that individuals who are immunocompro-
mised have a much higher incidence of certain cancers [165]. However many of these are
cancers caused by viruses, and so it would seem that perhaps the role of the immune system in
cancer prevention is just minimizing the viral load on a body. Recently however, some studies
have shown that even in non-virus-induced cancer, the immune system still plays a significant
role as a barrier to cancer progression [75].
Studies with genetically engineered mice back up this claim. Mice that had been engineered
to lack various pieces of the immune system had an increased incidence of tumour formation.
Mice that were engineered to be deficient in multiple pieces of the immune system had even
higher rates of cancer [162], [94].
Other interesting work on this emerging hallmark has been done involving transplanta-
tion of cancer cells between immunocompromised and immunocompetent mice [162], [94]. It
has been shown that cancer cells that originated in immunodeficient mice often cannot initi-
ate tumour growth when transplanted into immunocompetent hosts; conversely, cancer cells
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that initially grow in an immunocompetent host are just as able to develop cancer in either
immunocompetent or immunocompromised hosts. One theory is that the immune system rou-
tinely edits cell growth, deleting any immune-susceptible early cancer cells, and so if cancer
develops it is a collection of cells able to avoid the immune system. If these are put in any host
the same outcome will occur. However cancer cells which survive in an immunocompromised
mouse have not yet had to come up against a competent immune system and so are often elim-
inated when that occurs, upon transplantation into a immunocompetent host [151].
Interestingly, some human organ transplant recipients have been found to develop donor-
derived cancers while the donor did not present with cancer. It is believed the healthy donor
was able to keep early cancer growth in check via their immune system, however the transplant
recipient is not able to do so [155]. Other work in this area has found that patients with ovarian
and colon cancers have a better prognosis when large amounts of natural killer and cytotoxic T
lymphocyte cells are found in their tumour [128].
It is not a given that immunosuppressed patients will get cancer, however it should be
noted that many immunocompromised people are only lacking in certain immune system func-
tions, and still have others, for example, natural killer cells. Perhaps the reason for a lack of a
strong increase in cancer among immunocompromised patients is that they still contain certain
components of the surveillance system, perhaps a more critical component than that which is
compromised.
Hanahan and Weinberg believe there is some evidence of anti-tumour immunity but that it
has yet to be proven ubiquitously enough to be considered a core hallmark and as such have set
it as an “emerging hallmark”, along with reprogramming energy metabolism. We have chosen
to include both of these hallmarks in this study, as we are interested in a high-level, abstract
model. We could assume this general model is of a type of solid mass tumour that is affected
by both the immune system and the reprogramming of energy metabolism. This simulation has
a very simple, basic model of immune system surveillance. In the model, cells with mutations
have a probability of being killed by the immune system at every life cycle (exact numbers can
be found in Table 4.1). We then model cancers ability to possibly avoid this with the avoids
immune system hallmark (AI) which when activated lowers the chances of a cancer cell being
killed by the immune system by a factor of aip, the avoids immune system parameter.
56 Chapter 2. Biological Background and Model Rationale
2.2.8 Features not simulated
This model specifically models 5 of the original 6 hallmarks of cancer, both of the emerging
hallmarks, and one of the two enabling characteristics. The choice of what to model was a
complex one, and was largely impacted by the scope and type of study, the biological relevance
at the early growth phase, and the computational and modelling feasibility. The hallmark and
enabling characteristic that were not included in this model are described in more detail below
for completeness. A rational for not including these hallmarks follows each description.
Tumour-promoting inflammation
Immune cells are present in virtually every neoplastic legion in some amount. Some lesions
have very small infiltrations that can only be detected using cell type-specific antibodies, how-
ever others have such large densities of immune cells they can be seen using standard histo-
chemical staining [128]. As mentioned above, there is an immune response that attempts to
stop tumour growth, however in the last two decades there have been hints that the tumour-
associated inflammatory response might paradoxically also be promoting tumour growth [52],
[181], [72]. In fact, research in the last decade has found multiple ways that the innate im-
mune system actually contributes to neoplastic progression and hallmark acquisition, largely
by supplying bioactive molecules to the microenvironment of the tumour such as:
• Growth factors that maintain signalling for proliferation [52], [72], [181]
• Survival factors that assist in avoiding cell death [72], [181]
• Proangiogenic factors that facilitate in the development of tumour vasculature [49], [47],
[123]
• Extracellular matrix-modifying enzymes that can assist in angiogenesis, invasion and
metastasis [46], [179]
• Inductive signals that lead to hallmark-facilitating programs [52]
Hanahan and Weinberg point out that inflammation is sometimes present at very early
stages of neoplastic progression, and has been found to be clearly capable of assisting in the
progression from incipient neoplasias to fully functioning cancer tumours [75]. Also, some
inflammatory cells release reactive oxygen species which are mutagenic to the surrounding
cells, possibly assisting these cells in gaining advantageous mutations. As such, Hanahan and
Weinberg have classified inflammation as an “enabling characteristic” of cancer, however they
stated that of the two enabling characteristics, the most prominent is genomic instability. I
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have chosen not to include tumour promoting inflammation in our simulation. The role of in-
flammation is still mostly unknown. Many of the cell types that lead to inflammation, such
as cells of the innate immune system, play a dual role of assisting in cancer development and
trying to stop it. Inflammation appears to be involved in a host of developments, specific to
what cells are present, the microenvironment, etc. As such, there is no obvious single impact
on early tumour growth that can be abstracted to a parameter that could be modelled in the
type of high level, broadly applicable model we are interested in studying. I have chosen to
model the tumour growing in an empty environment, only looking at the development from
1 cell onward, focusing on the impact of oxygen in the environment and no other microen-
vironmental conditions. As such, I believe it is sufficient to model the 8 other hallmarks and
characteristics mentioned above. In the future adding in a more realistic microenvironment
would be beneficial and would allow the addition of inflammatory modelling.
Invasion and metastasis
When Hanahan and Weinberg originally proposed the hallmarks of cancer, the process of tis-
sue invasion and metastasis was largely unknown [74], [75]. It had been noticed however that
cancer cells often lose E-cadherin, a cell-to-cell adhesion molecule. Epithelial cells are joined
together by E-cadherin forming sheets and helping maintain quiescence. Cancer cells lose this
adhesion and are then more able to migrate and not remain in a quiescent state. It has been
found that increased expression of E-cadherin slowed invasion and metastasis, and that a re-
duction in it would increase the likelihood of invasion and metastasis [75].
Interestingly, other cell-to-cell and cell-to-ECM (extracellular matrix) adhesion molecules
have been found to be undeniably altered in some highly aggressive cancers [75]. In addition
to this, some molecules that are active during normal cell migration, such as during embryoge-
nesis, are found to upregulated in some cancers [75].
Since the initial publication of the hallmarks, more information on cancers ability to mi-
grate has come out, however the entire process is still somewhat elusive. Certain mechanisms
have been implicated, such as the epithelial-mesenchymal transition (EMT) whereby cells lose
their epithelial traits, such as staying in sheets and being quiescent, and gain more traits of mes-
enchymal cells including migratory and invasive behaviors [75]. Also, many transcriptional
factors have been identified in this process – factors which contribute to things like expression
of matrix-degrading enzymes, increased motility and increased resistance to apoptosis [75].
There has even been implication that the transition from stationary cancer cells to invasive or
metastatic cancer does not require any additional mutations on top of those which occur when
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the initial tumour is being formed.
Complicating matters is the existence of multiple forms of invasions. There is “collec-
tive invasion” where whole groups of cells will migrate into adjacent tissue, and “amoeboid
invasion” where cells slither to new regions without clearing a path (which is done in EMT
migration). There is also some thought into whether a patient’s own inflammatory response is
involved in invasion and metastasis.
Beyond the initial problem of migrating, a second piece of the metastasis puzzle is foreign
tissue colonization. Cells may manage to be invasive and migrate away from the primary tu-
mour, but the ability to seed a new macroscopic tumour in a new location is not a given. In fact
it is possible that colonization may be even more challenging than the initial issue of migrat-
ing. A variety of interesting situations has been noticed in the problem of cell dissemination
and colonization. For example, cells that migrate may be prevented from colonization by anti-
growth forces exhibited by the primary tumour. In some cases after primary tumour resection
many distant colonies have suddenly arose [51]. It has also been observed that limited nutrient
availability can cause distant micrometastasis to shrink and become dormant, only to be rea-
woken when environmental conditions change [93], [104]. Distant site tumour cells may also
lay dormant because of tumour surpressors in the environment or normal antigrowth signals in
the extracellular matrix [24], [162], [5].
Other factors complicating the situation include the microenvironment of the new cells.
The cancer cells may have been perfectly adapted to the primary location, however when they
migrate they may not have the mutations necessary to thrive in the new environment. The cells
may require many changes to be able to proliferate in the new environment.
There are many interesting and open research problems in this area, such as:
• When do cancer cells acquire the ability to spread?
• When do cancer cells acquire the ability to colonize?
• What sets of genes (or “metastatic signatures”) are responsible for the ability to spread
and colonize?
• What kind of microenvironment is needed to facilitate tumour development at distant
sites?
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These questions are quite complex and beyond the scope of this research, however included
for completeness. This particular cancer simulation is focused on the early, pre-metastatic
growth phase of cancer. I am interested in early growth, the appearance of the hallmarks, the
time when tumours reach visible size and what hallmark-stopping efforts are most useful at
this time. Patients whose tumours are found before they spread have a much better chance of
survival and we are interested in this early phase [13], [9], [14], [8]. For completeness, I have
included a small summary of this hallmark. Those interested in learning more are directed
to the revised Hallmark paper, Hallmarks of cancer: The next generation [75] and the papers
referenced therein. This simulation looks specifically at early tumour growth and the develop-
ment of the primary tumour, and as such does not include this hallmark in the simulation.
2.3 Cellular automaton modelling
A cellular automaton is a discrete unit that can exist in a finite number of states based on how
an internal rule set processes given information. Automata are commonly placed on a grid
structure and are updated at discrete time intervals to reflect their new states based on changes
in the environment. In this model they are autonomous units that are independent from the
states of those cells around them, and their next state is selected at each time point solely based
on internal rules and input from the environment.
Cellular automata are a natural tool for modelling cancer cells; much like cancer cells, they
operate somewhat autonomously and choose their next state based on the input they receive
from their environment. This mimics cancer’s loss of collective behaviour – cancer ignores
contact inhibition signals from surrounding cells, stops listening to growth or anti-growth sig-
nals, and operates in a manner resembling “survival of the fittest” focusing on itself. Cancer
cells receive information from their environment, such as the amount of oxygen or nutrients
present, and then this data is transmitted through various biochemical pathways that eventually
lead the cell to make a decision such as divide, move, die, or do nothing. The state-transition
model implicit in the evolution of cellular automata capture this property. The logic and use-
fulness of using cellular automata to model cancer has been proven time and again, and the
reader is directed to Chapter 1, the literature review, as well as Section 2.1 to learn more about
previous models of cancer based on cellular automata.
The cellular automata used in the model described herein can exist in one of six states:
Alive (healthy or cancerous), Apoptotic, Necrotic, Quiescent, Glycolytic and Dead. At time
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point zero in the simulation, there is a single healthy Alive state cell surrounded by empty grid
sites. At every time step in the simulation, each currently alive or quiescent cancer cell is up-
dated based on current environmental variables and the cellular automaton’s internal rule set.
These “rules” represent the phenotype of an individual cancer cell, and can change due to mu-
tations. Each automaton is given its own phenotype (a collection of parameters and rules), and
at each replication it is possible for the phenotype to be altered based on sustained mutations.
In this introduction I have outlined the biological relevance of each state with high level
information as to how the state is represented in the model. More specific implementation
details as to how the phenotype of each cell is defined, what transition rules are, how parameters
can impact transition rules, what parameters were used and how overall growth occurs in the
simulation can be found in Sections 3.2 and 4.2.
2.3.1 The automaton states
Alive
The initial cell in the simulation starts in the alive state. This original cell has no mutations and
has therefore acquired no hallmarks. Throughout the simulation, cells that are not dead (by any
means), quiescent or glycolytic are alive, regardless of if they have mutations or not. Whether
a cell in the Alive state is cancerous or not is determined by its genotype and phenotype. These
consist of a variety of parameters that impact the rules of the cellular automaton. Cells in this
state are bound by things like growth factor, local vasculature, cell-cell adhesion and telomere
length – all of which can be impacted by mutations that change cell rules.
Apoptotic
Apoptosis is the process of programmed cell death. The cell is deconstructed and packaged up
for elimination by both the neighbouring cells and autophages, and this occurs in a coordinated,
programmed manner. Apoptosis is a critical part of the cell lifecycle, as just as cells need to
grow and divide, they also need to die in order to maintain homeostasis. In fact, misregulation
of apoptosis causes a variety of diseases. AIDS and various neurodegenerative diseases are the
result of too much apoptosis with a lack of proper cell replenishment, while cancer and many
auto-immune diseases are riddled with a lack of apoptosis [180]. Apoptosis can be triggered
by both intrinsic pathways, where signals inside the cell activate the process, or extrinsic path-
ways, where death ligands (molecules that bind to others) bind to death receptors on the cell
surface. Regardless of which pathway initiates the process, caspases are activated and begin a
chain reaction which destroys the cell [180]. The cell is then disassembeled and consumed by
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both neighbouring cells and phagocytic cells [75].
Apoptosis can be triggered by a variety of mechanisms, not all of which are completely
clear at this point. A key distinguisher of the apoptotic form of cell death is that while outside
forces and trauma often initiate it, the end state of the cell is self-determined [182]. One well
known initiating force of apoptosis is DNA damage, the most notable player in this pathway
being tumour suppressor protein 53 (often referred to as p53 or TP53) [75]. p53 induces apop-
tosis after sensing large amounts of irreversible DNA damage by upregulating certain proteins
that begin the caspase cascade [75].
Since the most well known inducer of apoptosis is DNA damage, we have chosen to model
apoptosis as a state a cell can enter once a mutation has occurred. Once the cell is in the
apoptotic state, it is also dead. The cell will have no further events scheduled for it and will not
take part in any cell activities including consumption of oxygen or mitosis. The space where
the cell resided is made available again in the system, to model the apoptotic cell being broken
up and consumed, no longer taking up space. In this model, the apoptotic state can be entered
only once a cell has sustained at least one mutation. During each event progression, the cell
is checked for entering into the apoptotic state. Every time a mutated cell goes through the
event process, there is a (numberO f Mutations)/evadeApoptosisFactor probability the cell
will enter the apoptotic state. Cells with fewer mutations have a smaller probability of entering
the apoptotic state since their damage is presumably less and may not be large enough to trigger
apoptosis. As the cell sustains more damage the probability of apoptosis increases, both in cell
biology and our model. The base evadeApoptosisFactor can be found in Table 3.1.
Necrotic
In addition to apoptosis, cells can also die via necrosis. This process has long been thought
to be the result of extreme damage to the cell – a process which is beyond the cells control.
The term necrosis comes from the Greek “nekros” for corpse, and has been used to describe
pathologic cell death [182]. New research is showing that this process may be under genetic
control in some circumstances, similar to apoptosis, however the actual process of how the cell
dies is different than in apoptosis [182]. In contrast to apoptosis, necrosis does not involve the
organized dismantling of a cell but rather is characterized by cell bloating, loss of cell energet-
ics and membrane rupture [182]. In fact, necrotic cells often remain and cause issues for the
host. Gangreen is a potentially serious condition caused by a lack of blood supply in which
cells die via necrosis and remain in the body, forming a dead mass of tissue.
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While it was thought that this was a processes not controlled by the cell, various pieces
of evidence are showing that may be incorrect, including the observations that necrotic death
can be induced by certain ligands, necrotic death can be upregulated by various factors and
that when apoptotic mechanisms are not available cells die via necrosis [64]. If a cell’s ability
to create ATP is damaged, these same events can occur, suggesting that loss of ATP creation
can lead to necrosis over apoptosis, as ATP is needed for the process of self-degredation [182].
The relationship between apoptosis and necrosis is complex, however it is believed that the two
lie on a continuum, with necrosis being the result of extreme insults to the cell, and apoptosis
being the response to less extreme insults [182].
If ATP creation is lessened in the cell, it can lead to necrosis. The cytoplasmic membrane
of the cell has ATP dependent ion pumps that maintain electrical balance in the cell. If their
functioning is reduced, it can open the “death channel” in the membrane making it selectively
permeable to anions. This leads to entry of cations and cytoplasmic membrane swelling and
eventual rupture [182]. Lack of oxygen can cause this ATP depletion, as oxygen is needed to
power the most efficient pathway for ATP creation. Necrosis is often observed in the center of
tumours where nutrient and oxygen supplies are limited [182].
In our model, the necrotic state is entered whenever a cell severely lacks oxygen. Some-
times cells can survive in low oxygen environments by entering a quiescent state (described
below), however when oxygen levels severely drop (such as at the center of a tumour) the cell
cannot survive and, in our simulation, dies via necrosis. This is supported by both the observa-
tion that tumours have a central necrotic core [182], [61], [159] and that lack of ATP can lead to
necrosis (ATP being created in a process that is oxygen dependent). If a cell enters the necrotic
state, it no longer partakes in any new events (no growth and no oxygen consumption) however
it remains in the grid. This is in contrast to the apoptotic state. If a cell dies via apoptosis,
that space is reclaimed and new cells can enter that location. This models the biologic process
where the cell is neatly packaged up and consumed. However, when a cell dies via necrosis,
it bloats and the membrane becomes damaged, but the cell material often builds up, forming a
necrotic core. Because of this, cells in the necrotic state remain physically present but inactive
in the simulation, taking up space just as in cancer biology. A cell enters the necrotic state
when there is not enough oxygen to survive actively or in a quiescent state, and this oxygen
threshold varies based on how aggressive the cancer cell is and what form of metabolism it is
dependent on. Baseline oxygen thresholds can be found in Table 3.1.
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Quiescent
Cell division is tightly regulated within healthy tissue. Cells take part in a lifecycle, which
ensures that DNA is completely replicated and that the cell splits into two equal daughter cells
at each division [147]. Various pathways control the transitions between different cell states
including G0 (a resting state where cells are neither dividing nor preparing to divide), G1 (a
gap phase where cells grow in size and prepare for division), S (where DNA replication occurs
and all chromosomes are duplicated), G2 (a second gap phase where the cell continues to grow
in size and prepare to divide) and M phase (where the cell stops growing and divides in two).
Cancer is often thought of as a disease of this cycle, since uncontrolled growth is one of the
main characteristics of cancer ([108]). In fact, cancer cells often sustain mutations in pathways
critical to regulating this cycle, throwing off the delicate homestasis and trapping cells in a state
of constant replication. Cancer cells often have mutations in the RB (retinoblastoma) pathway
or the p53 pathway, both of which can cause them to replicate indefinitely ([147]).
Quiescent cells are cells that are neither preparing for division nor actively dividing [160].
They can be in the G0 state of the cell cycle, in which case they can reenter the cycle if con-
ditions favour it, or they can be post-mitotic where they are very unlikely to ever divide again.
Studies of tumour microspheroids have shown that as the tumour grows it develops a necrotic
core, followed by a quiescent ring and then a small proliferating rim of actively dividing cells
[160]. Often this necrotic core and quiescent rim is the result of a lack of oxygen and/or nu-
trients getting to these cells. In fact, quiescent cells survive while consuming half as much
oxygen as proliferating cells, and quiescent cells also have roughly half the rate of respiration
[62], [63].
Since tumours are heterogeneous and contain not only actively dividing and dead cells, I
have incorporated a state of “quiescence” into the cellular automaton model. Since oxygen
availability is one of the factors in a cell becoming quiescent, and since this work focuses on
modelling early cancer growth with an emphasis on biologically relevant oxygen modelling,
I have used oxygen availability as the regulator of cells entering the quiescent state. Cells
that do not have some minimum amount of oxygen available for consumption (specific values
can be found in Tables 3.1 and 4.1), but who do have a minimum amount needed to survive,
enter into a quiescent state. Cells that are quiescent cannot divide, even if they otherwise meet
requirements for division (available space, telomere length, etc). As the oxygen concentration
in the model is fluid, the cell could eventually exit the quiescent state if it again has access
to enough oxygen. At this point, it becomes a normal proliferating cell again. Cells can also
be forced into quiescence if they do not have any space to divide. Once a cell is completely
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surrounded, if it has not attained the ignore growth inhibition mutation, it has no way of
dividing. These cells also become quiescent as there is no need for them to be consuming high
levels of oxygen and nutrients or preparing to divide. Cells in the quiescent state do not have
a mitotic event scheduled, but are still checked regularly for having enough oxygen to survive,
still consume oxygen, and can transition to the Alive state (where they can proliferate) at any
time if space and oxygen are available in the correct amounts.
Glycolytic
As mentioned in 2.2.7, cancer cells often transition to a glycolytic phenotype – one in which the
cell preferentially upregulates glycolysis for metabolism. Glycolysis involves breaking down
glucose to yield energy and acid, however it is negatively regulated by the presence of oxygen
[65]. The presence of oxygen usually makes a cell perform aerobic metabolism which is 18x
more efficient at producing energy molecules for the cell (ATP). In cancer there is an increase
in glycolysis, which was first reported by Warburg in the 1920s (cancer cells upregulating gly-
colysis is now termed “the Warburg effect”) [173]. This change has a few repercussions on
the growing community. Firstly, glycolysis has a by-product of acid, making the environment
the tumour is growing in highly acidic. Secondly, the cell is less dependent on oxygen since
glycolysis requires significantly less oxygen then aerobic respiration, the process used by most
healthy cells for ATP creation. It has been observed that cancer cells often use glycolysis even
in the presence of oxygen, although it is less efficient, and the reason for this is still somewhat
unknown. It was proposed however that cancer cells use glycolysis even in the presence of
oxygen as an adaptation to intermittent hypoxia in early growth, as often oxygen levels will
drop below that required for aerobic metabolism throughout growth [65]. Also, cancer cells
that adapt to survive in this kind of an environment, one with high acid and low oxygen, have
a selective advantage over nearby healthy cells allowing for faster growth and invasion [65].
Reprogramming of energy metabolism was identified as an “emerging hallmark” in the
updated hallmarks of cancer [75]. I have included it in this model as a hallmark that can be
acquired by cancer cells. This allows the cells to live in low oxygen environments, effec-
tively eliminating their need for oxygen. This particular hallmark is actually a state the cellular
automata cells can enter. When cells acquire this hallmark they automatically enter the “gly-
colytic” state and no longer require oxygen for growth. Cells that acquire hallmarks never lose
them in this simulation, so cells in the glyolytic state remain in that state until they are forced to
transition to another state. Of the other states, these cells can either become quiescent (if they
run out of space to grow), apoptotic, or dead. They cannot become necrotic (in this simulation,
death via lack of oxygen) as they no longer have an oxygen requirement [127].
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Dead
The last state a cell can enter is the dead state. While other states mean a cell is dead (such as
apoptotic or necrotic), the dead state is for cells that have been killed via random cell death or
the immune system. Cells in this state cannot divide nor consume oxygen, but do remain in
their grid location. For the sake of analysis, which mechanism kills the cell (random death or
the immune system) is recorded, but has no impact on the cells behaviour and so these are not
represented as separate states in the cellular automata.
2.4 Current treatment approaches and challenges
Currently, cancer treatment in Canada has a 63% five-year survival rate, in that the likelihood
of surviving for at least 5 years after a cancer diagnosis is 63%. This is a broad figure, en-
compassing survival rates for all cancers, which actually vary widely (for example, thyroid is
98% while pancreatic is 8%) [33]. In Canada it is estimated that 22 people are diagnosed with
cancer every hour, and males have a 45% lifetime chance of getting cancer with females close
behind with a 41% chance [33]. Even with the seemingly high survival rate, there will still be
an estimated 76,600 deaths from cancer in Canada alone in 2014.
Some cancers are more prevalent than others. For example, in men, prostate, colorectal
and lung make up approximately 49% of all new cancer cases, while in women the top three
(breast, lung and colorectal) make up 51% of all cases. That still leaves another approximately
50% of 191,300 new cancer cases this year, which are split between over 150 different dis-
eases. Figure 2.2 shows just the top 20 different cancers that will impact Canadians this year.
Not only is cancer varied across the population, it is extremely varied over the course of a
person’s lifetime. Different age populations have very different cancer rates, with childhood
cancer diagnoses being largely made up of leukemia and cancers of the central nervous system,
and elderly diagnoses largely lung and colorectal (see Figure 2.3 for a more complete break-
down). The vast diversity seen with cancer diagnoses shows that a treatment regime capable
of treating multiple types at once is highly desirable. This research aims to give support to
targeted combination therapy by simulating cancer in general, hopefully allowing the results to
be broadly applied to many different cancers.
Much research is done every year to improve these statistics. This includes trying to bet-
ter understand causes so that its incidence can be reduced and/or prevented, learning how to
improve patient outcomes once a cancer diagnosis has been made, and how to improve quality
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Figure 2.1: A summary of current cancer statistics in Canada. Reproduced with permission
from [33].
of life and progression-free survival time. A large amount of money is funnelled towards this
endeavour. The Canadian Cancer Society, which is the largest supporter of cancer research in
Canada, donated $44,989,000 to cancer research in Canada last year. In the United States, the
National Cancer Institute, which is that country’s primary agency for cancer research, spends
half of its annual 4.9 billion dollar budget on basic science and cancer specific research [119].
Research into cancer is helping, and mortality rates of most cancers are declining. Figure 2.4
shows the overall decreases in cancer mortality that have been occurring over the last 20 years.
These decreases are due to a variety of reasons, including more information on causes, bet-
ter preventive care and better treatment options. Treatment options are given with a variety of
intents, including to cure (curative), to relieve symptoms when a cure is not possible (palliative)
and as preparation for other treatments. Currently treatment options are varied and include:
• Surgery: For most cancers the most effective treatment option, surgery involves phys-
ically removing the cancer from the body. Surgery can be used in a variety of ways
including prevention (removing tissues with high risk of developing cancer), diagnosis,
primary treatment (as the main treatment – for most cancers if possible this is the best
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Figure 2.2: Percent distribution of estimated new cancer cases, by sex, in Canada in 2014.
Reproduced with permission from [33].
chance for a cure), debulking (to stop it from severely hurting an organ) and relieving
symptoms [110].
• Chemotherapy: The use of drugs to kill cancer cells. Often, chemotherapy drugs are
given in combination with other drugs or treatment regimes, such as radiation therapy
or biological therapy. Chemotherapy can be given in an attempt to cure cancer (often
successful in some leukaemias [118]), prolong life or reduce symptoms (e.g. gemcitabine
for pancreatic cancer). Traditional chemotherapy is cytotoxic in that it targets and kills
cells that rapidly divide (one of the hallmarks of cancer). Since some healthy cells rapidly
divide, such as bone marrow, blood cells, and hair follicles, chemotherapy often kills
these cells as well, resulting in unpleasant side effects. These side effects are not only
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Figure 2.3: Cancer distribution for certain cancers in Canada by age. N is the total number
of cases over 5 years (2006-2010) for each age group; CNS = central nervous system; PNC =
peripheral nervous cell tumours. Reproduced with permission from [33].
unpleasant, but can be life threatening. Bone marrow suppression, for example, can lead
to fatal sepsis as a result of a dramatic reduction of circulating neutrophils in the blood.
Chemotherapy has other limitations including that many chemotherapy agents cannot
easily pass through the blood-brain barrier and reach brain tumours. Also since tumour
vasculature is often poorly developed, actually delivering the drugs into tumours can be
challenging.
• Radiation therapy: Also called radiotherapy, radiation therapy uses ionizing radiation
to kill cancer cells. Often radiation is used with chemotherapy, either before, during or
after, and is also used after surgery to prevent tumour recurrence. Since ionizing radiation
damages DNA and causes cell death of both cancerous and healthy cells, shaped beams
are used from several different angles all pointed at the tumour so the intersection gives
the tumour the highest dose, while sparing the surrounding healthy tissue as much as
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Figure 2.4: Deaths and age-standardized mortality rates (ASMR) for all cancers in Canada
between 1985 and 2014. Reproduced with permission from [33].
possible. Some tumours respond very well to radiation, including germ cell tumours
and lymphomas, while others are largely radioresistant, such as renal cell cancer and
melanoma. In general early stage cancers are better targets for radiation therapy since
they are still contained. Once cancer has spread it is usually incurable with radiation
alone as it is not safe to radiate the whole body. One specific type of radiation therapy is
brachytherapy, which is often used to treat prostate and breast cancer. In brachytherapy,
radioactive seeds are placed inside the area to be irradiated and radiate outwardly to
radiate the tumour without hurting surrounding tissue.
• Hormone therapy: Hormones are a type of chemical messenger produced by glands
and organs in the body. They regulate a wide variety of processes including growth and
development, sexual function and reproduction. Some organs are more responsive to
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hormones than others – such as the breast, prostate and ovaries. When these organs have
cancer, the disease is often hormone-driven, as hormones have a strong impact on gene
expression. Cancers can be tested for their hormone sensitivity, and those that are sen-
sitive can often be treated by either preventing the hormones driving growth from being
created or preventing their impact on the tumour [35]. One of the most common uses
of hormone therapy is for breast cancer. Hormone-receptor positive breast cancer has
receptors to bind the hormone oestrogen, which when bound, stimulates growth. Ta-
moxifen also can bind into this receptor, blocking oestrogen from reaching the receptor,
and stopping the growth stimulating impact of oestrogen. [35]. Therefore, tamoxifen
can be thought of as stopping (or at least, slowing down) the “self growth” hallmark of
cancer.
• Immunotherapy As discussed in Section 2.2.7, the immune system appears to be con-
stantly on surveillance for early cancer growth, finding it and eradicating it. However,
obviously this does not always work as cancer still grows and is diagnosed in 1 out of
3 people [33]. Immunotherapy involves activating or strengthening the immune system
to fight the cancer itself. It was named “Breakthrough of the Year” in 2013 by the jour-
nal Science. Immune therapy can work via a variety of mechanisms including immune
checkpoint modulation, immune cell therapy, vaccines and immune modifying agents
[35]. The immune system is designed to only attack foreign cells and as such needs a
way to recognize these cells. Proteins and other chemical signals are present on cells and
can either attract or elude the immune system. In cancer it is possible the “checkpoint
proteins” may be abnormal and assist cancer in avoiding the immune system. Blocking
these checkpoints can let the immune system know that the cells are not meant to be
in the body. This class of drugs was started in 2011 when ipilimumab was approved
for the treatment of metastatic melanoma [117]. Another form of immune therapy, im-
mune cell therapy, involves taking cancer-fighting T-cells out of the body, harvesting
them in the lab, and then reinjecting them into the patient. Currently vaccines are also
under development and involved in trials for the treatment of certain cancers, including
the already-approved GardasilTMfor prevention of cervical cancer, and sipuleucel-T for
the treatment of metastatic prostate cancer [90]. Lastly, immune modifying agents such
as antibodies, can be used to enhance a persons immune response to cancer. One such
agent, bevacizumab, actually targets one of the cancer hallmarks – angiogenesis – and is
approved for use in a variety of cancers [144].
• Targeted therapy Lastly, targeted therapy involves drugs that target certain molecules
involved with cancer growth. Targeted therapy is part of the new medical field of “per-
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sonalized medicine” where knowledge of an individual’s genetics influences the course
of treatment. Hormone therapy and immunotherapy are two examples of targeted ther-
apy. Another common target for cancer therapy are proteins which are over-expressed in
tumours. Vemurafenib is an example of such a treatment approved for use in metastatic
melanoma [120].
The sheer size of cancer treatment options available is overwhelming. Often treatment op-
tions are very limited for any given cancer and are given according to algorithms that have
evolved over time, however selecting possible treatment combinations to research can be much
more complicated. The advances in our understanding of cancer have been helpful (most can-
cers have shown an increase in 5-year survival over the last 30 years, with initial diagnoses
made in 1975-2003 [83]), and new techniques such as machine learning and data mining are
making it easier to see connections between symptoms, genetics, treatments, outcomes and
more. However, cancer research at the bench is still a slow and meticulous process. Drugs, or
even combinations, need to be approved over the course of many years. The process of getting
an idea to an approved, in-use drug can take anywhere from 10-15 years, and involves many
stages including preclinical testing, new drug applications and three phases of clinical (human)
trials [164]. In addition to a large number of treatments, there are over 200 different types of
cancer [35]. With treatments being tested in combination, and combinations requiring testing
for each different type of cancer, there is a staggering amount of possibilities.
With such a large number of possibilities and potentially years to determine their efficacy,
it would be highly beneficial to reduce the number of options. This research seeks to assist
with this problem in the following ways:
• pair more accurate oxygen modelling with traditional modelling techniques to give more
biologically relevant results that show the impact of oxygen availability on tumour growth
• show that combination treatments will not always work in an additive manner, but rather
multiplicatively beneficial or potentially detrimental
• be a proof of concept that some treatment pairs need not be tested for certain cancers,
environments, patients, etc. as they can be ruled out by accurate modelling
These aims were achieved using the cellular automata model of cancer growth and lattice
Boltzmann model of oxygen distribution in the blood presented in the rest of this thesis. This
model simulates early solid-mass tumour growth with sizes and time lines that match those seen
in vivo. Once the model was capable of growing an “average” tumour, the model was used to
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simulate pairs of “treatments” via hallmark knockouts that represent a high level abstraction of
combination treatments. Hallmarks were removed from the system in pairs to simulate the im-
pact of a combination cancer treatment that is targeted at stopping that particular behaviour of
the cell (e.g. knocking out the hallmark self growth simulates a drug that stops the overgrowth
of cancer, paired with knocking out angiogenesis to model stopping the development of new
blood vessels). For an example of actual cancer treatments aimed at each hallmark, please see
Appendix D. This initial work supported my research aims and was extended to include triplet
and quadruplet knockouts, eventually simulating over 150 different “treatment” combinations.
The results are outlined throughout Chapters 3 and 4 and conclusions and future directions are
outlined in Chapter 5.
Chapter 3
Impact of paired hallmarks on cancer
growth
Sections of this chapter have been reproduced from:
Butler, J., Mackay, F., Denniston, C., Daley, M. Simulating cancer growth using cellular au-
tomata to detect combination drug targets. Unconventional Computation and Natural Compu-
tation. Springer International Publishing, 67-79, 2014.
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3.1 Introduction
As of 2004, cancer was the leading cause of death in the developed world and the second lead-
ing cause of death in the developing world [177], with about 12.7 million cases of cancer in
2008 alone [59]. While much time, money and research are dedicated to cancer the statistics
are grim, with little to no progress in some cancers - for example, there has been no signifi-
cant improvement in survival rates of pancreatic cancer in two decades [145]. We have created
a highly abstract cellular automaton model of early cancer growth and a lattice Boltzmann
model of oxygen flow in blood that investigates the impact of knocking out pairs of “cancer
hallmarks”.
As described previously, both Abbott et al. and Santos et al. have developed models look-
ing at the hallmarks of cancer [1],[143],[113],[114],[115]. Santos et al. built on the work of
Abbott by using a similar modelling approach, but focused on the impact of removing different
hallmarks on tumour growth.
We have used model parameters and methods similar to those outlined in Abbott et al.’s
work to build upon Santos et al.’s hallmark relevance study. We have implemented five of the
six original hallmarks as well as two of the newly introduced hallmarks and enabling charac-
teristics (focusing on those relevant during initial tumour growth), and knocked them out in
pairs to see which have the greatest combined effect.
Henderson stated that “in the most general sense, combinations of therapies, whether drugs
and/or other modalities, will always play an important role in the management of diseases for
which there exists no single specific and totally effective treatment” [78]. Combination treat-
ment involves pairing multiple treatments with the hope that two in combination will not just
be an additive advantage but a multiplicative one. Targeted therapy involves identifying key
pathways involved in cancer progression and creating drugs to target these pathways. This
model simulates targeted combination therapy as we remove key cancer properties (hallmarks)
in pairs and compare cancer growth rates to tumours with all hallmarks active. We hypothesize
that knocking out pairs of hallmarks will not necessarily have the additive effect of knocking
the hallmarks out separately but rather will sometimes have an even greater, potentially multi-
plicative, combined impact.
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3.2 Methods
We have chosen to model two dimensional cancer growth where the biological cells are repre-
sented by cellular automata and the oxygen in the environment is modelled as a two-phase fluid
using the lattice Boltzman method. Most models in the literature currently restrict themselves
to two dimensions as it is more computationally feasible and since cancer does not grow in a
sphere but rather an oblate spheroid. Our 2D simulation is easily compared with both existing
models and 2D biopsy slices. Here we will present a high level outline of the method, and
each section will be covered in more detail below. Pseudocode describing the simulation is
provided in Section 3.2.4. The simulation begins with a single healthy cell at the center of a
2-dimensional grid. An event queue keeps track of cellular events, and initially a single mitotic
event is placed on the queue for the healthy cell. Each event dequeued from the queue is an-
other loop in the model and puts that cell through a life cycle. The cell is checked for whether it
still has enough oxygen to survive, is in a location with growth factor, has access to blood, has
space to grow, and has sufficiently long telomeres. If all of these checks are successful, or if
mutations confer these abilities, the cell enters a mitotic event. This creates a daughter cell and
potentially introduces mutations into the daughter or parent. Both cells have events scheduled
for some point in the future and are added to the event queue, then the next event is popped.
Oxygen is consumed by cells when they divide or every 25 time steps of the main simulation
if they are not actively dividing.
3.2.1 Modelling the hallmarks
We have simulated 5 of the 6 original hallmarks and two of the recently added characteris-
tics and hallmarks that were described in [75]. This model is specifically interested in pre-
metastatic growth, when a patient has the greatest chances of survival. Therefore, we have
not modelled the sixth hallmark, tissue invasion and metastasis. To keep our results credi-
bly comparable with previous work in this field, we have not included inflammation or energy
metabolism in our model. Our model is inspired by work in artificial life where agent based and
mathematical models have been used to simulate cancer growth and angiogenesis [107], [28].
In general, each hallmark is modelled as a change to the rules of the life cycle or automata.
For example, if a cell needs to be within growth factor to grow, at each potential growth time
point it is checked if there is growth factor present at the cell’s location, and it can only grow
if there is. However, if the hallmark sustained growth has been activated in that cell, the rule
no longer applies and the cell can grow regardless of the availability of growth factor. Here we
will briefly describe each hallmark put forth by Hanahan and Weinberg that we are including in
this model, as well as their implementation. At the end of this section pseudo code describing
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the cell lifecycle is included.
Sustained growth
Normal tissue function is regulated by growth signals which instruct cells when to grow. These
signals are involved in a signalling cascade that eventually instructs the cell to divide. Muta-
tions in genes that act early in this pathway have been thought to be cancer causing [32]. To
model this process, healthy cells can only grow within a predefined boundary of growth fac-
tor. Outside of this, cells can not actively divide unless they have the sustained growth (SG)
mutation.
Evading growth suppressors
Similarly, healthy cells are instructed when to stop growing, and eventually reach a state of
replicative maturity (senescence). One way cells receive this instruction is via contact inhibi-
tion - pressure from surrounding cells signals that the cell no longer needs to grow. Contact
inhibition is not present in cancer cells in cultures. Contact inhibition is modelled in our sys-
tem by a space requirement. Healthy cells stop actively growing once there is no more space
adjacently or diagonally available on the lattice. Cancer cells in our system can have the ignore
growth inhibition (IGI) hallmark activated which allows cells to grow even without space. If
a cell with the IGI hallmark attempts to grow and is out of space, it competes for space with
its neighbour. The cancer cell has a 1/c likelihood of success, success being that it divides and
takes over its neighbour’s space.
Avoiding programmed cell death
When a healthy cell sustains too many mutations it can undergo programmed cell death (apop-
tosis) often initiated by TP53 which is mutated in approximately 50% of all cancers, allowing
cells to continue living and dividing even after substantial genetic changes. In our simulation,
apoptosis can occur to any cell that has a single mutation. Since apoptosis is initiated when
aberrant activity is detected, the chances of a cancer cell dying via apoptosis increases with
each subsequent mutation (m/a likelihood of death). Cells with a mutation in this mechanism
(referred to as AA throughout) cannot die by apoptosis.
Enabling replicative immortality
One unique property of cancer cells is their ability to grow seemingly forever. Usually cells
are limited to a certain number of replication cycles, which research suggests is controlled
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by telomeres, DNA caps, that shorten and prevent replication once at a certain length [31],
[146]. We have modelled telomeres as an integer in each cell that decreases by one after every
division, and must be greater than zero for division to occur. Cells with the ignore telomere
(IG) hallmark turned on will replicate regardless of telomere length.
Inducing angiogenesis
Typically in humans the vasculature is quiescent, in a sleeping state, and not actively building
new blood vessels except during certain circumstances (such as wound healing). Conversely in
cancer there is an “angiogenic switch” that becomes and stays active sometime during cancer
growth and develops new vasculature for the tumour, delivering nutrients, removing waste,
potentially delivering drugs and immune cells, and giving a pathway to spread [73]. Cells with
the angiogenesis (A) mutation in our model are thought to be on the path of new vasculature,
and any cells neighbouring an angiogenic cell have access to oxygen regardless of existing
vasculature or surrounding oxygen levels. These cells also have a higher chance of being killed
by the immune system, as immune cells travel through the blood system. Anigogenic cells and
their neighbours have a (ai) ∗ (1/i) (ai being the angiogenesis immunity parameter and i being
the immunity death parameter, both described in Table 3.1) probability of being killed by the
immune system.
Genetic instability
The body has a remarkable set of machinery that detects and resolves changes in the DNA
which often prevents large amounts of mutations being propagated from one cell to the next.
Cancer cells however display an increase in the rate of mutation, often as a result of the break-
down of this protective machinery [91]. We model this behaviour with the genetically unstable
hallmark (GU) which, when active, increases the chances of mutation in each mitotic event by
a factor of (1/gif) where gif is the genetic instability factor parameter.
Evading immune destruction
There is a theory that the immune system is always watching for the development of cancer
cells, and is able to eradicate them quickly before they become solid tumours. Therefore it is
believed that when a tumour does form, its cells must have somehow avoided or limited the
impact of the immune system. We model this characteristic of cancer cells with the avoids
immune system hallmark (AI) which when activated lowers the chances of a cancer cell being
killed by the immune system by a factor of aip, the avoids immune system parameter.
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3.2.2 A note on hallmarks not included
We have not modelled the emerging hallmark of “deregulated cellular energetics” in this ver-
sion of the model (however it was included in the next iteration of the software, described
in Chapter 4). This potential hallmark involves a cancer cell’s ability to change their energy
metabolism pathway from the high efficiency aerobic respiration, to the lower efficiency anaer-
obic respiration. As this is an emerging hallmark, Hanahan and Weinberg have not decided that
it is common enough to be a full hallmark. Also, this high level model is only looking at one
aspect of the tumour microenvironment - the impact of oxygen availability on the hallmarks.
We are not specifically modelling ATP creation or glucose, and as such we have not included
this emerging hallmark at this time.
3.2.3 Event queue
Mitotic events are the driving force in this model. An event queue keeps track of all events
scheduled for the simulation. Initially, a starter cell has a mitotic event scheduled for 5-11 time
steps in the future. When the event is dequeued, the time is checked. If the time for the event
is beyond the current time in the simulator the current time is updated to reflect the new time.
When a mitotic event is scheduled a time is calculated for that event. If the cell is to grow
in a North, East, South or West direction, the time is scheduled 5-11 time points in the future
(chosen by random number). If the cell is growing on a diagonal on the grid then the event is
scheduled for 7-14 time points in the future, to account for the increase in spatial distance.
Since the cells in the simulation (the biologic cells, not necessarily “cells” in the classical
cellular automaton sense) are impacted by rules that use probability, this model deviates slightly
from standard cellular automata. Also, at every time step only a handful of cells are actually
updated (those that were scheduled for a mitotic event). As pointed out by Abbott et al.,
the cells could instead have a counter that is updated each time as it progresses through the life
cycle, but since real biological cells are not updating that often it makes more sense to schedule
their events for some time in the future and save the computation time [1].
3.2.4 Lifecycle pseudocode
1: f irstCell← Cell
2: time← 0
3: f irstCell.scheduleMitoticEvent()
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4: eventQueue.push( f irstCell)
5: S ← 0
6: while eventQueue not empty do
7: currentCell← eventQueue.pop()
8: if currentCell.isAlive then
9: time← currentCell.time()
10: dead ← currentCell.died {check for random cell death}
11: if currentCell.isMutated then
12: apop ← currentCell.apoptosis {check for death via apoptosis if cell is mutated
(avoided if apoptosis hallmark is on)}
13: end if
14: cangrow← false
15: if sel fGrowthHall or withinGrowthRange then
16: cangrow← true
17: end if
18: if spaceToGrow then
19: space ← true {if ignore growth inhibition is on, it can compete for space if no
space available}
20: end if
21: telo← false
22: if currentCell.getTelomere > 0 or currentCell.ignoresTelomereHallark then
23: telo← true
24: end if
25: if currentCell.withinBlood or currentCell.isOrWithinAngiogeneic then
26: blood ← true
27: end if
28: if currentCell.killedByImmune != true or currentCell.avoidsImmune then
29: stillAlive← true
30: end if
31: if currentCell.enoughOxygen then
32: oxygen← true
33: end if
34: if cangrow and space and telo and blood and stillAlive and oxygen then
35: daugtherCell← currentCell.mitosis {daughter cell may be mutated during mitosis
event}
36: currentCell.mitosisOccured() {opportunity for mutation during a mitosis event}
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37: currentCell.scheduleMitoticEvent()
38: daughterCell.scheduleMitoticEvent()
39: eventQueue.push(daughterCell, currentCell)
40: end if
41: end if
42: end while
3.3 Lattice-Boltzmann implementation details
Lattice-Boltzmann algorithms [41], [156], have become increasingly popular as methods used
to model coarse-grained fluid dynamics. These methods use a discretization of time, space, as
well as velocity in order to solve for the motion of a set of partial distribution functions, fi(x, t),
each corresponding to a discrete velocity vector, ei, which evolve according to a discretized ver-
sion of the linearized Boltzmann equation. Macroscopic fluid quantities are then determined
via moments of these distribution functions. Lattice Boltzmann algorithms have even recently
been paired with a cellular automata cancer model in the 2012 paper by Alemani et al. wherein
they coupled a 2-state cellular automata model of cancer with a lattice-Botlzmann fluid model
of nutrient diffusion [7].
In order to model the transport of oxygen dissolved in blood, we use a two component
lattice-Boltzmann algorithm. Here, the quantities of interest are the total density ρ = ρB + ρO
which should satisfy both the continuity and Navier-Stokes equations, and the density differ-
ence between the two components φ = ρO − ρB, which will evolve according to a convection-
diffusion equation. In these expressions, ρO corresponds to the density of oxygen in the blood,
and ρB is the density of the remaining blood constituents. In order to model these two quanti-
ties we follow the binary fluid approach of [126], [161], and introduce two sets of distribution
functions, fi and gi, whose moments correspond to the physical variables,
ρ =
∑
i
fi
ρuα =
∑
i
fieiα (3.1)
φ =
∑
i
gi, (3.2)
where u is the local fluid velocity. The time evolution of these distribution functions is governed
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by the following discretized Boltzmann equations,
fi(x + ei∆t, t + ∆t) − fi(x, t) = −∆t
τρ
(
fi(x, t) − f eqi (x, t)
)
gi(x + ei∆t, t + ∆t) − gi(x, t) = −∆t
τφ
(
gi(x, t) − geqi (x, t)
)
+ hi(x, t)∆t. (3.3)
The first term on the right hand side describes a single time relaxation towards the equilibrium
distribution functions, f eqi and g
eq
i [30], while hi is a forcing term we have introduced in order
to remove oxygen locally from the system when it is consumed by the cancer cells. To model
these equations we use a nine velocity, 2D algorithm with velocity vectors,
ei = [(0, 0), (±vc, 0), (0,±vc), (±vc,±vc)] , (3.4)
where vc = ∆x/∆t, with ∆x and ∆t corresponding to the lattice spacing, and timestep respec-
tively.
In order to satisfy conservation of mass and momentum we choose the equilibrium distri-
bution functions according to, ∑
i
f eqi = ρ∑
i
f eqi eiα = ρuα∑
i
geqi = φ (3.5)∑
i
geqi eiα = φuα, (3.6)
and define the higher moments and forcing term by the following equations,∑
i
f eqi eiαeiβ = Pαβ + ρuαuβ∑
i
geqi eiαeiβ = Γµδαβ + φuαuβ∑
i
hi = F∑
i
hieiα = 0. (3.7)
Here Pαβ is the pressure tensor, Γ is the mobility, which is related to the diffusion constant,
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µ is the chemical potential difference between the fluid components, and F is an oxygen sink
term describing the amount by which φ changes at a given timestep. With these choices, a
Chapman-Enskog expansion of our Boltzmann equations (equations (3.3)) can be shown to
reproduce the continuity and Navier-Stokes equations,
∂tρ + ∂αρuα = 0
ρ∂tuα + ρuβ∂βuα = −∂βPαβ + η∇2uα, (3.8)
as well as a convection-diffusion equation with oxygen sink term, F,
∂tφ + ∂α(φuα) = (τφ − ∆t/2)
[
Γ∇2µ − ∂α
(
φ
ρ
∂βPαβ
)]
+ F. (3.9)
to second order in the derivatives. Here, the viscosity, η, is defined according to ρ(τρ −
∆t/2)v2c/3. For the pressure, Pαβ, and chemical potential difference, µ, we use the equations
given in [126], [161], which were derived based on a free energy description of the fluid mix-
ture,
µ = −λ
2
φ
ρ
+
ξ
2
ln
(
ρ + φ
ρ − φ
)
Pαβ =
[
ρξ + φµ
]
δαβ. (3.10)
Here λ and ξ are parameters determining the state of the system; for ξ < λ/2 phase separation
of the two components occurs. We therefore always work in a regime where ξ > λ/2 and the
oxygen remains mixed in the blood. In this framework, the diffusion constant for the model,
D, is given by,
D =
(τφ − ∆t/2)Γλ
2ρ
. (3.11)
For the lattice-Boltzmann algorithm, we use a density of ρB = 300mol/m3 [57] through-
out the simulation domain, and set the density of oxygen to ρO = 9mol/m3 at the boundary,
representing a continual supply of oxygen to the system. We choose a diffusion constant,
D = 0.134mm2/s [166], corresponding to the thermal diffusivity of colon cancer. The oxygen
grid is updated every 25 time steps (time in the cellular automata model) and each cell at that
point consumes oxygen if it has not consumed already during a mitotic event. The consumption
level for normal cancerous cells is 0.019. The lattice Boltzmann grid is finer than the CA grid,
and so at each time step of the cancer cells, each cancer cell calculates the amount of oxygen
present in all lattice Boltzmann cells mapped to it and gets a total oxygen value. These are
dimensionless and are parameters chosen by fixing the consumption and diffusion rates, and
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Table 3.1: Parameters used in simulations.
Description Symbol Value Ref
Initial telomere length t 100 [1]
Evade apoptosis factor ev 10 [1]
Mutation rate m 500
Chosen to lay between
two used in
[143]
Random death rate d 10000 Simulation
Competition likelihood c 10 [1]
Angiogenesis immunity ai 10 Simulation
Avoid immunity aip 10 Simulation
Immunity death i 1000
Simulation (equal to
random cell death in
[143])
Genetic instability factor gi f 10 Simulation
Blood density ρB 300 mol/m3 [57]
Boundary oxygen density ρO 9 mol/m3 [111]
Thermal diffusivity D 0.134 mm2 ∗ s−1 [166]
iteratively determining what requirements gave the most physiologically relevant results.
3.3.1 Parameter values
Parameters (Table 3.1) for the model were either chosen from the literature or by searches
of the parameter space. Parameters used in the models by Abbott [1] and Santos [143] were
held constant (except mutation rate which was selected to be between the two values used by
Santos) and other parameters were varied iteratively. The output was examined for concordance
with in vivo tumours. We examined the physical structure of the tumours, and found that the
tumours resemble the classic solid mass tumour structure of a necrotic core with a quiescent
rim and proliferating rim [61], [159]. We also examined the growth rates and sizes of the
tumours to compare to in vivo tumours. The tumours grow to roughly 2mm to 2.5mm before
overwhelming the nutrients available and needing their own vasculature [60] and then grow to
a maximum of 5.5mm. All calculations were done using an average cell diameter of 25 µm
[163]. The tumours grow to this final size over a period of approximately two years, assuming
a cell division time of 16-24 hours. This is in line with growth times for fast growing tumours,
which reach clinically detectable size (0.2 cm to 1 cm) within two years [111].
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Figure 3.1: A simplified UML diagram showing the major objects involved in the simulation.
This image was created using Microsoft Visual Studio.
3.3.2 Implementation details
The simulation software was implemented in C++ and compiled and run on the Sharcnet com-
puting cluster at The University of Western Ontario. Figure 3.1 shows the main objects in-
volved in the simulation.
3.4 Results
With all hallmarks active, every simulation run produced a tumour using parameters described
in Table 3.1. A “tumour” is classified as a mass in which 99% or more of its alive cells have at
least one mutation. The growth over time for a simulation with all hallmarks available can be
seen in Figure 3.2.
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Figure 3.2: Cell counts and growth images for a tumour with all hallmarks available for ac-
tivation. a and b: Total cell count for cancerous, non cancerous, and each hallmark is shown
for an entire simulation. a) Regular verses cancerous cell growth b) Each individual hallmark
growth and total cancer cell growth. c - h: Simulation of a colony of cells with all hallmarks
available for activation at event steps 1 to 32. Dead cells are black, healthy cells are blue, all
other colours represent some kind of unique cancer phenotype. Simulation steps: c) 1 d) 6 e)
12 f) 18 g) 24 h) 32
Figure 3.2a shows total cell counts throughout growth. Initially healthy cells grow rapidly,
however around step 20 they sharply decline. Then, around step 25 cancer cells rapidly start
to increase. This corresponds to a sharp increase in angiogenic cells as well as cells that avoid
apoptosis, and relatively stable numbers of healthy cells. Figure 3.2c through h show the im-
ages produced from the same simulation. It can be seen in Figure 3.2c that initially healthy
cells dominate the clone. Death is occurring, most likely due to random cell death or the ini-
tial fast killing of any cancerous cells by apoptosis and the immune system. By 3.2d we can
already see the emergence of different cancer phenotypes. There are three major phenotypes
present in the tumour from early on. The center of the tumour also begins to die at 3.2d. This
is due to a lack of oxygen getting to the center of the tumour (causing necrosis). In 3.2g the
outside of the tumour is also dying, as regular cells can go no further as they are outside the
growth factor and blood range. In 3.2h we see the tumour is almost entirely cancerous, with a
few different phenotypes protruding from the mass. This “fingering morphology”, where the
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border is not smooth but rough, is consistent with other models and histopathological observa-
tions [26], [18], [27]. It is believed that there are two forms of tumour invasion - either tumour
cells outgrow normal tissue and expand as a bulk mass, or they form invasive contingents by
intermingling with stromal cells. The fingering morphology is a consequence of this intermin-
gling [88]. It has been noted that this fingering morphology looks like a crab, from which the
word cancer was derived [88]. The fingering morphology is correlated with harsher microen-
vironments where only cells with particular phenotypes survive. This behaviour is evident in
our model where certain subclones and phenotypes dominate the tumour.
To look at the impact of removing hallmarks, the total number of alive cancer cells at the
end of the simulation when hallmarks were removed was compared to the total number of alive
cancer cells at the end of a normal simulation, with all hallmarks available. Removing some
hallmarks in pairs had very little effect on the growth of the tumour. In fact, knockout pairs
SG & IGI, SG & AA, SG & IT, IGI & AA, IGI & GU, IGI & AI, AA & GU, AA & AI,
IT & GU and GU & AI had no significant effect (all p values greater than 0.05 using Mann-
Whitney U test) (see Figure 3.3 b and c for examples of final simulation image when cancer
took over despite hallmark pair knockouts). Other pairs of hallmarks had such a large effect
that a cancerous tumour never took over and the simulation ended prematurely as not enough
cells survived. The normal cells continued to grow to the edge of the growth factor barrier, and
then eventually consumed all of the oxygen in the system and the healthy cells died off. This
can be seen in Figure 3.3 d and e. The following hallmark pairs significantly decreased cancer
growth (as confirmed using Mann-Whitney U test): SG & A, SG & GU, SG & AI, IGI & A,
AA & A, IT & A (p=9.134×10−5) and A & GU and A & AI (p=9.083×10−5). Other pairs had
a smaller but still significant effect, using Mann-Whitney U test: AA & IT (p=6.574×10−4),
SG & AA (p=1.414×10−3), IGI & AA (p=3.642×10−3), AA & AI (p=5.665×10−3) and GI &
AI (p=1.560×10−2).
Figure 3.3: End of simulation images for 4 different hallmark-knockout pairs. a) no hallmarks
knocked out b) IGI & AA c) IGI & IT d) SG & A e) IGI & A
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Figure 3.4: Total alive cancer cell count every 400 simulation steps is shown. Each hallmark-
knockout pair was simulated and run 10 times. The average cell count from these runs was
calculated and plotted
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Figure 3.5: Each tumour at the end of the simulation had different phenotypes present. The top
10 phenotypes, by total number in the tumour, in each separate simulation were recorded at the
end of simulation and totals were plotted
The effect of various hallmark pairs can be seen in Figure 3.4. This shows that some hall-
mark knockouts (A & GU, IGI & A, IT & A, SG & A, A & AI, SG & AI) do not result in a
tumour. Cancer growth is fairly consistent across all of the simulations, regardless of knock-
out, until step 20. Here, all cell populations take a dip however certain simulations show strong
growth after this point. The knockout pairs listed above however die off at this point, and these
simulations do not result in a cancerous tumour.
Figure 3.5 shows a histogram of phenotypes that were in the top 10 phenotypes by cell
count during the last stage of simulation for 14 unique simulations (knockout pairs that still re-
sulted in a tumour). IDs can be mapped to phenotype using Table 3.2. While it is obvious that
phenotype 0 (dead phenotype) will be present in large numbers in all runs, it is interesting that
phenotype 4 and 132 are also present in every run in large numbers - these are cells with the
angiogenesis hallmark activated and no other hallmarks, both alive and dead. Also, by the end
of simulation almost all tumours have a large population of dead self growth cells and avoids
3.4. Results 89
Table 3.2: Phenotype codes and the corresponding hallmarks present in the phenotype.
Code Hallmarks Present
0 Healthy
128 Healthy dead
4 Angiogenesis
132 Dead, angiogenesis
192 Dead, self growth
144 Dead, avoids apoptosis
169 Dead, ignores growth inhibition, ignores telomers, avoids immunity
29 Avoids immunity, angiogenesis, ignores telomere, avoids apoptosis
136 Dead, ignore telomeres
139 Dead, avoids immunity, genome unstable, ignores telomere
22 Genome unstable, angiogenesis, avoids apoptosis
68 Angiogenesis, self grows
36 Angiogenesis, ignores growth inhibition
64 Self growth
16 Avoids apoptosis
8 Ignores telomeres
2 Genome unstable
86 Genome unstable, angiogenesis, avoids apoptosis, self growth
82 Genome unstable, avoid apoptosis, self growth
196 Dead, angiogenesis, self grows, dead
134 Dead, genome unstable, angiogenesis
54 Genome unstable, angiogenesis, avoids apoptosis, ignores growth inhibition
52 Angiogenesis, avoids apoptosis, ignores growth inhibition
178 Dead, genome unstable, avoids apoptosis, ignores growth inhibition
6 Genome unstable, angiogenesis
164 Dead, angiogenesis, ignores growth inhibition
32 Ignores growth inhibition
28 Angiogenesis, ignores telomere, avoids apoptosis
12 Angiogenesis, ignores telomere
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apoptosis cells. It is interesting that alive angiogenesis cells dominate, but the self growth
and apoptosis cell group that dominates is dead. Also present in the majority of simulations in
large numbers are dead cells with ignores growth inhibition activated and ignores telomeres
activated, as well as alive cells that are both angiogenic and avoid apoptosis.
3.5 Discussion
As expected, when all hallmarks are available for activation the tumour grows to the largest
extent, presumably as these tumours can take advantage of all hallmarks and the different abili-
ties each confers. It was also expected that knocking out 2 hallmarks would significantly lower
the growth of cancer. We hypothesized that certain pairs would perform better than others, and
that knocking out hallmarks in pairs could have more than just an additive effect.
Half of all tumours with self growth knocked out did not result in a tumour. SG allows a
tumour to extend beyond the normal boundary of growth. In areas of the body where growth
factor is limited, this would be a very important hallmark. However if a tumour is growing
where there is ample growth factor the hallmark may be less effective as a drug target.
All simulations with angiogenesis knocked out failed to result in a tumour. Similar to SG,
angiogenesis allows a cell to live outside the predefined blood boundary. One reason the an-
giogenesis hallmark is more powerful is because it conveys benefit to not just the cell with the
mutation, but surrounding cells, as all nearby cells benefit from the new vasculature.
The last hallmark that was knocked out in more than one pair that did not lead to a tumour
is genome instability. Since genome instability can lead to all of the other mutations being
activated more frequently this is understandable.
As evident in Figure 3.4, there is a bifurcation in total cell count - either similar to both
hallmarks or almost none. This is because cell populations which result in a tumour show al-
most exponential growth and are not limited by oxygen or space due to acquired mutations.
Cell populations that do not result in a tumour are limited by both of these factors, and so even-
tually almost all cells die as this overpopulation cannot be sustained by the normal vasculature.
It is interesting that of the phenotypes that dominated clones at the end of simulation (shown
in Figure 3.5), many cells with a single mutation grew quickly but died off. Single mutation
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phenotypes were largely present, but in dead cells. In contrast, the phenotypes that dominated
and were still alive had multiple mutations. While multiple mutations increase the chances of
death by the immune system and apoptosis, this suggests it still conveys a very strong advan-
tage overall. This supports the hypothesis that knocking out multiple hallmarks, if you can find
the correct pairs, will be better than single-target treatments.
Many knockouts did not prevent the tumour from forming. For example, all knockouts that
included ignoring growth inhibition still resulted in a tumour, except for one (IGI & A). In our
model IGI allows cells to grow even when there is no space around them, but this only conveys
an advantage to internal cells. Cells on the proliferating edge always have space, and therefore
removing it does not seem to hurt growth to a significant degree. This could be a limitation
of the model as in reality the proliferating rim of a tumour may have space constraints from
surrounding tissue.
Other limitations of the model include the fact that angiogenesis only provides a benefit to
itself or cells immediately around it. In addition, it only provides an advantage while the cell
is living. In reality angiogenic cells start the creation of blood vessels and those remain even if
the cells die.
3.6 Conclusions
We have modelled the impact of cancer hallmarks, as proposed by Hanahan and Weinberg, on
early tumour growth using a cellular automaton model of cancer cells and lattice Boltzmann
methods for two phase fluids (oxygen in the blood) [74], [75]. Our results show that knocking
out pairs of hallmarks does not necessarily have an additive effect. Santos et al. found that
avoiding apoptosis and ignoring growth inhibition were the most critical hallmarks indepen-
dently when cells had a high rate of mutation, and they also found that ignoring telomeres
and self growth had a small impact [143]. Looking at the impact of knocking out both avoid-
ing apoptosis and ignoring growth inhibition, we did not see a significant decrease in tumour
growth. This is interesting as it is not what would be expected from the findings of knocking
out singular hallmarks if one assumes linear combination of knockout effects.
We found that knocking out the ability for a cancer cell to self grow and avoid immune
system, as well as self grow and be genetically unstable, prevent a tumour from growing.
Neither self growth nor genetic instability had a great effect in the simulations done by San-
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tos et al. (the immune system was not modelled in this work) however in combination they had
a strong and significant effect. This supports our hypothesis that knowing the impact of indi-
vidual hallmarks, which can be extended to individual drugs, does not necessarily give insight
into the impact of combining those knockouts and drugs.
Lastly, we found that knocking out the ability for cells to induce angiogenesis combined
with any other hallmark prevented tumour growth. Research has been done into anti-angiogenesis
drugs however the conclusions were not always positive. Patients still died from small tumours
throughout the body as opposed to one large tumour, which was seen without the drugs [55]. It
is hypothesized that without angiogenesis, other factors became important, such as metastasis.
Perhaps the key is preventing cells from inducing angiogenesis and limiting other cancerous
abilities. Currently trials are underway to test pairing anti-angiogenesis drugs with various
chemotherapy drugs for multiple types of cancer including breast, colon and medulloblastoma
[43], [84], [81], [112], [77] - in other words, combination therapy trials.
We have found that the effect of knocking out cancer hallmarks in pairs can have varying
levels of success. This suggests that clinical research should be done into combination drug
treatment as not all drugs that are strong individually will necessarily be strong in combination.
Since cancer treatments can be physically and emotionally challenging for patients, knowing
in advance what combinations will not be successful could greatly enhance the quality of life
of people undergoing cancer treatment.
A natural question that arose after this analysis was what would be the impact of knocking
out hallmarks in triplets, or even groups of four? Cancer patients are often treated using combi-
nations of two drugs, as shown above, however clinical trials have previously been conducted,
and some are currently under way, investigating the safety and efficacy of using three and even
four drugs at a time [167], [171], [125], [122]. The results of knocking out pairs of hallmarks
was enough to show that knowledge of a drug’s individual effect may not confer knowledge
of drug effects in combination. This leads to the question of whether drugs (or in this case,
hallmark knockouts) in triplets or quads would also have varying levels of effectiveness, and
whether some would have a multiplicative effect or not effect at all.
Chapter 4
Impact of triplet and quadruplet
knockouts of cancer hallmarks on tumour
growth
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4.1 Introduction
In 2012 Santos and Monteagudo set out to determine the relative importance of different cancer
hallmarks on the overall growth of a tumour [143]. They concluded that parameters such as
mutation rate and telomere length had an impact on the relative importance of hallmarks.
If it is the case that tumour composition factors, such as mutation rate and cell division
rate, affect the relative importance of individual hallmarks, how much more might that be the
case when looking at the combinations of hallmarks? As shown in the previous chapter, not
all hallmarks that are strong individually are strong in combination; in fact, the key combina-
tions involved angiognesis with other hallmarks, not evade apoptosis. With pairs, it seemed that
being able to grow in more areas, with hallmarks such as angiogenesis and self growth was
more important than avoiding death mechanisms (through evades apoptosis or ignore growth
inhibition).
Research in the medical field recognizes the need for combination therapy and many clini-
cal trials are underway looking at pairs of drugs for various cancer types. Pancreatic cancer, a
cancer with an 8% survival rate, is a common combination drug target [33]. Gemcitabine (the
standard treatment for advanced pancreatic cancer) is a nucleoside analog (meaning it mimics
one of the building blocks of DNA). It causes apoptosis by interfering with DNA construction.
For pancreatic cancer unfortunately it does not appear to have curative effects, but rather is pal-
liative, allowing patients a better quality of life as they die. A better quality of life is a relative
term however as gemcitabine causes neutropenia (a reduction in the number of neutrophils, a
type of infection-fighting white blood cells) which makes patients susceptible to life threaten-
ing bacterial or fungal infections. Gemcitabine also causes flu like systems, fatigue, nausea,
vomiting, weakness, hair loss and more. However, clinical trials are under way to pair it with
other chemotherapy drugs which could have the potential to actually stop cancer growth, not
just slow it down.
Gemcitabine was tested in combination with oxaliplatin in a trial conducted in 2005 [102].
Oxaliplatin is a platinum-based antineoplastic agent that is believed to inhibit DNA synthesis
by creating inter- and intra-strand cross links in DNA, preventing it from being replicated [34],
[71]. The study found that the combination had a statistically significant effect on progression-
free survival (9.0 months in combination vs 7.1 months without, p=.04) and clinical benefit
(38.2% vs 26.9%, p=.03). Despite a seemingly small improvement in survival time, patients
lived approximately 30% longer free of progression with the combination treatment [102].
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Since then more combination trials have been completed, including one in 2007 looking at
gemcitabine alone and in combination with erlotinib for pancreatic cancer – a disease which
had not shown an improvement in survival since the introduction of gemcitabine in 1996 [116].
Erlotinib is a reversible tyrosine kinase inhibitor which binds to cell receptors usually bound
by ATP, causing signalling cascades to not be initiated [35].
The study tested the combination on 569 patients (half of which received the combination,
and half of which received gemcitabine plus placebo) and found that progression free survival,
one-year survival and overall survival were all significantly improved when the combination
treatment was administered [116].
These combinations showed promise; however, after completion of the work in chapter
two, I wondered if three or even four drugs would be a possibility, and if it would have a better
effect. In 2009, following the study described above, another study was initiated that looked at
gemcitabine and erlotinib in combination with a third drug, bevacizumab [167]. Bevacizumab,
sold under the trade name AvastinTM, is an angiogenesis inhibitor (stops the growth of new
blood vessels). It inhibits vascular endothelial growth factor, one of the chemicals that signals
angiogenesis. Of the 607 participants in the trial, the triplet combination was tested on 306
patients, and 301 patients received just the double combination treatment of gemcitabine and
erlotinib. Unfortunately this combination did not lead to a statistically significant overall sur-
vival, but progression free survival was improved significantly (p=0.002) [167]. Perhaps more
importantly, the triplet was well tolerated by patients and safety data did not differ from previ-
ously described safety profiles of the individual drugs. This suggests that triplet combinations
are possible, however it also underscores the need to find the correct triplets.
Currently, trials are under way to address the question of what triplets are best as well as
safe. VU (Vrije Universiteit) University Medical Center currently has an ongoing study look-
ing at the effect of chemoradiation with gemcitabine in combination with panitumumab (trade
name VectibixTM) for patients with pancreatic cancer [171]. Panitumumab blocks one of the
receptors commonly over expressed in cancer [35]. It has also been used in colorectal cancer.
This trial is looking at combining three different treatments - a traditional chemotherapy drug,
an immunotherapeutic agent, and radiation.
Another currently ongoing study looking at triplet combinations is being performed by
OncoMed Pharmaceuticals, Inc, the creator of a novel anti-cancer stem cell antibody named
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OMP-59R5 (tarextumab). This drug appears to have anti-tumour activity through various
mechanisms including interfering with tumour angiogenesis and cancer stem cell growth [125].
Even more recent is a study being performed by New Mexico Cancer Care Alliance that is
currently recruiting patients for a trial of three different drugs for metastatic pancreatic cancer
[122].
Lastly, studies have even been conducted with up to four different treatments in combina-
tion. A study from 2007 looked at the effects of combining oxaliplatin, fluorouracil, leucovorin
and bevacizumab on previously treated metastatic colorectal cancer. The quadruplet combina-
tion of these drugs found a statistically significant improvement in survival [70].
These studies highlight the benefit of combination treatment beyond just two drugs. They
also show that it is hard to predict what triplet or quadruplet combinations will have a statis-
tically significant improvement over the drugs alone or the drugs in pairs. In addition, it is
critical to determine the safety of combinations, as it is possible that the drugs in combina-
tion will have more severe effects. Because of this risk, it is even more critical to eliminate
combinations that would either be too toxic to be tolerable and/or ineffective from the pool of
possible treatments, before testing on humans.
As there are over 160 different approved chemotherapy drugs [40], not to mention different
forms of radiation, selecting possible combinations is a daunting task, and one that cannot be
done by brute force trials. Combinations could include multiple chemotherapeutic agents or
chemotherapy drugs with radiation. The choice of which drugs and modalities to pair together
is challenging, and the repercussions of incorrect choices are great in the world of clinical tri-
als. However, with computer modelling, it is possible to quickly and safely test many possible
combinations.
This model seeks to assist in this task of determining what drug and treatment combinations
are most effective for the treatment of solid mass tumours. This model is a high level, abstract
model of cancer growth, modelling cancer as a collection of 8 hallmarks, as described by
Hanahan and Weinberg [74], [75]. Instead of modelling individual drugs, we have chosen
to model the impact drugs could have if they successfully stopped a hallmark’s ability. For
example, drugs that inhibit angiogenesis, such as bevacizumab, can be modelled by turning
off the angiogenesis hallmark in the model. In this way, we classify all drugs by their impact
on a hallmark, and are able to model multiple combinations by looking at the combinations
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of hallmarks they impact. Following this heuristic we have created a model of early tumour
growth that models knocking out hallmarks in triplets and quadruplets to see which have the
greatest effect on overall tumour growth. For a list of the hallmarks modelled and drugs that
are either currently available or in trials to target them, please see Appendix D.
4.2 Methods
This two dimensional cellular automaton simulation models early tumour growth of a solid
mass tumour. There is a highly abstract model of the immune system as well as tumour in-
duced vasculature. In combination with the cellular automaton model of the individual cells,
we have included a two-phase fluid model of oxygen in the blood around the tumour. This
is implemented using lattice Boltzmann methods. The oxygen modelling implementation was
previously described in Section 3.3.
This version of the model builds on that described in Chapter 3. The hallmarks are mod-
elled in the same way as described in Chapter 3, as is the event process. One major update
has been included in this iteration of the model – the inclusion of the “emerging hallmark”
reprogramming energy metabolism via a new cellular automaton state “Glycolytic phenotype”.
Hanahan and Weinberg introduced reprogramming energy metabolism as an emerging hall-
mark in their updated hallmark paper in 2011 [75]. Healthy cells usually rely on a form of
metabolism that uses oxygen to create ATP, the energy molecule of the cell. Cells that are in
a low oxygen environment can switch to a form of metabolism that is more heavily dependent
on gylcolysis, a process of ATP creation that is 18x less efficient but has less dependency on
oxygen. Cancer cells have been found to reprogram their glucose metabolism to rely largely
on this alternative mechanism. This was first observed by Otto Warburg, and has since been
termed “the Warburg effect” [173], [175]. There are many different theories as to why cancer
cells would choose this alternative mechanism, see Chapter 2 Section 2.2.7 for a discussion of
this effect.
Life cycle pseudocode
The lifecycle event process is similar to that of Chapter 3, however with the addition of the
glycolytic phenotype. An updated version of the pseudocode is included here for the ease of
the reader.
1: f irstCell← Cell
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2: time← 0
3: f irstCell.scheduleMitoticEvent()
4: eventQueue.push( f irstCell)
5: S ← 0
6: while eventQueue not empty do
7: currentCell← eventQueue.pop()
8: if currentCell.isAlive then
9: time← currentCell.time()
10: dead ← currentCell.died {check for random cell death.}
11: if currentCell.isMutated then
12: apop ← currentCell.apoptosis {check for death via apoptosis if cell is mutated.
Avoided if apoptosis hallmark is on}
13: end if
14: cangrow← false
15: if sel fGrowthHall or withinGrowthRange then
16: cangrow← true
17: end if
18: if spaceToGrow then
19: space ← true {If ignore growth inhibition is on, it can compete for space if no
space available}
20: end if
21: telo← false
22: if currentCell.getTelomere > 0 or currentCell.ignoresTelomereHallark then
23: telo← true
24: end if
25: if currentCell.withinBlood or currentCell.isOrWithinAngiogeneic then
26: blood ← true
27: end if
28: if currentCell.killedByImmune ! = true or currentCell.avoidsImmune then
29: stillAlive← true
30: end if
31: if currentCell.enoughOxygen or currentCell.glycolytic then
32: oxygen← true
33: end if
34: if cangrow and space and telo and blood and stillAlive and oxygen then
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35: daugtherCell← currentCell.mitosis {daughter cell may be mutated during mitosis
event}
36: currentCell.mitosisOccured() {opportunity for mutation during a mitosis event}
37: currentCell.scheduleMitoticEvent()
38: daughterCell.scheduleMitoticEvent()
39: eventQueue.push(daughterCell, currentCell)
40: end if
41: end if
42: end while
4.2.1 Oxygen modelling
Please see Section 3.3 for information on the oxygen modelling in this simulation.
4.2.2 Knockouts
All eight hallmarks modelled were knocked out in all possible groups of three or four. All
combinations of triplet knockouts (58) and quadruplet knockouts (70) were analyzed. Each
simulation started with one healthy cell that had the ability to sustain a mutation. Only muta-
tions not knocked out were able to be sustained by the cell. The full simulation, from initial
healthy cell to death or tumour takeover, was completed 10 times for every triplet and quadru-
plet hallmark in order to perform statistical analysis.
4.2.3 Parameters
The parameters used in this version of the simulation are the similar to those described in Table
3.1 with the addition of the glycolytic phenotype oxygen requirement of zero and different,
more aggressive levels of oxygen intake.
Parameters for the model were chosen from the literature and those that were not found
in previous publications were chosen via a parameter search looking for strong concordance
with in vivo tumours (please see Table 4.1 for values). Parameters used in the models by
Abbott [1] and Santos [143] were held constant (except mutation rate which was selected to
be between the two values used by Santos) and other parameters were varied iteratively. The
output was examined for concordance with in vivo tumours. The tumours all resemble the
classic spherical solid mass tumour structure consisting of a necrotic core with a quiescent
rim and proliferating rim [61, 159]. The tumours also grow to roughly 2mm to 2.5mm before
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Table 4.1: Parameters used in simulations.
Description Symbol Value Ref
Initial telomere length t 60 Similar to [153]
Evade apoptosis factor ev 10 [1]
Mutation rate m 300
Chosen to lay between
two used in
[143]
Random death rate d 10000 Simulation
Competition likelihood c 10 [1]
Angiogenesis immunity ai 10 Simulation
Avoid immunity aip 10 Simulation
Immunity death i 1000
Simulation (equal to
random cell death in
[143])
Genetic instability factor gi f 5 Simulation
Blood density ρB 300 mol/m3 [57]
Boundary oxygen density ρO 9 mol/m3 [111]
Thermal diffusivity D 0.134 mm2 ∗ s−1 [166]
Oxygen requirement for Og 0.0 [127]
glycolytic cells
Oxygen requirement for Oh 0.015 Simulation
healthy cells
Oxygen requirement for Oq 0.0075 [63]
quiescent cells
Oxygen requirement for Oa1 0.0136 Simulation
aggressive level 1 cells
Oxygen requirement for Oa2 0.0125 Simulation
aggressive level 2 cells
Oxygen requirement for Oa2 0.0115 Simulation
aggressive level 3 cells
4.3. Results 101
overwhelming the nutrients available and needing their own vasculature [60] and then grow to
a maximum of 5.5mm. All calculations were done using an average cell diameter of 25 µm
[163]. The tumours grow to this final size over a period of approximately two years, assuming
a cell division time of 16-24 hours. This is in line with growth times for fast growing tumours,
which reach clinically detectable size (0.2 cm to 1 cm) within two years [111].
4.3 Results
When all hallmarks were available for activation (that is, a mutation could potentially give a
cell the abilities conferred by every hallmark), cancer took over in 92% of simulations with a
mutation rate of 1 in 300. In the cases when cancer did not take over, there were cancer cells but
they were not able to overcome the growth factor limitations or the oxygen limitations imposed
by the healthy cells in the area. In cases when cancer did take over, the simulation was stopped
after an arbitrary number of steps because the tumour had begun to grow uncontrollably. The
cancer cells represented greater than 95% of the alive cells in the simulation, which has been
previously used as a measure for when cancer has officially “taken over” [1].
Figure 4.1 shows the growth progression over time for the simulation with all hallmarks
available for activation. Figure 4.4a also shows the cell count for cancerous cells, healthy cells,
and all mutations over time for this growth. Initially the simulation starts with one healthy cell
that does not have any mutations. This cell has a mitosis event scheduled for some point in the
future, and the event queue begins processing events.
It can be seen in Figure 4.1a that from one cell the group of cells has continued to grow
into a spheroid with a necrotic core, quiescent rim (grey) and proliferating rim. A few pock-
ets of cancer (green colours) are already visible in the proliferating rim. Dead cells are seen
both in the necrotic core (making up 88% of the dead cell content of the tumour) and in the
proliferating rim (here cells have died from apoptosis as they have acquired mutations). A few
cells have died from the immune system, but only 3. The majority (68%) of alive cells are still
healthy cells at this point.
The tumour continues to grow in this way with cancer cells on the rim pushing forward and
the immune system and cell systems trying to keep them at bay via apoptosis. By time 403, in
Figure 4.1b, the central necrotic core is growing and fewer healthy cells are surviving (56% of
alive cells). More pockets of cancer have developed and at this point the heterogenous mix of
cells contains over 115 unique phenotypes (combinations of mutations).
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Figure 4.1: A sample simulation of tumour growth when all hallmarks are available for acti-
vation. This simulation shows the tumour at events 5000 through 40000 (increasing by 5000
steps per image), which corresponds to timepoints 292 to 864. Different colours represent dif-
ferent cell phenotypes. Black cells are dead (necrotic, apoptotic, random death or due to the
immune system), blue cells are non-cancerous and alive, grey cells are quiescent (cancerous
or healthy) and all other colours are some set of mutations (of which there are over 40,000
possible combinations). Time points are: a) 292 b) 403 c) 487 d) 590 e) 739 f) 795 g) 834 h)
864.
As growth continues it reaches a point where the healthy cells can no longer proliferate
actively (between Figure 4.1d and 4.1e). At this point the actively dividing areas are only the
two cancer subclones that are on the outer edge. Healthy cells remain in the center, those that
are along a blood system provided by angiogenic cancer cells, however they have no space to
divide. At this point the number of healthy alive cells plummets, making up only 18% of the
total alive cell fraction. Cancerous cells make up the remaining 82%, with over 160 different
phenotypes present. At this point, a few distinct phenotypes are dominating the tumour. The
two most prominent phenotypes are: AI, GU, A, IT, AA, IGI, SG and GP, AI, GU, A, IT, AA,
IGI, SG.
These clones continue to dominate until the simulation ends with two large subclones
emerging from the mass of dead, healthy cells. In Figure 4.1h cancer cells make up 93%
of the total alive cells, and almost all of the proliferating cells.
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Growth of this tumour is considered baseline – a tumour growing with no “treatments” ap-
plied. At the last time point shown above, this tumour is roughly 3.875 mm using an average
cell size of 25 µm [163]. This tumour takes roughly two years to get to this size. We compared
the growth of tumours grown in an environment where some hallmarks are removed (in groups
of three or four) to the growth of this ideal growth.
In order to simulate combination targeted drugs, the tumour was grown without the ability
to ever activate groups of three and four hallmarks. Many drugs specifically target behaviours
of cancer cells, such as their ability to self grow or induce angiogenesis, and so we have mod-
elled the impact of these drugs by removing that hallmark from the system. Figures 4.2 and
4.4 show sample final growth images and the cell growth numbers over time for representative
hallmark groups. Figure 4.3 shows the overall success of the hallmark knockouts with respect
to stopping cancer growth.
For the triplet knockouts, 66% of them halted tumour growth. An example of what this
looks like can be seen in Figure 4.2f. In these cases, some cancer cells would still appear but
would not manage to dominate the growth. The simulation would end prematurely as there
were no actively proliferating cells. Cancer and healthy cells may have been alive at the end,
however either they did not have enough oxygen or space to be actively dividing. To determine
the statistical significance of the changes seen when treatments were applied, the total number
of alive cancer cells at the end of the simulations with treatments present were compared to
the total number of alive cancer cells at the end of a regular simulation. Each treatment was
simulated 10 times, as was the normal tumour simulation, and these sets of 10 numbers were
compared. The number of alive cancer cells at the end of simulation was statistically decreased
from that at the end of simulation will all hallmarks active (all 36 groups had p <0.01, and 10
combinations had p <0.00009 using the Mann-Whitney-U test).
Other groups of triplets caused a statistically significant decrease in cancer growth but did
not completely stop it (see Figure 4.2d for an example of this growth). There were 10 com-
binations of three hallmarks removed that caused a decrease in growth however still resulted
in cancer in some iterations of the simulation. These combinations had cancer in 60% of sim-
ulations or less with one exception having cancer in 90%. When the total numbers of alive
cancer cells at the end of simulation were compared with those at the end of simulation with
all hallmarks active, there was significantly less in these combinations (p <0.01 using Mann-
Whitney-U test).
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Six sets of triplet knockouts had no significant effect on growth and cancer still took over
to the same effect. An example of how the tumour looked at the end of simulation can be found
in Figure 4.2b.
Lastly, four sets of hallmark knockouts caused a statistically significant increase in growth.
These hallmark knockouts were: IGI, IT, GLY; IGI, IT, GU; IGI, GLY, AI and IGI, GU, AI.
In these cases cancer still arose in 90% of runs, the same number of events progressed further
in time, and ended with larger numbers of alive cancer cells (p <0.01 using Mann-Whitney-U
test). An example of the growth that resulted in these cases can be found in Figure 4.2h.
For the quadruplet knockouts, 79% of the combinations (55 of the 70 possible combina-
tions) resulted in a complete halting of cancer growth (this can be seen in Figure 4.2g). None
of these simulations resulted in a tumour and each was run 10 different times. Similar to the
triplets, some alive healthy and cancerous cells existed but were not actively proliferating.
This was significantly different than the growth with all hallmarks active (p <0.01 using Mann-
Whitney-U test).
Another 14% of knockout combinations resulted in a significant decrease in cancer growth.
In these, cancer still dominated some simulations (at most 70% of the simulations run, as few
as 20% in some cases) but the final amount of cancer present was significantly different than
that present with all hallmarks available for activation (p <0.01 using Mann-Whitney-U test).
Figure 4.2e shows an example of a quadruplet knockout at the end of simulation with statisti-
cally less alive cancer cells than baseline.
One combination actually increased the amount of cancer in the simulation by a statisti-
cally significant amount (p = 0.0086 using Mann-Whitney-U test). The final growth of this
quadruplet can be seen in Figure 4.2i. This was the knockout combination of IGI, IT, GLY, AI,
meaning that the hallmarks present were SG, AA, A, GU. This tumour also grew to approxi-
mately 6 mm, a 33% increase in tumour size over baseline growth. Lastly, a few combinations
had no statistically significant effect on the growth (4/70).
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Figure 4.2: Examples of final growth images for a variety of growth outcomes. Each image is
the last image produced by the simulation. a) all hallmarks available for activation; b) a triple
knockout with no effect on final growth; c) a quadruple knockout with no effect on growth; d)
a triple knockout with less total cancer than baseline; e) a quadruple knockout with less total
cancer than baseline; f) a triple knockout that resulted in the simulation ending prematurely
when no proliferating cells remained; g) a quadruple knockout that ended prematurely when
no proliferating cells remained; h) a triple knockout that resulted in more overall cancer; i) a
quadruple knockout that resulted in more overall cancer.
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Figure 4.3: Comparisons of success of hallmark knockouts in triplets and quadruplets.
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4.4 Discussion
As expected, the addition of more “treatments” was correlated with less overall cancer growth.
The triplets combinations effectively stopped the growth of cancer in 69% of cases, and the
quadruplet combinations stopped growth in 79% of cases. There were fewer combinations that
had no effect with the quadruplets as well (6% of quadruplet knockouts had no effect while
11% of triplets had no effect). It is expected that combination treatments will be better than
individual, and, in general, this held true. However, interestingly, both the triplet groups and
quadruplet groups had some combination(s) that statistically increased the cancer growth.
In the triplet groups, the hallmark knockout groups of: IGI, IT, GLY; IGI, IT, GU; IGI,
GLY, AI and IGI, GU, AI all caused a significant increase in cancer growth. For the quadru-
plets, the knock out of IGI, IT, GLY, AI caused an increase. All of these groups share the
ignore growth inhibition hallmark; three of the five have the ignore telomere hallmarks; three
out of five have the glycolytic phenotype and three out of five have avoids immune system.
While Hanahan and Weinberg identified 10 hallmarks and characteristics, they are not all
necessarily equal in their ability to spur on cancer growth. In this simulation, Ignore growth
inhibition appears to be less necessary for growth. The way this hallmark works is it allows
cells to grow even when there is no space immediately around them, effectively ignoring the
“contact inhibition” normally seen in healthy cells. This does not convey any benefit to cells
on the outside proliferating rim of the tumour, where they always have space, by definition.
Since the outside rim is usually the area with the most proliferation, it is understandable that
ignore contact inhibition would not be as critical to growth. However, in vivo the tumour may
not have space on the proliferating rim once it bumps into other organs and internal structures.
In this case, the ignore growth inhibition hallmark might become much more important. In
this simulation the tumour did not get to that stage and as such it appears to be a less critical
hallmark.
The ignore telomere hallmark allows cells to survive for much longer than a cell normally
could, giving them effective immortality. However this immortality is only with respect to
age, not surroundings. Cells with this hallmark can still be killed due to lack of oxygen, the
immune system, apoptosis and random cell death. Cells with naturally short telomeres might
benefit more from this, and it might allow them to propagate more mutations, however in this
simulation it appears it is not critical to rapid cancer growth. The telomere length was chosen
based on average life span of a cell, however depending on the cell type of a specific tumour
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this hallmark may become more or less critical.
The glycolytic phenotype hallmark allows cells to survive in low oxygen environments.
However, this mutation only benefits the cell that has the mutation and not the surrounding
cells. The angiogenesis mutation conveys the same ability, living in an area of low oxygen
as provided by the existing vasculature, however that mutation benefits the cell with it and all
neighbouring cells, since new vasculature would provide oxygen to surrounding areas. Perhaps
because of this weakness the glycolytic phenotype appears to be less necessary for growth, if
cells can attain the angiogenesis hallmark. This model of glycolytic phenotype is very high
level and ignores the side benefits of the phenotype, including the production of acid that may
make an unfavourable environment for healthy cells, making more room for cancerous cells. In
the future adding this layer to the model may show glycolytic phenotype to be more critical for
cancer growth. However, in this simulation it appears to be slightly less necessary than others.
Lastly, present in 3 of the 5 knockout pairs that increased growth was avoids immune system.
This hallmark decreases the probability a cell will die via the immune system. The immune
system can kill any cancerous cell, however it is more deadly to cells that are along the tumour
vasculature, as the immune cells travel through this. The probability of a cell dying via the
immune system increases with increased mutations. This hallmark would not be as beneficial
to cells with fewer mutations, so perhaps as more hallmarks are removed from the simulation,
the benefit of this hallmark is reduced.
In contrast to examining what hallmarks were removed in stronger tumours, looking at
what hallmarks were left leads to even more insight about the relative strength of hallmarks
and their communal behaviour. In all five hallmark groups left after knock outs that resulted in
more cancer growth there were the following hallmarks: self growth, angiogenesis and avoids
apoptosis. Genetic instability was present in three of the five as well, and glycolytic pheno-
type was present in two of the five.
Self growth and angiogenesis both have very critical roles in this simulation, and in cancer
in general. Healthy cells can only grow where there is enough growth factor. Cancer cells
often acquire the ability to grow without this growth factor present, and in fact, it is such a
strong influence in cancer growth that most chemotherapy drugs target the result of this ability
(the result being rapid cell growth). It has been stated that self sufficiency in growth signals
is the most fundamental trait of cancer cells [75]. In this simulation there was a boundary
of growth factor. Beyond this healthy cells could still grow but with decreasing likelihood
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as the growth factor dropped off, and eventually it was not possible. In order to grow large
enough to take up the vast majority of the simulation space the tumour would need some self
growth cells. Similarly, the existing “vasculature” in the system only delivered a sufficient
amount of blood to a predefined area and dropped off outside of this. Cells therefore needed
angiogenesis to continue getting large amounts of oxygen for survival. Angiogenesis also is the
only hallmark which conveyed a benefit to not only the cell with the mutation but surrounding
cells, which may have made it even more beneficial to cancer growth (as would be the case
in vivo). In reality, anti-angiogenesis drugs are looking promising in combination treatments.
Bevacizumab was the first approved by the FDA, and since then more have been approved for
various cancers (including sorafenib, sunitinib, pazopanib, and everolimus). Some trials have
already been conducted pairing anti-angiogenesis drugs (most commonly bevacizumab) with
other chemotherapy agents [70], [167]. The success of these and other trials has spurred more
trials, and currently trials are underway pairing anti-angiogenesis drugs with one and up to five
other drugs [81], [77] and [112].
Avoids apoptosis was also a strong influencer of cancer growth. This hallmark prevents a
cell from dying via apoptosis, regardless of the number of mutations the cell has sustained.
Cells can still die via the immune system or lack of oxygen, but this in combination with
angiogenesis (which was in all of the groups causing increased growth) would allow a cell to
be close to immortal. Apoptosis is one of the cell’s only built in safety mechanisms to stop the
propagation of mutations and as such it is not surprising that removing it causes much damage.
All groups that still had cancer, whether decreased, increased or significantly unchanged,
had both self growth and angiogenesis hallmarks. Most had avoids apoptosis and many had
ignore growth inhibition. Since ignore growth inhibition was knocked out in groups that lead
to increased growth this is somewhat surprising. It underscores that fact that not all hallmarks
always behave the same way. Clearly their pairing is crucial to their importance in the growth
over time. In some cases and some situations (mentioned earlier) ignores growth inhibition
appeared to not be very beneficial. However, it was present in 10 out of 16 triplets that resulted
in cancer growth.
While self growth was present in all groups that still resulted in tumour growth, it was not
necessary to knock it out in order to stop tumour growth. For the triplets, 15 out of 36 treatment
combinations did not have self growth knocked out and still completely halted growth. For
the quadruplets, 20 of the 55 did not have self growth and stopped growth. The exact same
number for both groups did not have angiogenesis knocked out and still stopped growth. All
4.5. Conclusions 111
36 triplet and 55 quadruplet knock outs that stopped cancer growth were missing either self
growth or angiogenesis however. According to this simulation, these are very powerful knock-
outs however not the “magic bullet” of curing cancer either.
It was hypothesized that not all groups would be equal in their effect, and that more drugs
would not necessarily be beneficial. Some triplet and quadruplet pairs had no significant change
in the growth at all. What was more surprising was that some triplet and even quadruplet knock
outs resulted in an increase in the cancer growth. One would assume that more treatments
against a cancer would result in increased success, and in the vast majority of cases this is true,
however this is not always the case.
4.5 Conclusions
This work shows that combination treatments, in this high level simulation, are beneficial for
stopping cancer growth. It also underscores the critical point that not all combinations have
this effect. This simulation showed that some hallmarks are stronger than others and removing
the ability for weaker mutations to occur self-selects for only the strongest mutations possible
to occur. This does not guarantee that the strongest phenotypes will arise, but it limits the
possibility for lesser combinations. This has been seen in vivo as well when cancer recurs after
treatment. For example, the childhood brain cancer medulloblastoma has very low survival
after recurrence [23]. The initial treatment includes surgery, radiation and often chemotherapy,
however if there is recurrence there is very little that can be done and very few documented
survivors [23]. It is hypothesized that this is because the cells that survived the initial onslaught
of treatments either were or are now resistant to those treatments, and so there is nothing more
that can be done. The litany of treatments given selects for the strongest cells, and if they repop-
ulate the tumour, it will be even stronger. However, Koschmann et al. suggest that retreatment
with chemotherapy and radiation can be helpful in these patients and also recommends that
novel combinations should be investigated for these cases [96].
This work found that both self growth and angiogenesis were strong hallmarks. Anti-
angiogenesis drugs have been investigated for use in combination therapy, and many combina-
tions are still undergoing clinical trials. A 2013 study looked at anti-angiogenesis clinical trials
in stage II of the testing process [174]. The authors looked at 5 year reports of anti-angiogenesis
trials in gynecological cancers and concluded:
These anti-angiogenic drugs while used either alone or in combination with chemother-
apy, presented mixed results in treating gynecological cancers. The real challenge
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is how to take best advantage of the anti-angiogenesis hypothesis for therapeutic
benefit. Much remains to be done before these molecules work efficaciously in
treating gynecological cancer. [174]
This simulation clearly emphasis this point. While knocking out angiogenesis was often
beneficial (similar to self growth) the real key is combining it properly. It was not sufficient to
knock out either of these two hallmarks, and some combinations that were successful in halting
cancer growth did not involve them. Overall however, they appear to be quite strong, and when
paired correctly in a combination, resulted in decreased growth.
In addition to combining the hallmarks correctly, it is important to consider the role of
more specific details than this high level simulation shows, such as tissue type, patient genetics
and history. In some circumstances, for example a tumour growing in a tissue-dense area, other
hallmarks may be more beneficial (like ignore growth inhibition). In areas that are oxygen rich,
angiogenesis may be less beneficial. All of these factors underscore the need for research into
what combinations are best and when, and point away from a “one-sized fits all” approach to
medicine. With increasing interest in “individualized medicine” there should be more focus on
modelling and detecting, for a particular case, what combinations are best. This simulation acts
a proof of concept that not all combinations are created equal, and that different circumstances
(in this high level case, oxygen availability) could change the efficacy of a treatment course.
Chapter 5
Conclusions
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It is known that cancer is a leading cause of death and suffering throughout the world, with
much money, time and energy going towards the search for a “cure” [119], [33]. However,
there exists no single cure for this group of diseases, and as such, it is critical that researchers
look into multiple treatment options, building an arsenal against cancer consisting of different
chemotherapy drugs, radiation, surgery, hormone therapy and any other individually-successful
treatment types. In the 1969 Cancer Research paper Evidence that drugs in multiple combina-
tions have materially advanced the treatment of human malignancies, Henderson and Samaha
state:
In the most general sense, combinations of therapies, whether drugs and/or other
modalities, will always play an important role in the management of diseases for
which there exists no single specific and totally effective treatment [78].
For over 40 years we have known that combination therapy is critical for the treatment of
this group of diseases, however much more needs to be done to identify which combinations
are likely to be most effective with the least toxicity. Clinical trials are continually evaluat-
ing this question however they are lengthy (taking up to 15 years to go from idea conception
to drug combination approval), costly (estimates range from US$1.3 billion to US$1.7 billion
[44]) and potentially dangerous to patients [102], [70], [167], [125],[122], [171], [81]. In 2012,
Rejniak and Anderson published a paper on the current state of the art of cancer modelling, and
outlined why we need to move beyond the traditional reductionist approach of studying cancer,
and look at modalities that can model cancer across scales [140]. Computer simulations of can-
cer have existed for over 50 years, however it is only recently they have gained in popularity
as computer power and memory have begun to match researchers ambitions for simulations.
Now it is clear that these computer simulations of cancer growth can yield accurate results and
be a strong additional tool in the fight against cancer.
This work aimed to bridge two scales – the microscopic scale of the cell and the meso-
scopic scale of blood flow around a tumour – in order to make a biologically relevant model of
cancer growth that could be used for cancer treatment investigations. Using cellular automata
as cancer cells and lattice Boltzmann methods for fluid dynamics, this simulation proved it
could grow a tumour from one healthy cell in a reasonable amount of time, up to a biologically
consistent size. Once a working model existed, I wanted to answer the question of how combi-
nations of treatments would impact growth. Specifically, were good individual treatments al-
ways better together? Was a combination always the best from a strictly cellular growth level?
In order to address these questions, it was necessary to model the treatments in a broad way so
the model stayed high level and applicable. As such, “treatments” consisted of removing from
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the simulation various cancer hallmarks, the critical cell changes that make cancer what it is, as
proposed by Hanahan and Weinberg in 2000 and revised in 2011 [74], [75]. These hallmarks
are often targeted using drugs (for example, many chemotherapies target the ability for a cell to
self grow) and so represent a good high level approach to modelling various cancer treatments.
Information on existing drugs that target each individual hallmark is available in Appendix D.
I used this concept of removing hallmarks to model the impact of over 150 different combi-
nations of abstract “treatments” to show the challenges and opportunities inherent to combina-
tion treatment of cancer. Building on the work of knocking out individual hallmarks presented
by Santos et al. [143], paired knockouts were initially investigated, and revealed that individual
knockouts in combination are not necessarily additive, but can be much more powerful when
paired correctly, having a multiplicative, and significant, impact on overall growth. This lead to
the natural question of “is more better”? Triplet and quadruplet hallmarks were then knocked
out in combination. These groups revealed even more interesting results. They validated the
earlier work, that some combinations are more than additive, but also revealed that some com-
binations are detrimental, causing more harm than leaving the tumour completely untreated.
The end question after applying a treatment was always did the treatment stop cancer
growth, lessen it, have no effect, or enhance it. The overall results of these questions for all
pairs, triplets and quadruplets can be seen in Figure 5.1. As more treatments were added, more
were successful at completely eliminating the cancer. This is to be expected as we would hope
removing many of cancer’s abilities would weaken it. However, as more treatments were added
the potential for the treatments to have negative interactions grew. Paired treatments never al-
lowed the cancer to grow more than it did without any treatment, however some triplets and
one quadruplet actually caused an increase in overall cancer growth.
In addition to looking at overall growth, I wanted to know what hallmarks occurred together
most often in “curative” treatments. In order to determine this, I assigned scores to all pairs of
hallmarks in every treatment. Any pair of two hallmarks that occurred together in a treatment
group (whether it be a pair, triplet or quadruplet) that cured cancer was given a score of two.
Any pair that occurred together in a treatment that significantly reduced cancer, but did not
stop it, was given a score of 1. Any pair that occurred together in a treatment that had no effect
was given a score of 0. Any pair that occurred together in a treatment that led to a statistically
significant increase in cancer growth was given a score of -5. Scores for all pairs were summed
and the results can be found in Figure 5.2.
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Figure 5.1: Comparisons of hallmark knockout success for doublet, triplet and quadruplet
knockouts (treatments). Significant decreases in growth were those treatments that lowered
cancer growth with a p <0.05, as compared to growth with all hallmarks available. Cancer
was considered cured if it did not take over in any of the 10 replicate simulations. Significant
increases in growth were those treatments that resulted in more growth than tumours grown
without any knockouts, with a p <0.05. All p-values were calculated using Mann-Whitney U
test.
Interestingly, the strongest score was avoids apoptosis and angiogenesis. However, the pairs
that were most often knocked out in successful cures were angiogenesis and self growth. It is
clear that both of these (self growth and angiogenesis) are very successful pairs (all pairs in-
volving either of these hallmarks are quite “hot” with scores at 30 or above), but they are not the
strongest pair together. This suggests that they are strong together, but that there exists tumour
conditions where they are not the optimal combination. It reveals as well that pairs that did not
necessarily seem obviously important could potentially be very strong because overall they had
the most positive impact. This diagram also shows clearly that certain pairs (such as ignores
growth inhibition with genetically unstable, avoids immune system with glycolytic phenotype
as well as avoids immune system with genetically unstable and avoids immune system with gly-
colytic phenotype) are not very strong overall, regardless of what treatment combination they
are included with. This kind of analysis could potentially eliminate pairs from clinical treat-
ment options for certain growth environments or tumour types if repeated with a simulation
programmed for those environments.
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Figure 5.2: A symmetric heat map of co-occurrences of hallmarks in knockout treatments.
Hallmarks that appeared together more often in cures are hotter. Values were calculated using
the following heuristic: pairs present in a treatment that cured (stopped) cancer growth were
assigned a score of +2; pairs present in a treatment that significantly lessened cancer growth
were assigned a score of +1; pairs present in a treatment that had no significant effect were
assigned a score of 0; pairs present in a treatment that made cancer growth significantly worse
were assigned a value of -5.
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While it might seem strange that knocking out two, three, or even four hallmarks could
result in no statistically significant change to cancer growth, in reality, it is not unusual for a
drug, or combination of drugs, to have no effect. Many clinical trials are terminated when it
is found that the treatment has no improvement over current available treatments [105], [169],
[99]. It sometimes even occurs that treatments or combinations of treatments have no impact
and in fact are more dangerous to a patient. Clinical trials have been halted when the study
shows no improvements but increased death or toxicity in patients as compared to traditional
treatments [132], [142], [149]. It does happen that a drug fails clinical trails for a particular
type of cancer, however proves to be effective and safe for others. In fact there is currently
an effort to reinvestigate “failed” trails where some small number of patients greatly benefited
from the “failed” treatment [97]. What used to be considered an anecdote, when one patient
would greatly benefit from a treatment that failed overall, is now being seen as an “n-of-1”
study with the potential for great success for a subgroup of patients. Perhaps that one patient
had a particular genetic makeup making them highly responsive to a treatment. Determining
what is unique to that patient may open the drug up to all patients with similar genetic mu-
tations in their tumour, allowing the drug to be beneficial to some subgroup. Since we know
cancers can vary greatly between patients, this idea of investigating the outliers could lead to
more “individualized” medicine that is highly effective in the right cases.
The fact that drugs are sometimes dangerous or useless in one case, only to be highly
effective in others, underscores the need for determining in what situations drugs are going to
be successful far in advance of costly clinical trials. This simulation was able to determine
that for a general, non-specific cancer, some combinations of treatments that were effective
individually are in fact useless or even detrimental when applied together. It is not obvious
a priori what combinations will be successful. However, models such as this can help shed
light on what combinations perhaps can be avoided all together, or which are most likely to
have a strong impact. Since we cannot test all possible drug combinations on every individual
looking for general effects or those specific “n-of-1” cases, we see the use and importance of
cancer simulation, with accurate oxygen modelling and cancer representations. Similar models
in the future could be more personalized in order to model treatments at the individual level.
Indeed, there are a variety of ways this model could be extended in the future to be even more
beneficial:
• Using more tunable parameters in order to simulate cancer growth with different initial
conditions and parameters.
• Adding more microenvironmental variables, such as glucose transport, growth factor
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diffusion and acid production.
• Providing more granular control over the cellular automata rules to model more individ-
ualized mutations.
• Knocking out hallmarks at different points in the simulation
• Incorporating a highly accurate vascular growth to model next phase of cancer progres-
sion.
A strength of this model is the generality of it, however this is also a weakness. Cancer
grows in a variety of environments and a great future step would be making the model more
highly tunable to simulate this. Redoing the analysis of combination treatments in changing
situations, such as cells with higher mutation rates, lower cell turnover, surrounding tissue
constraints, etc, would allow for more information on what combinations might be beneficial
in what circumstances. For example, perhaps increasing available oxygen to model cancers
growing in highly vascularized locations would reveal highly successful treatments not involv-
ing anti-angiogenesis.
This model was highly abstract, which is good for an initial high-level simulation, how-
ever in the future the addition of more microenvironmental factors would be beneficial. For
example, adding in a fluid model of acid around the tumour would allow for the glycolytic
phenotype to be modelled more precisely, including both its ability to allow cancer cells to
survive with low oxygen and also the production of a highly acidic environment. In addition
to modelling acid, other cell types could be added to simulate the tumour microenvironment,
including things such as immune cells, cells involved in inflammation response, and epithelial
cells.
Mutations in this model impact the rules of the cellular automata, however it would be ben-
eficial to allow more control over the changes to these rules. Many hallmarks were changed
in binary fashion, being either on or off. It may be beneficial to put these on a sliding scale
so hallmarks can be reduced or increased depending on mutations and treatments. Since it is
known treatments in reality are rarely 100% successful, this would allow for a more realistic
modelling of cancer treatment.
Hallmarks in this model were removed at the beginning of simulation. This is consistent
with the previous work looking at cancer hallmark’s relevance by Santos et al. [143]. However,
it would be better in the future to allow hallmarks to be removed at different points in the
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system. For example, a hallmark could be removed early on, and then later a second hallmark
removed, to model the case where one drug is applied and later it is realized a second is needed.
Lastly, the vascular model in this system was quite abstract and only provided oxygen to
angiogenic cells or their direct neighbours. It would be more accurate to decouple cancer cells
from the vasculature and model oxygen diffusing from the new vasculature points. A separate
model of the vasculature would allow for new branches to be added to existing vasculature
when a cell acquires the ability to stimulate angiogenesis. Modelling the oxygen diffusing out
of this would allow cells farther away from the new vasculature to benefit as well.
To summarize my contribution: this work uniquely pairs a lattice Boltzmann model (LBM)
of a two phase fluid, oxygen in the blood, with a seven-state cellular automata (CA) model of
cancer. To our knowledge, this is the first time such a two-phase fluid model has been paired
with a multi-state cellular automata model in order to simulate early growth with more accurate
oxygen availability. In addition, this work is the first to examine knocking out hallmarks in
pairs, triplets and quadruplets in order to create a highly abstract simulation of combination
cancer treatment. The model showed that firstly this pairing of LBM and CA can grow a
realistically shaped tumour on a biologically realistic time scale. Secondly, it sheds light on
the complicated, potentially counterintuitive, reality that individual drugs are not necessarily
better together. It emphasizes the need for critical investigation as to what pairs are best when
and in what situations. It also serves as a launching point for further study into what pairs are
best by having the ability to be extended in a personalized way. Variables, initial conditions and
rules can be altered to model more specific cancers or individual situations in order to be a first
line test for treatment ideas. Alexander Anderson from the Moffitt Cancer Research Center,
home to some of the most well known cancer simulation researchers, stated in their Integrated
Mathematical Oncology Newsletter “We ultimately see in silico models as a pre-treatment
protocol to suggest the best therapeutic regime or to indicate which should be avoided.” [16].
This model has added to the current array of cancer models in order to assist in this ultimate
goal and eventually increase survival for people diagnosed with this complicated group of
diseases we call cancer.
Bibliography
[1] RG. Abbott, S. Forrest, and KJ. Pienta. Simulating the hallmarks of cancer. Artificial
Life, 4(12):617–34, 2006.
[2] Abby Siegel. Siliphos in advanced hepatocellular carcinoma, 2013.
[3] TH Adair and JP Montani. Angiogenesis. Morgan and Claypool Life Sciences, 2010.
[4] JM Adams and S Cory. The Bcl-2 apoptotic switch in cancer development and therapy.
Oncogene, 26(9):1324–1337, 2007.
[5] Julio A Aguirre-Ghiso. Models, mechanisms and clinical evidence for cancer dormancy.
Nature Reviews Cancer, 7(11):834–846, 2007.
[6] KGMM Alberti and C Cuthbert. The hydrogen ion in normal metabolism: a review.
Metabolic acidosis, pages 1–15, 1982.
[7] Davide Alemani, Francesco Pappalardo, Marzio Pennisi, Santo Motta, and Vladimir
Brusic. Combining cellular automata and lattice boltzmann method to model multi-
scale avascular tumor growth coupled with nutrient diffusion and immune competition.
Journal of Immunological Methods, 376:55–68, 2012.
[8] American Cancer Society. Pancreatic cancer survival rates. http:
//www.cancer.org/cancer/pancreaticcancer/overviewguide/
pancreatic-cancer-overview-survival-rates, 2013.
[9] American Cancer Society. Breast cancer survival rates. http://www.cancer.org/
cancer/breastcancer/detailedguide/breast-cancer-survival-by-stage,
2014.
[10] American Cancer Society. Cancer facts and figures 2014. http://www.cancer.org/
acs/groups/content/@research/documents/webcontent/acspc-042151.pdf,
September 2014.
121
122 BIBLIOGRAPHY
[11] American Cancer Society. Cervical cancer. http://www.cancer.org/cancer/
cervicalcancer/detailedguide/cervical-cancer-survival, September
2014.
[12] American Cancer Society. The history of cancer. http://www.cancer.org/cancer/
cancerbasics/thehistoryofcancer/index, 2014.
[13] American Cancer Society. Liver cancer survival rates. http://www.cancer.org/
cancer/livercancer/detailedguide/liver-cancer-survival-rates, 2014.
[14] American Cancer Society. Prostate cancer survival rates. http:
//www.cancer.org/cancer/prostatecancer/detailedguide/
prostate-cancer-survival-rates, 2014.
[15] A. R. A. Anderson, K. A. Rejniak, P. Gerlee, and V. Quaranta. Modelling of Cancer
Growth, Evolution and Invasion: Bridging Scales and Models. Mathematical Modelling
of Natural Phenomena, 2(3):1–29, June 2008.
[16] Alexander Anderson, Robert Gatenby, David Basanta, and Ariosto Silva. Integrated
mathematical oncology newsletter.
[17] Alexander R A Anderson and Vito Quaranta. Integrative mathematical oncology. Nature
reviews. Cancer, 8(3):227–34, March 2008.
[18] Alexander R A Anderson, Alissa M Weaver, Peter T Cummings, and Vito Quaranta.
Tumor morphology and phenotypic evolution driven by selective pressure from the mi-
croenvironment. Cell, 127(5):905–15, December 2006.
[19] Alexander RA Anderson. A hybrid mathematical model of solid tumour invasion: the
importance of cell adhesion. Mathematical Medicine and Biology, 22(2):163–186, 2005.
[20] Steven E Artandi and Ronald A DePinho. Telomeres and telomerase in cancer. Car-
cinogenesis, 31(1):9–18, 2010.
[21] Anna Azvolinsky. Most cited cell article of all time, hallmarks of cancer gets an update,
2011.
[22] Natalia Bailo´n-Moscoso, Juan Carlos Romero-Benavides, and Patricia Ostrosky-
Wegman. Development of anticancer drugs based on the hallmarks of tumor cells.
Tumor Biology, 35(5):3981–3995, 2014.
BIBLIOGRAPHY 123
[23] Judith Balter-Seri, Celia Mor, Avinoam Shuper, Rina Zaizov, and Ian J Cohen. Cure of
recurrent medulloblastoma. Cancer, 79(6):1241–1247, 1997.
[24] Dalit Barkan, Jeffrey E Green, and Ann F Chambers. Extracellular matrix: a gatekeeper
in the transition from dormancy to metastatic growth. European Journal of Cancer,
46(7):1181–1188, 2010.
[25] David Basanta, Benjamin Ribba, Emmanuel Watkin, Benoit You, and Andreas Deutsch.
Computational analysis of the influence of the microenvironment on carcinogenesis.
Mathematical Biosciences, 229(1):22 – 29, 2011.
[26] Lorenzo Bello, Valeria Lucini, Francesco Costa, Mauro Pluderi, Carlo Giussani,
Francesco Acerbi, Giorgio Carrabba, Marilou Pannacci, Dario Caronzolo, Silvia Grosso,
Svetlana Shinkaruk, Federica Colleoni, Xavier Canron, Giustino Tomei, Gerard Deleris,
and Andreas Bikfalvi. Combinatorial administration of molecules that simultaneously
inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse mod-
els of malignant glioma combinatorial administration of molecules that simultaneously
inhibit angiogenesis. Clinical cancer research, 2004.
[27] Nicola Bellomo and Elena De Angelis. Selected topics in cancer modeling: genesis,
evolution, immune competition, and therapy. Springer, 2008.
[28] Katie Bentley, Paul Bates, and Holger Gerhardt. Artificial life as cancer research: em-
bodied agent modelling of blood vessel growth in tumours. In Proceedings of Artifical
Life XI, 2008.
[29] Marı´a Berdasco and Manel Esteller. Aberrant epigenetic landscape in cancer: how cel-
lular identity goes awry. Developmental cell, 19(5):698–711, 2010.
[30] E Bhatnagar, EP Gross, and M Krook. A model for collision processes in gases. i. small
amplitude processes in charged and neutral one-component systems. Phys. Rev., 94(3),
1954.
[31] Maria a Blasco. Telomeres and human disease: ageing, cancer and beyond. Nature
reviews. Genetics, 6(8):611–22, August 2005.
[32] Baste R C, Kufe D W, Pollock R E, Weichselbaum R R, Holland J F, and Frei E. Holland-
frei cancer medicine. B.C. Decker, 2000.
[33] Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian cancer
statistics 2014, 2014.
124 BIBLIOGRAPHY
[34] Cancer Alliance for Research, Education and Survivorship. Chemocare. http://
chemocare.com/chemotherapy/drug-info/Oxaliplatin.aspx#.VK7LyCvF-wU,
2014.
[35] Cancer Research UK. Cancer drugs. http://www.cancerresearchuk.org/
about-cancer/cancers-in-general/treatment/cancer-drugs/, 2014.
[36] Cancer Research UK. Leukaemia survival statistics. http://www.
cancerresearchuk.org/cancer-info/cancerstats/types/leukaemia/
survival/leukaemia-survival-statistics, September 2014.
[37] Cancer Research UK. Lung cancer survival statistics. http://www.
cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/
lung-cancer-survival-statistics, September 2014.
[38] Cancer Research UK. Pancreatic cancer survival statistics. http://www.
cancerresearchuk.org/cancer-info/cancerstats/types/pancreas/
survival/pancreatic-cancer-survival-statistics, 2014.
[39] CDC. Leading causes of death. Centers for Disease Control, 2009.
[40] CenterWatch. Fda approved drugs for oncology. https://www.centerwatch.com/drug-
information/fda-approved-drugs/therapeutic-area/12/oncology, 2015.
[41] Shiyi Chen and Gary D Doolen. Lattice boltzmann method for fluid flows. Annuual
review of fluid mechanics, 30:329–64, 1998.
[42] Koei Chin, Carlos Ortiz de Solorzano, David Knowles, Arthur Jones, William Chou,
Enrique Garcia Rodriguez, Wen-Lin Kuo, Britt-Marie Ljung, Karen Chew, Kenneth
Myambo, et al. In situ analyses of genome instability in breast cancer. Nature genetics,
36(9):984–988, 2004.
[43] Chinese Academy of Medical Sciences. Efficacy and safety study of recombinant en-
dostatic combined with chemotherapy to treat advanced colorectal cancer. ClinicalTri-
als.gov Bethesda (MD): National Library of Medicine (US), 2014.
[44] Roger Collier. Rapidly rising clinical trial costs worry researchers. Canadian Medical
Association Journal, 180(3):277–278, 2009.
[45] Francesco Colotta, Paola Allavena, Antonio Sica, Cecilia Garlanda, and Alberto Man-
tovani. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic
instability. Carcinogenesis, 30(7):1073–1081, 2009.
BIBLIOGRAPHY 125
[46] John Condeelis and Jeffrey W Pollard. Macrophages: obligate partners for tumor cell
migration, invasion, and metastasis. Cell, 124(2):263–266, 2006.
[47] Lisa M Coussens, Wilfred W Raymond, Gabriele Bergers, Marion Laig-Webster, Ole
Behrendtsen, Zena Werb, George H Caughey, and Douglas Hanahan. Inflammatory
mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes
& development, 13(11):1382–1397, 1999.
[48] Chi V Dang and Gregg L Semenza. Oncogenic alterations of metabolism. Trends in
biochemical sciences, 24(2):68–72, 1999.
[49] Michele De Palma, Mary Anna Venneri, Rossella Galli, Lucia Sergi Sergi, Letterio S
Politi, Maurilio Sampaolesi, and Luigi Naldini. Tie2 identifies a hematopoietic lineage
of proangiogenic monocytes required for tumor vessel formation and a mesenchymal
population of pericyte progenitors. Cancer cell, 8(3):211–226, 2005.
[50] Ralph J DeBerardinis, Julian J Lum, Georgia Hatzivassiliou, and Craig B Thompson.
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.
Cell metabolism, 7(1):11–20, 2008.
[51] R Demicheli, MW Retsky, WJM Hrushesky, M Baum, and ID Gukas. The effects
of surgery on tumor growth: a century of investigations. Annals of Oncology, page
mdn386, 2008.
[52] David G DeNardo, Pauline Andreu, and Lisa M Coussens. Interactions between lympho-
cytes and myeloid cells regulate pro-versus anti-tumor immunity. Cancer and Metastasis
Reviews, 29(2):309–316, 2010.
[53] Katharina M Detjen, Svenja Rieke, Antje Deters, Petra Schulz, Annett Rexin, Sonja
Vollmer, Peter Hauff, Bertram Wiedenmann, Marianne Pavel, and Arne Scholz.
Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clinical Can-
cer Research, 16(2):420–429, 2010.
[54] Sabine Dormann and Andreas Deutsch. Modeling of self-organized avascular tumor
growth with a hybrid cellular automaton. In silico biology, 2(3):393–406, January 2002.
[55] John M L Ebos, Christina R Lee, William Cruz-Munoz, Georg a Bjarnason, James G
Christensen, and Robert S Kerbel. Accelerated metastasis after short-term treatment
with a potent inhibitor of tumor angiogenesis. Cancer cell, 15(3):232–9, March 2009.
126 BIBLIOGRAPHY
[56] Elsevier. Most cited cell articles since 2010. http://www.journals.elsevier.com/
cell/most-cited-articles/.
[57] K. Erbertseder, J. Reichold, B. Flemisch, P. Jenny, and R. Helmig. A coupled dis-
crete/continuum model for cancer-therapeutic transport in the lung. PloS One, 7(3),
2012.
[58] Gerard Evan and Trevor Littlewood. A matter of life and cell death. Science,
281(5381):1317–1322, 1998.
[59] J Ferlay, HR Shin, F Bray, D Forman, CD Mathers, and D Parkin. Globocan2008 cancer
incidence and mortality worldwide: Iarc cancerbase no. 10, 2008.
[60] J. Folkman. Tumor angiogenesis: therapeutic implications. Nature Engl. J. Med.,
285:L529–L533, 1971.
[61] Judah Folkman and Mark Hochberg. Self-regulation of growth in three dimensions. The
Journal of experimental medicine, 138(4):745–753, 1973.
[62] J P Freyer, E Tustanoff, a J Franko, and R M Sutherland. In situ oxygen consump-
tion rates of cells in V-79 multicellular spheroids during growth. Journal of cellular
physiology, 118(1):53–61, January 1984.
[63] Christian Frezza, Liang Zheng, Daniel a Tennant, Dmitri B Papkovsky, Barbara a Hed-
ley, Gabriela Kalna, David G Watson, and Eyal Gottlieb. Metabolic profiling of hypoxic
cells revealed a catabolic signature required for cell survival. PloS one, 6(9):e24411,
January 2011.
[64] Lorenzo Galluzzi and Guido Kroemer. Necroptosis: a specialized pathway of pro-
grammed necrosis. Cell, 135(7):1161–1163, 2008.
[65] Robert A Gatenby and Robert J Gillies. Why do cancers have high aerobic glycolysis?
Nature Reviews Cancer, 4(11):891–899, 2004.
[66] P Gerlee and A R A Anderson. An evolutionary hybrid cellular automaton model of
solid tumour growth. Journal of theoretical biology, 246(4):583–603, July 2007.
[67] P. Gerlee and A R A Anderson. A hybrid cellular automaton model of clonal evolution
in cancer: the emergence of the glycolytic phenotype. Journal of theoretical biology,
250:705–722, 2008.
BIBLIOGRAPHY 127
[68] P Gerlee and A R A Anderson. Evolution of cell motility in an individual-based model
of tumour growth. Journal of theoretical biology, 259(1):67–83, July 2009.
[69] Jana L Gevertz, George T Gillies, and Salvatore Torquato. Simulating tumor growth in
confined heterogeneous environments. Physical biology, 5(3):036010, January 2008.
[70] Bruce J Giantonio, Paul J Catalano, Neal J Meropol, Peter J O’Dwyer, Edith P Mitchell,
Steven R Alberts, Michael A Schwartz, and Al B Benson. Bevacizumab in combina-
tion with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated
metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group
Study E3200. Journal of Clinical Oncology, 25(12):1539–1544, 2007.
[71] Joanne Graham, Mohamed Muhsin, and Peter Kirkpatrick. Oxaliplatin. Nature Reviews
Drug Discovery, 3(1):11–12, 2004.
[72] Sergei I Grivennikov, Florian R Greten, and Michael Karin. Immunity, inflammation,
and cancer. Cell, 140(6):883–899, 2010.
[73] D Hanahan and J Folkman. Patterns and emerging mechanisms of the angiogenic switch
during tumorigenesis. Cell, 86(3):353–64, August 1996.
[74] D. Hanahan and R.A. Weinberg. The hallmarks of cancer. Cell, 100(1):57–70, 2000.
[75] D. Hanahan and R.A. Weinberg. Hallmarks of cancer: the next generation. Cell,
144(5):646–674, 2011.
[76] Donna E Hansel, Alan K Meeker, Jessica Hicks, Angelo M De Marzo, Keith D Lillemoe,
Richard Schulick, Ralph H Hruban, Anirban Maitra, and Pedram Argani. Telomere
length variation in biliary tract metaplasia, dysplasia, and carcinoma. Modern pathology,
19(6):772–779, 2006.
[77] Hellenic Oncology Research Group. Paclitaxel plus bevacizumab for older patients with
breast cancer. ClinicalTrials.gov Bethesda (MD): National Library of Medicine (US),
2014.
[78] E.S. Henderson and R.J. Samaha. Evidence that drugs in multiple combinations
have materially advanced the treatment of human malignancies. Cancer Research,
29(12):2272–2280, 1969.
[79] Susanne Herwig and Michael Strauss. The retinoblastoma protein: a master regulator of
cell cycle, differentiation and apoptosis. European Journal of Biochemistry, 246(3):581–
601, 1997.
128 BIBLIOGRAPHY
[80] Yoshito Hirata, Nicholas Bruchovsky, and Kazuyuki Aihara. Development of a mathe-
matical model that predicts the outcome of hormone therapy for prostate cancer. Journal
of theoretical biology, 264(2):517–27, May 2010.
[81] Hoffmann-La Roche. A study of Avastin (bevacizumab) in combination with chemother-
apy in patients with breast cancer progressing after first-line therapy with avastin
and chemotherapy (TANIA). ClinicalTrials.gov Bethesda (MD): National Library of
Medicine (US), 2014.
[82] Peggy P Hsu and David M Sabatini. Cancer cell metabolism: Warburg and beyond.
Cell, 134(5):703–707, 2008.
[83] National Cancer Institute. Cancer trends progress report. http://progressreport.
cancer.gov/doc_detail.asp?pid=1&did=2009&chid=95&coid=927&mid, 2013.
[84] International breast cancer study group. Combination chemotherapy after surgery in
treating patients with stage i, stage ii or stage iii breast cancer. ClinicalTrials.gov
Bethesda (MD): National Library of Medicine (US), 2014.
[85] Arnaud Jacquel, Magali Herrant, Laurence Legros, Nathalie Belhacene, Frederic Lu-
ciano, Gilles Pages, Paul Hofman, and Patrick Auberger. Imatinib induces mitochondria-
dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward
the erythroid lineage. The FASEB journal, 17(14):2160–2162, 2003.
[86] Peter A Jones and Stephen B Baylin. The epigenomics of cancer. Cell, 128(4):683–692,
2007.
[87] Melissa R Junttila and Gerard I Evan. p53—a jack of all trades but master of none.
Nature Reviews Cancer, 9(11):821–829, 2009.
[88] Yoonseok Kam, Katarzyna A Rejniak, and Alexander R A Anderson. Cellular modeling
of cancer invasion: integration of in silico and in vitro approaches. Journal of cellular
physiology, 227(2):431–8, February 2012.
[89] A R Kansal, S Torquato, I V Harsh GR, E A Chiocca, and T S Deisboeck. Simulated
brain tumor growth dynamics using a three-dimensional cellular automaton. Journal of
theoretical biology, 203(4):367–82, April 2000.
[90] Philip W Kantoff, Celestia S Higano, Neal D Shore, E Roy Berger, Eric J Small, David F
Penson, Charles H Redfern, Anna C Ferrari, Robert Dreicer, Robert B Sims, et al.
BIBLIOGRAPHY 129
Sipuleucel-t immunotherapy for castration-resistant prostate cancer. New England Jour-
nal of Medicine, 363(5):411–422, 2010.
[91] Michael B Kastan. DNA damage responses: mechanisms and roles in human disease:
2007 G.H.A. Clowes Memorial Award Lecture. Molecular cancer research : MCR,
6(4):517–24, April 2008.
[92] Toshiaki Kawai, Sadayuki Hiroi, Kuniaki Nakanishi, and Alan K Meeker. Telom-
ere length and telomerase expression in atypical adenomatous hyperplasia and small
bronchioloalveolar carcinoma of the lung. American journal of clinical pathology,
127(2):254–262, 2007.
[93] Candia M Kenific, Andrew Thorburn, and Jayanta Debnath. Autophagy and metastasis:
another double-edged sword. Current opinion in cell biology, 22(2):241–245, 2010.
[94] Ryungsa Kim, Manabu Emi, and Kazuaki Tanabe. Cancer immunoediting from immune
surveillance to immune escape. Immunology, 121(1):1–14, 2007.
[95] James Korkola and Joe W Gray. Breast cancer genomes—form and function. Current
opinion in genetics & development, 20(1):4–14, 2010.
[96] C Koschmann, KL Schmidt, JR Geyer, and S Leary. Survival after recurrence of medul-
loblastoma in the contemporary era. Journal of clinical oncology, 29(15), 2011.
[97] Heidi Ledford. Cancer researchers revisit ’failed’ clinical trials, 2013.
[98] Yu-Zhen Li, Dao-Yuan Lu, Wei-Qi Tan, Jian-Xun Wang, and Pei-Feng Li. p53 initiates
apoptosis by transcriptionally targeting the antiapoptotic protein arc. Molecular and
cellular biology, 28(2):564–574, 2008.
[99] Lilly. Lilly announces Enzastaurin Phase III study did not meet primary endpoint in
diffuse large B-Cell lymphoma. https://investor.lilly.com/releasedetail.
cfm?ReleaseID=763858, 2013.
[100] Bryn A Lloyd, Dominik Szczerba, Markus Rudin, and Ga´bor Sze´kely. A computa-
tional framework for modelling solid tumour growth. Philosophical transactions. Series
A, Mathematical, physical, and engineering sciences, 366(1879):3301–18, September
2008.
[101] Wing-Cheong Lo, Edward W Martin, Charles L Hitchcock, and Avner Friedman. Math-
ematical model of colitis-associated colon cancer. Journal of theoretical biology,
317C:20–29, September 2012.
130 BIBLIOGRAPHY
[102] C Louvet, R Labianca, P Hammel, G Lledo, MG Zampino, T Andre, A Zaniboni,
M Ducreux, E Aitini, J Taieb, et al. Gemcitabine in combination with oxaliplatin com-
pared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results
of a GERCOR and GISCAD phase III trial. Journal of Clinical Oncology, 23(15):3509–
3516, 2005.
[103] Scott W Lowe, Enrique Cepero, and Gerard Evan. Intrinsic tumour suppression. Nature,
432(7015):307–315, 2004.
[104] Zhen Lu, Robert Z Luo, Yiling Lu, Xuhui Zhang, Qinghua Yu, Shilpi Khare, Seiji
Kondo, Yasuko Kondo, Yinhua Yu, Gordon B Mills, et al. The tumor suppressor gene
arhi regulates autophagy and tumor dormancy in human ovarian cancer cells. The Jour-
nal of clinical investigation, 118(12):3917–3929, 2008.
[105] John S Macdonald, Sheryl McCoy, Robert P Whitehead, Syma Iqbal, James L Wade III,
Jeffrey K Giguere, and James L Abbruzzese. A phase II study of farnesyl transferase
inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924)
study. Investigational new drugs, 23(5):485–487, 2005.
[106] Paul Macklin, Mary E Edgerton, Alastair Thompson, and Vittorio Cristini. Patient-
calibrated agent-based modelling of ductal carcinoma in situ (DCIS) I: Model formula-
tion and analysis. Journal of Theoretical Biology, 2011.
[107] C Maley and Stephanie Forrest. Exploring the relationship between neutral and selective
mutations in cancer. Artificial Life, 6(4):325–345, 2000.
[108] Marcos Malumbres and Mariano Barbacid. Milestones in cell division: to cycle or not
to cycle: a critical decision in cancer. Nature Reviews Cancer, 1(3):222–231, 2001.
[109] David A Mankoff, Janet F Eary, Jeanne M Link, Mark Muzi, Joseph G Rajendran,
Alexander M Spence, and Kenneth A Krohn. Tumor-specific positron emission to-
mography imaging in patients:[18f] fluorodeoxyglucose and beyond. Clinical Cancer
Research, 13(12):3460–3469, 2007.
[110] Mayo Clinic. Cancer surgery: physically removing cancer. http://www.
mayoclinic.org/diseases-conditions/cancer/in-depth/cancer-surgery/
art-20044171, 2014.
[111] W. D. McArdle, F. I. Katch, and V. L. Katch. Essentials of Exercise Physiology. Lippin-
cott Williams & Wilkins, third edition, November 2005.
BIBLIOGRAPHY 131
[112] Medical University of Vienna. Metronomic and targeted anti-angiogenesis therapy for
children with recurrent/progressive medulloblastoma (MEMMAT). ClinicalTrials.gov
Bethesda (MD): National Library of Medicine (US), 2014.
[113] A Monteagudo and J Santos. A cellular automaton model for tumor growth simulation.
Advances in Intelligent and Soft Computing, 154:147–155, 2012.
[114] A Monteagudo and J. Santos. Cancer stem cell modeling using a cellular automaton.
IWINAC LNCS, 7931:21–31, 2013.
[115] A Monteagudo and J Santos. Studying the capability of different cancer hallmarks to
initiate tumor growth using a cellular automaton simulation. Application in a cancer
stem cell context. BioSystems, 115:46–58, 2014.
[116] Malcolm J Moore, David Goldstein, John Hamm, Arie Figer, Joel R Hecht, Steven
Gallinger, Heather J Au, Pawel Murawa, David Walde, Robert A Wolff, et al. Erlotinib
plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic
cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology, 25(15):1960–1966, 2007.
[117] J Naidoo, DB Page, and JD Wolchok. Immune modulation for cancer therapy. British
journal of cancer, 2014.
[118] Loretta J Nastoupil, Adam C Rose, and Christopher R Flowers. Diffuse large B-cell
lymphoma: current treatment approaches. Oncology, 26(5):488–95, 2012.
[119] National Cancer Institute. Cancer research funding. http://www.cancer.gov/
cancertopics/factsheet/NCI/research-funding, 2014.
[120] National Cancer Institute. Targeted cancer therapies. http://www.cancer.gov/
cancertopics/factsheet/Therapy/targeted, 2014.
[121] Simona Negrini, Vassilis G Gorgoulis, and Thanos D Halazonetis. Genomic
instability—an evolving hallmark of cancer. Nature reviews Molecular cell biology,
11(3):220–228, 2010.
[122] New Mexico Cancer Care Alliance. Combination of irinotecan, oxaliplatin and cetux-
imab for locally advanced or metastatic pancreatic cancer, 2014.
[123] Hiroaki Nozawa, Christopher Chiu, and Douglas Hanahan. Infiltrating neutrophils me-
diate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Pro-
ceedings of the National Academy of Sciences, 103(33):12493–12498, 2006.
132 BIBLIOGRAPHY
[124] Kenneth P Olive, Michael A Jacobetz, Christian J Davidson, Aarthi Gopinathan, Do-
minick McIntyre, Davina Honess, Basetti Madhu, Mae A Goldgraben, Meredith E
Caldwell, David Allard, et al. Inhibition of hedgehog signaling enhances delivery of
chemotherapy in a mouse model of pancreatic cancer. Science, 324(5933):1457–1461,
2009.
[125] OncoMed Pharmaceuticals, Inc. A phase 1b/2 study of omp-59r5 in combination with
nab-paclitaxel and gemcitabine in subjects with previously untreated stage iv pancreatic
cancer (alpine), 2014.
[126] Enzo Orlandini, Michael R Swift, and JM Yeomans. A lattice Boltzmann model of
binary-fluid mixtures. EPL (Europhysics Letters), 32(6):463, 1995.
[127] A R A Anderson P Gerlee. A Hybrid cellular automaton model of clonal evolution in
cancer: The emergence of the glycolytic phenotype. Journal of Theoretical Biology,
250(4):705–722, 2010.
[128] F Page´s, J Galon, MC Dieu-Nosjean, E Tartour, C Sautes-Fridman, and WH Fridman.
Immune infiltration in human tumors: a prognostic factor that should not be ignored.
Oncogene, 29(8):1093–1102, 2009.
[129] Zhaohui Peng. Current status of gendicine in china: recombinant human Ad-p53 agent
for treatment of cancers. Human gene therapy, 16(9):1016–1027, 2005.
[130] S. Pennacchietti, P. Michieli, M. Galluzzo, M. Mazzone, S. Giordano, and P.M. Co-
moglio. Hypoxia promotes invasive growth by transcriptional activation of the met pro-
tooncogene. Cancer Cell, 2:347–361, 2003.
[131] Rosario Perona. Cell signalling: growth factors and tyrosine kinase receptors. Clinical
and Translational Oncology, 8(2):77–82, 2006.
[132] Pfizer. Pfizer discontinues a phase 3 trial of figitumumab in non-small cell lung can-
cer (NSCLC) for futility. http://www.pfizer.com/news/press-release/
press-release-detail/pfizer_discontinues_a_phase_3_trial_of_
figitumumab_in_non_small_cell_lung_cancer_nsclc_for_futility, 2009.
[133] Monika Joanna Piotrowska and Simon D Angus. A quantitative cellular automaton
model of in vitro multicellular spheroid tumour growth. Journal of theoretical biology,
258(2):165–78, May 2009.
BIBLIOGRAPHY 133
[134] Van R Potter. The biochemical approach to the cancer problem. Federation proceedings,
17(2):691–697, 1958.
[135] An-Shen Qi, Xiang Zheng, Chan-Ying Du, and Bao-Sheng An. A cellular automaton
model of cancerous growth. Journal of theoretical biology, 161:1–12, 1993.
[136] Marius Raica, Anca Maria Cimpean, and Domenico Ribatti. Angiogenesis in pre-
malignant conditions. European journal of cancer, 45(11):1924–1934, 2009.
[137] Ignacio Ramis-Conde, Mark A.J. Chaplain, and Alexander R. A. Anderson. Mathemati-
cal modelling of cancer cell invasion of tissue. Mathematical and Computer Modelling,
47(5-6):533–545, March 2008.
[138] Christophe M Raynaud, Juana Hernandez, Fre´de´rique P Llorca, Paolo Nuciforo, Marie-
Christine Mathieu, Frederic Commo, Suzette Delaloge, Laure Sabatier, Fabrice Andre´,
and Jean-Charles Soria. DNA damage repair and telomere length in normal breast,
preneoplastic lesions, and invasive cancer. American journal of clinical oncology,
33(4):341–345, 2010.
[139] Katarzyna A Rejniak and Alexander R A Anderson. Hybrid models of tumor growth.
Wiley interdisciplinary reviews. Systems biology and medicine, 3(1):115–25, 2011.
[140] Katarzyna A Rejniak and Alexander R A Anderson. State of the art in computa-
tional modelling of cancer. Mathematical medicine and biology: a journal of the IMA,
29(1):1–2, March 2012.
[141] B Ribba and T Alarc. The use of hybrid cellular automaton models. Training, pages
444–453, 2004.
[142] Everardo D Saad, Paulo M Hoff, et al. Molecular-targeted agents in pancreatic cancer.
Cancer Control, 11(1):32–38, 2004.
[143] J. Santos and A´. Monteagudo. Study of cancer hallmarks relevance using a cellular
automaton tumor growth model. Parallel Problem Solving from Nature-PPSN XII, pages
489–499, 2012.
[144] Andrew M Scott, James P Allison, and Jedd D Wolchok. Monoclonal antibodies in
cancer therapy. Cancer immunity, 12, 2012.
[145] S.F. Sener, A. Fremgen, H.R. Menck, and D.P. Winchester. Pancreatic cancer: a report
of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using
134 BIBLIOGRAPHY
the national cancer database. Journal of the American College of Surgeons, 189(1):1–7,
1999.
[146] J W Shay and W E Wright. Hayflick, his limit, and cellular ageing. Nature reviews.
Molecular cell biology, 1(1):72–6, October 2000.
[147] Charles J Sherr. Cancer cell cycles. Science, 274(5293):1672–1677, 1996.
[148] Sachin Man Bajimaya Shrestha, Grand Roman Joldes, Adam Wittek, and Karol Miller.
Cellular automata coupled with steady-state nutrient solution permit simulation of large-
scale growth of tumours. International journal for numerical methods in biomedical
engineering, 29(4):542–559, 2013.
[149] Sidney Kimmel Comprehensive Cancer Center. Ipilimumab +/- vaccine therapy in treat-
ing patients with locally advanced, unresectable or metastatic pancreatic cancer, 2013.
[150] J Smolle. Cellular automaton simulation of tumour growth – equivocal relationships
between simulation parameters and morphologic pattern features. Analytical cellular
pathology : the journal of the European Society for Analytical Cellular Pathology,
17(2):71–82, January 1998.
[151] Mark J Smyth, Gavin P Dunn, and Robert D Schreiber. Cancer immunosurveillance and
immunoediting: the roles of immunity in suppressing tumor development and shaping
tumor immunogenicity. Advances in immunology, 90:1–50, 2006.
[152] S. L. Spencer, M. J. Berryman, J. A. Garcia, and D. Abbott. An ordinary differential
equation model for the multistep transformation to cancer. Journal of Theoretical Biol-
ogy, 231:515–524, 2004.
[153] Sabrina L Spencer, Ryan A Gerety, Kenneth J Pienta, and Stephanie Forrest. Modeling
somatic evolution in tumorigenesis. PLoS computational biology, 2(8):e108, 2006.
[154] Statistics Canada. Leading causes of death, by sex. Statistics Canada, 2009.
[155] Dirk C Strauss and J Meirion Thomas. Transmission of donor melanoma by organ
transplantation. The lancet oncology, 11(8):790–796, 2010.
[156] S Succi. The Lattice Boltzmann Equation for Fluid Dynamics and Beyond. Oxford
University Press, 2001.
BIBLIOGRAPHY 135
[157] Xiaoqiang Sun, Le Zhang, Hua Tan, Jiguang Bao, Costas Strouthos, and Xiaobo Zhou.
Multi-scale agent-based brain cancer modeling and prediction of TKI treatment re-
sponse: Incorporating EGFR signaling pathway and angiogenesis. BMC Bioinformatics,
13(1):218, 2012.
[158] Surveillance, Epidemiology, and End Results Program. National Cancer Insitute. Cancer
Stat Facts Sheet. http://seer.cancer.gov/statfacts/, 2014.
[159] RM Sutherland, B Sordat, J Bamat, H Gabbert, B Bourrat, and W Mueller-Klieser.
Oxygenation and differentiation in multicellular spheroids of human colon carcinoma.
Cancer research, 46(10):5320–5329, 1986.
[160] Robert M Sutherland. Cell and environment interactions in tumor microregions: the
multicell spheroid model. Science, 240(4849):177–184, 1988.
[161] Mr Swift, E Orlandini, Wr Osborn, and Jm Yeomans. Lattice Boltzmann simulations
of liquid-gas and binary fluid systems. Physical review. E, Statistical physics, plasmas,
fluids, and related interdisciplinary topics, 54(5):5041–5052, November 1996.
[162] Michele WL Teng, Jeremy B Swann, Catherine M Koebel, Robert D Schreiber, and
Mark J Smyth. Immune-mediated dormancy: an equilibrium with cancer. Journal of
leukocyte biology, 84(4):988–993, 2008.
[163] Baldwin H Tom, Lynne P Rutzky, Milda M Jakstys, Ryoichi Oyasu, Celia I Kaye, and
Barry D Kahan. Human colonic adenocarcinoma cells. In vitro, 12(3):180–191, 1976.
[164] U.S. Food and Drug Administration. The FDA’s drug review process: Ensuring drugs are
safe and effective. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/
ucm143534.htm, 2014.
[165] Claire M Vajdic and Marina T van Leeuwen. Cancer incidence and risk factors after
solid organ transplantation. International journal of cancer, 125(8):1747–1754, 2009.
[166] J. W. Valvano, J. R. Cochran, and K. R. Diller. Thermal conductivity and diffusivity of
biomaterials measured with self heated thermistors. International Journal of Thermo-
physics, 6(3), 1985.
[167] Eric Van Cutsem, Walter L Vervenne, Jaafar Bennouna, Yves Humblet, Sharlene Gill,
Jean-Luc Van Laethem, Chris Verslype, Werner Scheithauer, Aijing Shang, Jan Cosaert,
et al. Phase iii trial of bevacizumab in combination with gemcitabine and erlotinib in
136 BIBLIOGRAPHY
patients with metastatic pancreatic cancer. Journal of clinical oncology, 27(13):2231–
2237, 2009.
[168] Matthew G Vander Heiden, Lewis C Cantley, and Craig B Thompson. Understand-
ing the warburg effect: the metabolic requirements of cell proliferation. Science,
324(5930):1029–1033, 2009.
[169] Vical. Vical Phase 3 Trial of Allovectin Fails to Meet Efficacy Endpoints. http:
//www.vical.com/investors/news-releases/News-Release-Details/2013/
Vical-Phase-3-Trial-of-AllovectinR-Fails-to-Meet-Efficacy-Endpoints/
default.aspx, 2013.
[170] Bert Vogelstein and Kenneth W Kinzler. The multistep nature of cancer. Trends in
Genetics, 9(4):138–141, 1993.
[171] VU University Medical Center. Chemoradiation with gemcitabine in combination with
panitumumab for patients with locally advanced pancreatic cancer (vectibix), 2014.
[172] Zhihui Wang, Christina M Birch, Jonathan Sagotsky, and Thomas S Deisboeck. Cross-
scale, cross-pathway evaluation using an agent-based non-small cell lung cancer model.
Bioinformatics (Oxford, England), 25(18):2389–96, September 2009.
[173] Otto Heinrich Warburg and Frank Dickens. The metabolism of tumours: investigations
from the Kaiser Wilhelm Institute for Biology, Berlin-Dahlem. Constable & Company
Limited, 1930.
[174] Xia-wei Wei, Zhi-rong Zhang, and Yu-Quan Wei. Anti-angiogenic drugs currently in
phase ii clinical trials for gynecological cancer treatment. Expert opinion on investiga-
tional drugs, 22(9):1181–1192, 2013.
[175] Sidney Weinhouse, Otto Warburg, Dean Burk, and Arthur L Schade. On respiratory
impairment in cancer cells. Science, 124(3215):267–272, 1956.
[176] Esther Witsch, Michael Sela, and Yosef Yarden. Roles for growth factors in cancer
progression. Physiology, 25(2):85–101, 2010.
[177] World Health Organization. The global burden of disease: 2004 update, 2008.
[178] Jennifer A Woyach, Gerard Lozanski, Amy S Ruppert, Arletta Lozanski, Kristie A
Blum, Jeffrey Alan Jones, Joseph M Flynn, Amy J Johnson, Michael R Grever, Nyla A
Heerema, et al. Outcome of patients with relapsed or refractory chronic lymphocytic
BIBLIOGRAPHY 137
leukemia treated with flavopiridol: impact of genetic features. Leukemia, 26(6):1442–
1444, 2012.
[179] Jeffrey Wyckoff, Weigang Wang, Elaine Y Lin, Yarong Wang, Fiona Pixley, E Richard
Stanley, Thomas Graf, Jeffrey W Pollard, Jeffrey Segall, and John Condeelis. A
paracrine loop between tumor cells and macrophages is required for tumor cell migra-
tion in mammary tumors. Cancer research, 64(19):7022–7029, 2004.
[180] Xiao-Ming Yin and Zheng Dong. Essentials of apoptosis: a guide for basic and clinical
research. Springer, 2009.
[181] Hua Yu, Drew Pardoll, and Richard Jove. Stats in cancer inflammation and immunity: a
leading role for stat3. Nature Reviews Cancer, 9(11):798–809, 2009.
[182] Wei-Xing Zong and Craig B Thompson. Necrotic death as a cell fate. Genes & devel-
opment, 20(1):1–15, 2006.
Appendix A
Glossary
Aerobic Metabolism Oxygen-using metabolism that extracts energy (ATP molecules) from
carbohydrates, such as glucose
Agent Based Model A type of computational model which simulates the actions of autonomous
agents
Anastomosis Connection of separate branches of the vascular system to form a network
Angiogenesis The formation of new blood vessels
Apoptosis Programmed cell death that occurs as a natural part of tissue life and can occur as
the result of damage to a cell
Basal level The base or minimum level
Cellular automata (CA) A discrete model where individual autonomous units exist in a finite
number of states and can change states based on rules and their environment
Capillary The smallest blood vessels in the body
Caspase Cystine-dependent aspartate-specific proteases
Cell surface receptors Proteins on the surface of a cell that help the inside of the cell com-
municate with the environment on the outside
Chemotaxis Movement by a cell or organism in reaction to a chemical stimulus
Endothelial cells The cells lining the walls of blood vessels. These cells migrate towards
tumours when tumour cells produce TAF
Epigenetic Genetic influences that are not related to the actual sequence of DNA
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Extracellular Matrix All connective tissue and fibres that are not inside the cell but provide
support for the environment outside of the cell
G0 Phase A resting phase of the cell cycle
G1 Phase A step in the cell cycle where the cell grows and creates building blocks needed for
DNA replication
G2 Phase A gap time in the cell cycle where the cell grows and when it is ensured the cell is
ready to divide
Glioblastoma multiforme A highly malignant brain tumour
Haematocrit The ratio of the volume occupied by packed red blood cells to the volume of the
whole blood
Haptotaxis Migration of a cell down a concentration gradient
Homeostasis The balance maintained in the body e.g. regulating temperature
Hypoxia Oxygen deficiency causing a very strong drive to correct the deficiency
Ligand A molecule that can bind to another molecule
M Phase A part of the cell cycle when cell growth stops and the cell splits in two
Metabolism The breakdown and creation of metabolites in order to power the cell
Metastasis The spreading of a disease (especially cancer) to another part of the body
Matrix metalloproteinase Enzymes that degrade the matrix
Mesenchymal cell A type of cell that can easily migrate through the body
Mitosis Cell division
Necrosis The localized death of living cells (as from infection or the interruption of blood
supply)
Neoplasm An abnormal growth of tissue, often a characteristic of cancer
Oncogene A gene with the potential to cause cancer
Oncoprotein A protein encoded by an oncogene that has the potential to cause cancer
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Perfusion Pumping a liquid into an organ or tissue (especially by way of blood vessels)
Phenotype The set of observable characteristics of an organism that are the result of its en-
vironment and genetics interacting. In this model this is specifically the result of all
hallmarks, rules and parameters for each cellular automata
Protease An enzyme that breaks down proteins and peptides
Proteolysis The process of breaking down proteins or peptides
Retinoblastoma A rare malignant tumour of the retina
S Phase A part of the cell cycle where DNA replication occurs
Senescence A cell state that is viable but non-proliferative
TAF Chemicals secreted by tumours, frequently when the tumour is experiencing hypoxia
Telomere Short, repeating cap of DNA on the ends of chromosomes
Telomerase An enzyme that builds telomeres
Tumour An abnormal mass of tissue
Tumour supressor gene A gene that protects a cell from some step on the path towards cancer
Vascular Relating to the system of blood vessels
Vascularization The organic process whereby body tissue becomes vascular and develops
capillaries
Appendix B
Abbreviation List
A Angiogenesis hallmark
AA Avoid apoptosis hallmark
AI Avoid immune system hallmark
ASMR Age-standardized mortality rates
CA Cellular automata
ECM Extracellular matrix
IGI Ignore growth inhibition hallmark
IMS Intracellular mechanical stress
GBM Glioblastoma multiforme
GP Glycolytic phenotype hallmark
GU Genetically unstable hallmark
IT Ignores telomere hallmark
LBM Lattice Boltzmann Methods
MMP Matrix metalloproteinases
MTS Multicellular tumour spheroid
p53 Protein 53
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RAS Rat sarcoma
RSA Random sequential addition process
RB Rentinoblastoma
SG Self growth hallmark
TAF Tumour angiogenic factor.
TP53 Tumour protein 53
Appendix C
Raw p-values for all knockout data
C.1 Doublet knockout data
Hallmarks knocked out p-value Additional notes
SG, IGI 2.137×10−1 No change
SG, AA 1.414×10−3 Less cancer
SG, IT 1.061×10−1 No change
SG, A 9.134×10−5 Cancer cured
SG, GI 9.134×10−5 Cancer cured
SG, AI 9.134×10−5 Cancer cured
IGI, AA 3.642×10−3 Some cancer still grew
IGI, IT 2.363×10−1 No change
IGI, A 9.134×10−5 Cancer cured
IGI, GI 4.250×10−1 No change
IGI, AI 3.669×10−1 No change
AA, IT 6.574×10−4 Some cancer still grew
AA, A 9.134×10−5 Cancer cured
AA, GU 7.010×10−3 No change
AA, AI 5.665×10−3 Some cancer still grew
IT, A 9.134×10−5 Cancer cured
IT, GU 1.805×10−3 No change
IT, AI 3.201×10−2 No change
A, GU 9.083×10−5 Cancer cured
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A, AI 9.083×10−5 Some cancer still grew
GI, AI 1.560×10−2 Some cancer still grew
Table C.1: Hallmark paired knockout data. Each hallmark
knockout was simulated 10 times. The final cancer growth
was compared to growth when all hallmarks were available
for activation using the Mann-Whitney-U test.
C.2 Triplet knockout data
Hallmarks knocked out p-value Additional notes
GI, GLY, AI 3.388×10−1 Cancer in 7/10
IGI, IT, AI 1.923×10−1 Cancer in 6/10
SG, IGI, GU 2.898×10−3 Cancer cured
A, GLY, AI 9.1336×10−5 Cancer cured
IGI, IT, GLY 4.554×10−3 Cancer in 9/10
Significantly more growth
SG, IGI, A 2.914×10−4 Cancer cured
A, GU, AI 2.914×10−4 Cancer cured
IGI, IT, GU 8.629×10−3 Cancer in 10/10
Significantly more growth
SG, IGI, IT 2.898×10−3 Cancer cured
A, GU, GLY 1.230×10−4 Cancer cured
IGI, IT, A 1.649×10−4 Cancer cured
SG, IGI, AA 2.198×10−4 Cancer cured
IT, GLY, AI 2.137×10−1 Cancer in 10/10
IGI, AA, AI 2.293×10−3 Cancer in 4/10
IT, GU, AI 2.363×10−1 Cancer in 9/10
IGI, AA, GLY 1.413×10−3 Cancer in 5/10
IT, GU, GLY 4.849×10−1 Cancer in 9/10
IGI, AA, GU 8.629×10−3 Cancer in 9/10
IT, A, AI 6.574×10−4 Cancer cured
IGI, AA, A 9.1336×10−5 Cancer cured
IT, A, GLY 9.1336×10−5 Cancer cured
C.2. Triplet knockout data 145
IGI, AA, IT 2.898×10−3 Cancer in 6/10
IT, A, GU 3.843×10−4 Cancer cured
SG, GLY, AI 7.010×10−3 Cancer cured
AA, GLY, AI 5.665×10−3 Cancer in 7/10
SG, GU, AI 4.554×10−3 Cancer cured
AA, GU, AI 8.531×10−4 Cancer in 3/10
SG, GU, GLY 4.554×10−3 Cancer cured
AA, GU, GLY 1.805×10−3 Cancer in 4/10
SG, A, AI 3.843×10−4 Cancer cured
AA, A, A 9.1336×10−5 Cancer cured
SG, A, GLY 9.1336×10−5 Cancer cured
AA, A, GLY 1.231×10−4 Cancer cured
SG, A, GU 2.198×10−4 Cancer cured
AA, A, GU 2.198×10−4 Cancer cured
SG, IT, AI 2.898×10−3 Cancer cured
AA, IT, AI 4.554×10−3 Cancer in 7/10
SG, IT, GLY 5.665×10−3 Cancer cured
AA, IT, GLY 4.554×10−3 Cancer in 7/10
SG, IT, GU 1.101×10−3 Cancer cured
AA, IT, GU 3.642×10−3 Cancer in 6/10
SG, IT, A 6.575×10−4 Cancer cured
AA, IT, A 9.0826×10−5 Cancer cured
SG, AA, AI 8.531×10−4 Cancer cured
IGI, GLY, AI 5.665×10−3 Cancer in 9/10
Significantly more growth
SG, AA, GLY 5.040×10−4 Cancer cured
IGI, GU, AI 8.629×10−3 Cancer in 9/10
Significantly more growth
SG, AA, GU 3.843×10−4 Cancer cured
IGI, GU, GLY 0.4849 Cancer in 6/10
SG, AA, A 9.1336×10−5 Cancer cured
IGI, A, AI 9.1336×10−5 Cancer cured
SG, AA, IT 3.843×10−4 Cancer cured
IGI, A, GLY 9.1336×10−5 Cancer cured
SG, IGI, AI 2.293×10−3 Cancer cured
IGI, A, GU 9.1336×10−5 Cancer cured
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SG, IGI, GLY 3.642×10−3 Cancer cured
Table C.2: Hallmark triplet knockout data. Each hallmark
knockout was simulated 10 times. The final cancer growth
was compared to growth when all hallmarks were available
for activation using the Mann-Whitney-U test.
C.3 Quadruplet knockout data
Hallmarks knocked out p-value Additional notes
A, GU, GLY, AI 2.198×10−4 Cancer cured
IGI, AA, GU, AI 1.805×10−3 Cancer in 5/10
SG, AA, IT, GLY 1.649×10−4 Cancer cured
IT, GU, GLY, AI 4.251×10−1 Cancer in 8/10
IGI, AA, GU, GLY 3.642×10−3 Cancer in 6/10
SG, AA, IT, GU 1.649×10−4 Cancer cured
IT, A, GLY, AI 1.230×10−4 Cancer cured
IGI, AA, A, AI 1.649×10−4 Cancer cured
SG, AA, IT, A 9.1336×10−5 Cancer cured
IT, A, GU, AI 1.230×10−4 Cancer cured
IGI, AA, A, GLY 9.1336×10−5 Cancer cured
SG, IGI, GLY, AI 1.414×10−3 Cancer cured
IT, A, GU, GLY 1.230×10−4 Cancer cured
IGI, AA, A, GU 9.1336×10−5 Cancer cured
SG, IGI, GU, AI 1.805×10−3 Cancer cured
AA, GU, GLY, AI 1.414×10−4 Cancer in 5/10
IGI, AA, IT, A 1.414×10−4 Cancer in 5/10
SG, IGI, GU, GLY 5.040×10−4 Cancer cured
AA, A, GLY, AI 9.1336×10−5 Cancer cured
IGI, AA, IT, GLY 2.898×10−3 Cancer in 6/10
SG, IGI, A, AI 2.914×10−4 Cancer cured
AA, A, GU, AI 9.1336×10−5 Cancer cured
IGI, AA, IT, GU 2.293×10−3 Cancer in 4/10
SG, IGI, A, GLY 1.231×10−4 Cancer cured
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AA, A, GU, GLY 9.1336×10−5 Cancer cured
IGI, AA, IT, A 9.083×10−5 Cancer cured
SG, IGI, A, GU 1.649×10−4 Cancer cured
AA, IT, GLY, AI 6.574×10−4 Cancer in 2/10
SG, GU, GLY, AI 3.642×10−3 Cancer cured
SG, IGI, IT, AI 1.805×10−3 Cancer cured
AA, IT, GU, AI 6.575×10−4 Cancer in 3/10
SG, A, GLY, AI 1.649×10−4 Cancer cured
SG, IGI, IT, GLY 3.642×10−3 Cancer cured
AA, IT, GU, GLY 3.843×10−4 Cancer in 2/10
SG, A, GU, AI 3.843×10−4 Cancer cured
SG, IGI, IT, GU 8.531×10−4 Cancer cured
AA, IT, A, AI 9.1336×10−5 Cancer cured
SG, A, GU, GLY 1.649×10−4 Cancer cured
SG, IGI, IT, A 1.641×10−4 Cancer cured
AA, IT, A, GLY 9.1336×10−5 Cancer cured
SG, IT, GLY, AI 4.554×10−3 Cancer cured
SG, IGI, AA, AI 2.198×10−4 Cancer cured
AA, IT, A, GU 9.1336×10−5 Cancer cured
SG, IT, GU, AI 1.805×10−3 Cancer cured
SG, IGI, AA, GLY 1.640×10−4 Cancer cured
IGI, GU, GLY, AI 1.723×10−1 Cancer in 7/10
SG, IT, GU, GLY 6.574×10−4 Cancer cured
SG, IGI, AA, GU 5.040×10−4 Cancer cured
IGI, A, GLY, AI 9.1336×10−5 Cancer cured
SG, IT, A, AI 1.649×10−4 Cancer cured
SG, IGI, AA, A 9.1336×10−5 Cancer cured
IGI, A, GU, AI 1.231×10−4 Cancer cured
SG, IT, A, GLY 1.231×10−4 Cancer cured
SG, IGI, AA, IT 3.843×10−4 Cancer cured
IGI, A, GU, GLY 1.231×10−4 Cancer cured
SG, IT, A, GU 6.575×10−4 Cancer cured
IGI, IT, GLY, AI 8.629×10−3 Cancer in 9/10
Significantly more growth
SG, AA, GLY, AI 1.231×10−4 Cancer cured
IGI, IT, GU, AI 3.116×10−1 Cancer in 6/10
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SG, AA, GU, AI 3.842×10−4 Cancer cured
IGI, IT, GU, GLY 1.923×10−1 Cancer in 7 /10
SG, AA, GU, GLY 2.914×10−4 Cancer cured
IGI, IT, A, AI 9.1336×10−5 Cancer cured
SG, AA, A, AI 9.1336×10−5 Cancer cured
IGI, IT, A, GLY 9.1336×10−5 Cancer cured
SG, AA, A, GLY 9.1336×10−5 Cancer cured
IGI, IT, A, GU 1.649×10−4 Cancer cured
SG, AA, A, GU 9.1336×10−5 Cancer cured
IGI, AA, GLY, AI 2.989×10−3 Cancer in 6/10
SG, AA, IT, AI 1.649×10−4 Cancer cured
Table C.3: Hallmark quadruplet knockout data. Each hall-
mark knockout was simulated 10 times. The final cancer
growth was compared to growth when all hallmarks were
available for activation using the Mann-Whitney-U test.
Appendix D
Drugs that target hallmarks
An example of a drug that targets each of the hallmarks of cancer simulated in this paper. For
more examples and information on the development of cancer drugs based on the hallmarks of
cancer please see [22].
Drug Hallmark targeted Notes
Bevacizumab Angiogenesis Blocks VEGF to stop the angiogeneic
ability of cancer
Paclitaxel Self growth Inhibits mitosis to stop cancer cells
from dividing
Interleukin-2 Avoid immunity Boosts the natural immune response so the
immune system can attack the cancer
GV1001 Ignore telomeres A telomerase inhibitor vaccine currently in
development and trials
Imatinib Avoids apoptosis Used in leukemia where a chromosomal
abnormality stimulates abnormal proliferation
of hemopoietic precursor cells that are
inhibited from dying via apoptosis [85]
Silybin Glycolytic phenotype Clinical trial was recently completed
investigating using this in liver cancer to stop
glycolysis. No results yet posted [2]
Gendicine Genome Unstable A drug that activates normal p53, this is used
to treat head and neck cancers by activating
normal p53. p53 then guards the genome
properly, initiating apoptosis in cells with too
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much damage stopping the propagation of
damage and therefore stabilizing genomes of
remaining cells [129]
Flavopiridol Ignores Growth Inhibition Useful in treating relapsed or refractory
chronic lymphocytic leukemia (CLL);
targets over expressed cyclins that allow cells
to evade RB signals and over grow [178]
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